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ABSTRACT OF DISSERTATION

LEPTIN RESISTANCE INDUCED OBESITY AND DIABETES
PROMOTE NEUROPATHOLOGICAL CHANGES IN THE AGING BRAIN
The aging brain is prone to the development of pathology and dementia. With a
rapidly growing elderly population diagnoses of neurodegenerative diseases, such as
Alzheimer’s disease (AD), frontotemporal dementia (FTD), and Parkinson’s disease are
on the rise. Additionally, diabetes and obesity are linked to an increased risk of dementia.
The convergence of this increasingly aged population with the obesity and diabetes
epidemic give rise to new concerns regarding the future of prevention and treatment of
neurodegenerative diseases. Our lab has previously shown that leptin, an adipokine
involved in signaling satiety to the hypothalamus, can modulate the generation of the
amyloid beta (Aβ) peptide (a toxic peptide associated with neurologic disease) and
attenuate hyperphosphorylation of the tau protein (another peptide prone to forming large
insoluble structures causing neurodegeneration). From these studies we have elucidated
that leptin resistant mice (which develop severe obesity and type-2 diabetes mellitus)
with knock-in mutations for the amyloid precursor protein (APP) and presenilin-1 (PS1)
genes develop extensive vascular pathology and cognitive impairments. Interestingly,
these mice do not display increased levels of amyloid deposition in the brain.
Additionally, increased tau phosphorylation occurs in these mice with leptin resistance.
As a follow up to this study db mice were transduced, via adeno-associated virus, with
the tau P301L mutant to induce the development of tangle pathology. These mice
displayed no cognitive deficits, yet they displayed increases in both tau phosphorylation
and tangle count within the hippocampus. Collectively, these studies indicate leptin
resistance, obesity, and type-2 diabetes mellitus promote the development of
cerebrovascular and neurofibrillary tangle pathologies associated with neurodegeneration
and dementia. These observations open many previously unexplored avenues for
developing novel therapeutics to treat these devastating diseases.
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CHAPTER ONE: Introduction
1.1 - Alzheimer’s Disease and Other Dementias
1.1.1 - Alzheimer’s Disease Background
The brain becomes more susceptible to neurologic disease as it ages. Factors
which contribute to the development of these diseases are numerous; however, age is the
number one driving factor. Alzheimer’s disease (AD), for example, is the most common
neurodegenerative disease associated with age. Worldwide 36 million individuals have
AD, a number which is expected to double in the next 20 years. The healthcare system
already incurs huge financial costs due to AD, with over 200 billion dollars going
towards treatment and care of individuals with the disease annually. If the projected
estimates are correct, it will cost over 1.1 trillion dollars a year to care for these patients
by 2050. This burden will cripple the healthcare system if no therapeutics are developed.
Despite tremendous effort put toward understanding the mechanisms underlying the
disease, there is still no cure for AD, and no effective treatments to stop the development
of pathology.
There are several clinical characteristics of AD, the most well-known being loss
of memory and cognitive function. A variety of cognitive exams, such as the mini-mental
state exam (MMSE) and the mini-cog exam, evaluate memory, temporal awareness, and
basic cognitive skills. In addition to cognitive decline, patients tend to display behavioral
changes, such as depression, agitation, difficulty sleeping, and delusions. Physicians are
aware these changes occur and typically prescribe psychotropic drugs like
antidepressants, anxiolytics, etc. In the final stages of AD patients begin losing their
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ability to physically perform daily tasks or to care for themselves and ultimately spend
their last few months bedridden. Despite these hallmark symptoms a clinical diagnosis of
AD currently can’t be made until autopsy by identifying the key pathological hallmarks
of the disease: amyloid plaques (comprised of the Aβ peptide) and neurofibrillary tangles
(NFTs) made from hyperphosphorylated tau protein.
1.1.2 – Mechanisms of Amyloid Pathogenesis
The Aβ peptide is formed when APP (a membrane protein with 4 isoforms
ranging from 695 to 770 amino acids in length) (Sandbrink, Masters et al. 1996), is
cleaved by two enzymatic activities. Under non-amyloidogenic conditions, α-secretase
cleaves APP within the Aβ region, followed by γ-secretase cleavage, producing the APP
intracellular domain (AICD), the soluble APP fragment α (sAPPα), and the p3 fragment
(Selkoe 2001). In the amyloidogenic pathway APP is first cleaved by β-secretase. This is
again followed by γ-secretase cleavage, releasing the AICD, sAPPβ, and the Aβ peptide
(Fig. 1.1) (Chen, Hasegawa et al. 2006). Aβ peptides are 36–43 amino acids long, the
most common being Aβ40, which represents about 80% of the total pool. A less common
(10%) form of the peptide, Aβ42, is considered to be more pathogenic, having a high
tendency to aggregate (Tanzi and Bertram 2005, Karran, Mercken et al. 2011).
Aggregation creates oligomers, fibrils, filaments, and ultimately, plaques (Ohnishi and
Takano 2004). These plaques form in the cortex and hippocampus (Robinson, Geser et al.
2011). Neuritic plaques are surrounded by dystrophic neurites and activated glia (Hu and
Van Eldik 1999), and are likely an ongoing source of neuroinflammation (Griffin, Sheng
et al. 1998, Meda, Baron et al. 2001). Although plaques are directly connected to the
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disease process, recent evidence suggests that diffusible Aβ oligomers may play a greater
role in driving neurodegeneration than plaques (Demuro, Mina et al. 2005, Glabe 2006).
Under normal conditions, ~90% of APP processing is performed within the nonamyloidogenic pathway and ~10% by the amyloidogenic pathway (Ahmed, Holler et al.
2010). It is not known what causes the shift to increased APP processing by the
amyloidogenic pathway in AD (Fukumoto, Cheung et al. 2002). One hypothesis suggests
that increased cholesterol levels result in lipid raft formation, which has been suggested
to be the physiological site of β-secretase and γ-secretase activity (Korade and
Kenworthy 2008, Rushworth and Hooper 2010, Evangelisti, Wright et al. 2013). βsecretase cleavage is the rate-limiting step in Aβ generation, and β-secretase activity
levels are thought to increase throughout the progression of AD (Ahmed, Holler et al.
2010, Holler, Webb et al. 2012). In other cases, mutations in APP and processing
enzymes (APP, PS1, PS2); which are typical in cases of familial AD (FAD), can enhance
Aβ generation by increasing available substrate and promote amyloidogenic cleavage of
APP (Corder, Saunders et al. 1993, Sherrington, Rogaev et al. 1995, Jankowsky, Fadale
et al. 2004). Other findings point to a decrease in Aβ clearance from the brain, resulting
in a gradual accumulation during aging (Tanzi, Moir et al. 2004).
1.1.3 - Tau Pathogenesis
It is likely that a major portion of the neurodegeneration observed in AD and
other tauopathies, diseases involving the pathological aggregation of the tau protein,
results from tau pathology. For example, the number of NFTs correlates with clinical
disease severity (Arriagada, Marzloff et al. 1992, Gomez-Isla, Hollister et al. 1997). The
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amyloid cascade hypothesis suggests the series of pathologic events observed in AD are
driven by amyloid pathology (Hardy and Allsop 1991, Gotz, Chen et al. 2001, Lewis,
Dickson et al. 2001, Oddo, Caccamo et al. 2003, Ittner and Gotz 2011). As a result, the
equilibrium of tau phosphorylation and dephosphorylation is altered, ultimately leading
to tangle formation, neuronal dysfunction, and cell death (Hardy and Allsop 1991,
Karran, Mercken et al. 2011, Lambert and Amouyel 2011) (Fig. 1.2).
Tau is a microtubule-stabilizing protein present in the cytoplasm of axons but
generally absent in the dendrites (Maas, Eidenmuller et al. 2000). Tau acts on tubulin to
promote polymerization of the microtubule, paving the way for axonal transport
(Weingarten, Lockwood et al. 1975). The MAPT gene, which encodes the tau protein,
resides on chromosome 17 and is comprised of 16 exons (Duff, Knight et al. 2000).
MAPT has four domains: N-terminal, C-terminal, microtubule binding domain (MBD),
and a proline-rich domain (Mandelkow, Schweers et al. 1996, Ballatore, Lee et al. 2007).
The N-terminal and MBD regions are alternatively spliced to include or exclude exons 2,
3 and 10, resulting in 6 possible isoforms of the tau protein (Deshpande, Win et al. 2008).
The resulting isoforms contain either 3 or 4 microtubule binding domains (3R and 4R
respectively) and contain 0, 1 or 2 N-terminal domains (0N, 1N or 2N respectively)
separated by a proline rich domain (Forman, Lee et al. 2000). MAPT also contains two
haplogroups, H1 and H2, where increased H1 levels correlate with an increased risk of
tauopathy (Forman, Lee et al. 2000). The tau protein undergoes a variety of posttranslational modifications (Hasegawa, Morishima-Kawashima et al. 1992, Watanabe,
Takio et al. 1999, Morris, Maeda et al. 2011), including cross-linking (Chau, Radeke et
al. 1998), glycosylation (Robertson, Moya et al. 2004), nitration (Reynolds, Reyes et al.
4

2006), and phosphorylation (Morishima-Kawashima, Hasegawa et al. 1995). The large
number of post-translational modifications of tau suggests that tau is highly-regulated by
complex pathways. The primary cause of tau dysfunction is due to phosphorylation of tau
by enzymes such as GSK3β (Michel, Mercken et al. 1998), AKT (Ksiezak-Reding, Pyo
et al. 2003), or CDK5 (Lund, McKenna et al. 2001), along with many other kinases
(Forman, Lee et al. 2000, Martin, Latypova et al. 2013). Phosphorylation of tau occurs at
approximately 45 sites, at serine and threonine residues (Drewes, Trinczek et al. 1995,
Geschwind 2003, Hanger, Anderton et al. 2009). The microtubule binding domains
(MBDs) of tau confer a positive charge to the protein, allowing it to stably bind the
negatively charged microtubules (Duff, Knight et al. 2000). In the disease state tau
becomes hyperphosphorylated, resulting in the neutralization of its net positive charge
(Fig. 1.3). This causes tau to dissociate from the microtubules and aggregate to form
paired helical filaments (PHFs) with other hyperphosphorylated tau molecules (Alonso,
Zaidi et al. 2001, Geschwind 2003, Hernandez and Avila 2007). Upon the dissociation of
tau, the microtubule network becomes destabilized and axonal transport may be disrupted
(Cuchillo-Ibanez, Seereeram et al. 2008). Over time, PHFs will accumulate to form
neurofibrillary tangles, primarily in pyramidal neurons (Iqbal, Alonso Adel et al. 2005).
1.1.4 Frontotemporal dementia (FTD) and other Tauopathies
Tau pathology is not isolated to AD. There are several neurodegenerative diseases
which also have pathology associated with the tau protein, these diseases are classified as
‘tauopathies’(Lee, Goedert et al. 2001). Tauopathies are associated with a variety of
neurodegenerative diseases involving dementia and/or motor dysfunctions. AD is the
most well-known tauopathy, and involves gradual neurodegeneration radiating from the
5

entorhinal cortex, primarily causing cognitive decline in early stages of the disease
(Yassa 2014). Other tauopathies, such as progressive supranuclear palsy (PSP), develop
distinctly different high order tau structures (straight filaments instead of paired helical
filaments in AD) in different areas of the brain than seen in AD, resulting in different
clinical features. Often misdiagnosed as Parkinson’s disease, PSP patients suffer from
bradykinesia, dysphagia, ophthalmoplegia, and eventually dementia (Steele, Richardson
et al. 1964, Oba, Yagishita et al. 2005, Louis, Babij et al. 2013). In this disease tangles
form in neurons and glial cells of the substantia nigra, subthalamic nucleus, oculomotor
nucleus, and a variety of other structures in the mesencephalon (Barsottini, Felicio et al.
2010). PSP is just one of many other tauopathies, all of which are phenotypically varied
but mechanistically unified by the aggregation of the tau protein.
For many years it was unclear as to what initiated the development of tau
pathology in AD, and whether tau pathology alone could cause dementia. Because of this
tau pathology was largely disregarded as a byproduct of neurodegeneration or other
pathological changes. It wasn’t until the late 1990s that studies began to indicate tau may
play a larger role than previously suggested, as familial tau mutations were discovered to
promote the development of pathology and induce neurodegeneration and dementia in
patients with frontotemporal dementia and parkinsonism linked to chromosome-17
(FTDP-17)(Hutton, Lendon et al. 1998, Poorkaj, Bird et al. 1998, Spillantini, Murrell et
al. 1998, Morris, Khan et al. 2001). These tau mutations are observed in approximately
30% of FTD diagnoses, but there are no mutations in tau associated with AD (Morris,
Khan et al. 2001, Rosso, Donker Kaat et al. 2003). With the discovery of these mutations,
37 to date, many new mechanisms by which tau pathology can develop have been
6

discovered (Goedert and Jakes 2005). Mutations within intronic regions have been shown
to modulate splicing of tau mRNA, resulting in unequal N-terminal repeat isoforms (4R
to 3R) expression, which promotes the development of pathology (D'Souza, Poorkaj et al.
1999, Grover, Houlden et al. 1999, Yoshida, Crowther et al. 2002). Mutations found
within the exons, such as P301L and P301S in exon 10, promote the formation of tau
filaments, and pathogenesis (Hong, Zhukareva et al. 1998, Mirra, Murrell et al. 1999,
Rizzu, Joosse et al. 2000). These mechanisms which allow tau pathology to develop
independent of other known initiating factors have been useful insights into better
understanding a plethora of related neurodegenerative diseases.
1.2 – Obesity and Diabetes
1.2.1 – Background and Prevalence
Obesity is a disorder in which an individual has excessive adipose stores, and is
defined in adults by a body mass index, a measure of weight divided by the square of a
person’s height, of over 30kg/m2 (Mokdad, Serdula et al. 1999, Haslam and James 2005).
The World Health Organization officially declared obesity an epidemic in 1997, and has
since called childhood obesity the “most serious global public health challenge for the
21st century” (Caballero 2007). Obesity is the leading preventable cause of death
worldwide, and is associated with many life-threatening diseases such as type 2 diabetes
mellitus (T2DM), cardiovascular disease, and chronic obstructive pulmonary disease
(Haslam and James 2005, Poulain, Doucet et al. 2006). Currently there are no viable
pharmaceutical therapies which reduce body weight and the most successful intervention
to date is bariatric surgery (Colquitt, Picot et al. 2009, Chang, Stoll et al. 2014).
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T2DM is highly correlated with obesity and has been a gradually growing issue
across the world for the last 50 years. Obesity is a common driving factor for the
development of T2DM and the two diseases are highly associated, with 85.2% of T2DM
patients being classified as overweight or obese (Ford, Williamson et al. 1997, Resnick,
Valsania et al. 2000, Mokdad, Ford et al. 2003, Prevention 2011). T2DM greatly
increases the risk of developing other pathologies, including cardiovascular disease, renal
dysfunction, and dementias (Rewers, Zaccaro et al. 2004, Xu, Qiu et al. 2009, Seshasai,
Kaptoge et al. 2011, Association 2013). T2DM accounts for approximately 90% of all
diabetes diagnoses, affecting over 25 million individuals in the U.S. (Adeghate, Schattner
et al. 2006, Prevention 2011).
Obesity is not the only factor which can promote the development of T2DM. High
sugar consumption, lack of exercise, increased intake of partially hydrogenated fats, and
even residing in urban areas all increase the risk of developing T2DM (Riserus, Willett et
al. 2009, Abdullah, Peeters et al. 2010, Malik, Popkin et al. 2010, Lee, Shiroma et al.
2012). Hereditary factors can also influence the development of the disease. Mutations in
PPARγ, AKT2, TCF7L2, and the insulin receptor gene are associated with increased risk
of T2DM (Malecki 2005, Sladek, Rocheleau et al. 2007). Additionally, other medical
conditions can promote the development of T2DM, for example, women who develop
gestational diabetes are at a greater risk after pregnancy (Dornhorst and Rossi 1998,
Bellamy, Casas et al. 2009).
1.2.2 – Associated pathologies
T2DM is a metabolic disorder associated with insulin resistance, pancreatic β-cell
degeneration, and inappropriate signaling events (Insulin resistance, elevated glucagon
8

release, failure of glucose transporter recruitment, and reduced lipolysis to name a few),
which ultimately result in whole body glucose mishandling (Baker, Cross et al. 2011,
Accardi, Caruso et al. 2012, Bergman 2013). Insulin resistance primarily develops in
hepatocytes and skeletal muscle cells. Insulin resistance in hepatocytes or muscle cells
prevents the cells’ ability to uptake free glucose. Additionally, elevated glucagon release
from alpha-islets promotes mobilization of glycogen stores in the liver and
gluconeogenesis (D'Alessio 2011). This dysfunctional glucose handling results in highly
variable and uncontrolled blood glucose levels, and leaves the body prone to disease.
As blood glucose levels remain high for long periods of time endothelial cells
lining the walls of the vasculature take up excessive quantities of these sugars. As result
more glycoproteins are generated on the surface of these cells promoting the generation
of advanced glycation end-products (AGEs) which damage the underlying basement
membrane, making it weaker (Rahman, Rahman et al. 2007, Cade 2008). These vascular
changes can be classified as microvascular, in dealing with smaller structures such as
capillaries, or macrovascular which affect larger vessels (Clark and Lee 1995, Cooper,
Bonnet et al. 2001).
Microvascular pathology can result in the failure of major organ systems. For
example, diabetic retinopathy (the most common cause of blindness in the non-elderly) is
characterized by hemorrhages in the retina or edema of the macula (Orchard, Dorman et
al. 1990, Sheetz and King 2002). Similarly, in diabetic nephropathy the kidneys can
develop thickening of glomerular basement membranes, undergo hyperfiltration, develop
albuminuria, and end-stage renal disease before progressing to complete kidney failure
(Brenner, Cooper et al. 2001, Chen, Hong et al. 2001, Drummond, Mauer et al. 2002).
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Peripheral neuropathy can also be associated with microvascular abnormalities, which
may result in thickening of the basement membrane, demyelination of neurons,
endoneurial hypoxia (Young, Veves et al. 1992, Ibrahim, Harris et al. 1999).
Macrovascular changes can be just as deleterious, as changes to the seen in
microvascular pathologies. Cardiovascular disease is the leading cause of death in those
with T2DM. T2DM patients have the same risk of myocardial infarct as non-diabetic
individuals who have suffered previous infarcts (Laakso 1999, Nazimek-Siewniak,
Moczulski et al. 2002). This effect can be a result of high LDL cholesterol, low HDL
cholesterol, hypertension, and high triglyceride levels observed in T2DM which can lead
to atherosclerosis (Lehto, Ronnemaa et al. 1997, Facchini, Hua et al. 2001, Beckman,
Creager et al. 2002, Reusch and Draznin 2007). Cardiovascular disease isn’t the only
result of macrovascular insult associated with T2DM. The development of
cerebrovascular disease is 200-300% higher in patients with T2DM than those without,
and commonly results in ischemic strokes (Muntean, Mitrea et al. 2012).
1.2.3 – Influences of Obesity and T2DM on Neurodegeneration
T2DM contributes to approximately 20% of all cases of cerebrovascular disease
(Stegmayr and Asplund 1995, Tuomilehto, Rastenyte et al. 1996). T2DM patients with
cerebrovascular disease are more likely to die from an ischemic event, and those who do
survive are more likely to suffer from a disability (Haheim, Holme et al. 1995,
Elneihoum, Goransson et al. 1998, Megherbi, Milan et al. 2003, Ribo, Molina et al.
2005). Aside from the neurons and glial cells killed directly by an ischemic event, the
subsequent

fallout

(hypoxia induced cell

10

death,

inflammation, excitotoxicity,

accumulation of reactive oxygen species, etc.) makes surviving cells more susceptible to
death, leaving the individual more likely to develop dementia (Mattson, Duan et al. 2001,
Roman 2003). Large epidemiological cohort studies put the chance of individuals
developing dementia after stroke at five to nine times greater than the general population
(Tatemichi, Desmond et al. 1992, Tatemichi, Paik et al. 1994, Kokmen, Whisnant et al.
1996). Additionally, high hip-to-waist ratio and poor diet, characteristics associated with
T2DM, independently increase risk of stroke (O'Donnell, Xavier et al. 2010).
The Rotterdam Study explored the effects of T2DM in a large cohort of
individuals and revealed 8.8% of dementia cases were likely a result of T2DM (Ott, Stolk
et al. 1999). The authors in this study proposed that AGE generation in T2DM may play
an important role in disease development as AGE receptors are increased in the AD brain
(Yan, Chen et al. 1996, Munch, Schinzel et al. 1998, Ott, Stolk et al. 1999). Since the
Rotterdam Study other studies have implicated other mechanisms which may contribute
to neurodegeneration in T2DM. Insulin has been shown to protect primary rat neurons
from apoptosis, a process which is less likely to occur in the insulin resistant brain
(Tanaka, Sawada et al. 1995). Additionally, intact insulin receptor signaling is associated
with increased water-maze performance in rats (Zhao, Chen et al. 1999). High fat diet
and excessive weight gain promote the generation of ceramides in hepatocytes. These
lipid species are highly neurotoxic and easily cross the blood brain barrier (Lyn-Cook,
Lawton et al. 2009). Though the effects of insulin have been thoroughly explored in
relation to neurodegeneration, there are other major hormones which undergo huge
changes in disease.
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1.3 – Leptin
1.3.1 – Background and Signaling
Leptin is an adipokine released from white adipose tissue, and serum levels
correlate to body fat content. Leptin and its effects were discovered by the Jackson
Laboratories when a mouse line with mutations in the ob gene was found to be obese due
to an insatiable appetite (Ingalls, Dickie et al. 1950). Following this discovery, another
obese mouse line with a mutation in the db gene was discovered (Hummel, Dickie et al.
1966). Further analysis of the ob and db genes revealed the ob gene codes for leptin itself
and the db gene codes for the leptin receptor (Coleman 1978). Both of these lines are
hyperphagic, hyperglycemic, and display elevated plasma insulin and develop frank
diabetes as early as weaning (Coleman 1978).
The leptin receptor is highly expressed in the hypothalamus, and signaling
through the receptor modulates energy expenditure and satiety (Ahima, Prabakaran et al.
1996). Leptin secretion occurs according to circadian cues, being released mostly at night
to suppress hunger signals while sleeping (Sinha, Ohannesian et al. 1996, Licinio,
Mantzoros et al. 1997). Upon activation of the leptin receptor Janus Kinase and Signal
Transducer and Activator of Transcription (JAK/STAT) and PI3K signaling cascades are
activated (Figure 1.4) (Bates, Stearns et al. 2003). Upon activation STAT translocates to
the nucleus where it regulates expression of satiety signals and energy expenditure
(Myers, Cowley et al. 2008).
Interestingly, multiple isoforms of the leptin receptor are found throughout the
brain, and yet little is known about leptin’s role outside of canonical hypothalamic energy
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regulation (Tartaglia, Dembski et al. 1995, Chen, Charlat et al. 1996, Cioffi, Shafer et al.
1996, Lee, Proenca et al. 1996).
1.3.2 – Neuroprotective Effects and Leptin Resistance
Recent evidence suggests leptin may play a role outside of basic metabolic
reglation. In 2009 Lieb et. al. found plasma leptin levels positively correlated with
memory and cognition and negatively correlated to incidence of dementia (Lieb, Beiser et
al. 2009). In a study by the AD Neuroimaging Initiative (ADNI), approximately 70% of
individuals with mild cognitive impairment (MCI) display significantly decreased plasma
leptin levels, half of these individuals also carry the Apolipoprotein-E4 (APOE-ε4) allele
(Johnston, Hu et al. 2014). Administration of leptin to transgenic mouse models of AD
reduces the development of both amyloid and tau pathology while also improving
cognitive performance (Fewlass, Noboa et al. 2004, Greco, Bryan et al. 2009, Greco,
Bryan et al. 2010). A better understanding of the underlying mechanisms which impart
these neuroprotective effects is highly sought after.
The leptin receptor is expressed throughout the brain and is highly expressed in
the hippocampus, piriform cortex, cerebellum, and especially high in the reward centers
of the ventral tegmental area and substantia nigra (Elmquist, Bjorbaek et al. 1998,
Figlewicz, Evans et al. 2003). Leptin promotes NMDA mediated synaptic plasticity
within the rat hippocampus, a mechanism which is thought to be activated via PI3K,
MAPK, and Src kinase signaling cascades (Shanley, Irving et al. 2001). Additionally,
leptin has been shown to protect dopaminergic neurons from a mouse model of
dopaminergic cell death via MAPK signaling (Weng, Signore et al. 2007). The same
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study showed leptin’s effects to be blocked when JAK2 and GRB2 (downstream
signaling transducers) were knocked down, preventing MAPK activation. Leptin
treatment at physiological concentrations increases serine-9 phosphorylation of GSK-3β,
a potent tau kinase, which inhibits GSK-3β enzymatic activity (Valerio, Ghisi et al.
2006). Interestingly, insulin also promotes the inactivation of GSK-3β, and therefore
reduce tau phosphorylation, but only at concentrations 100 greater than is required of
leptin to see the same effects (Lesort, Jope et al. 1999, Planel, Tatebayashi et al. 2007,
Greco, Sarkar et al. 2008).
Chronic obesity results in gradual desensitization of the leptin receptor to its
ligand. The mechanism by which this occurs is unknown, but it is the primary reason
leptin itself cannot be used as a therapeutic. One proposed hypothesis suggests negative
feedback cascades, which function via suppressor of cytokine signaling-3 (SOCS-3),
which inhibits the tyrosine phosphorylation of the receptor, preventing its activation
(Bjorbaek, El-Haschimi et al. 1999, Myers, Cowley et al. 2008). Another proposed
mechanism suggests the ability of leptin to cross the blood brain barrier is impaired,
preventing leptin from accessing hypothalamic leptin receptors (Uotani, Bjorbaek et al.
1999, Myers, Cowley et al. 2008). It is important to better understand the mechanisms
involved in leptin resistance, as reduced leptin signaling will negate the neuroprotective
effects of leptin.
1.4 – Rationale of Study
Obesity and T2DM impart increased risk for developing neurodegenerative
disease directly via dysfunctional signaling events, or indirectly through other pathologic
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events associated with the disease states. With the global rise in obesity and T2DM rates
investigation into the underlying etiology of these mechanisms is warranted. It is not
clear as to how obesity and T2DM promote pathogenesis or exactly what types of
pathology are impacted.
Recently, out lab showed that total Aβ in the brain levels negatively correlate with
plasma leptin levels. These results are supportive of other observations in the literature
(Morrison 2009). Interestingly, it is known that leptin resistance occurs in chronically
obese individuals, and it is probable that the neuroprotective effects of leptin are lost.
Therefore, the purpose of this study was to determine if leptin resistance, and the
associated obesity and diabetes, may impart an increased chance for developing
neurodegenerative disease. The results of this study will advance the field of
neurodegeneration and have important implications for obesity, T2DM, AD, and
tauopathies.
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Figure 1.1 APP Processing and Generation of Toxic Beta-Amyloid.
APP is a transmembrane protein which can be processed by either the non-amyloidogenic
or amyloidogenic pathways. Upper panel: During non-amyloidogenic processing, an
enzymatic activity called α-secretase cleaves APP (1) to generate a soluble N-terminal
fragment (sAPPα) and an 83 amino acid C-terminal fragment (C83). Next, the γ-secretase
complex (2), with PS1 acting as the catalytic subunit, cleaves the C83 fragment within
the transmembrane domain, releasing a secreted peptide known as P3. Lower panel: In
amyloidogenic processing, an enzymatic activity called β-secretase (1) cleaves APP to
generate different soluble N-terminal (sAPPβ) and C-terminal (C99) fragments. Cleavage
of the C99 fragment by γ-secretase (2) results in the generation of the Aβ peptide.
Processing of APP in either pathway results in the production of an APP intracellular
domain (AICD) with poorly defined function.
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Figure 1.2 A Simplified Overview of the Amyloid Cascade Hypothesis.
One version of the amyloid cascade hypothesis proposes that the increase in Aβ
biosynthesis, resulting from alterations in APP processing, drives AD pathogenesis.
Aggregation of Aβ results in the formation of neuritic plaques, increased oxidative stress,
and NFT formation, resulting in neurodegeneration. Other variations are possible. For
example, altered clearance of Aβ likely plays a significant role in disease progression.
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Figure 1.3 Tau Hyperphosphorylation Leads to Neurodegeneration.
Tau is a cytosolic microtubule stabilizing protein. Under normal conditions tau’s
phosphorylation state is dynamic, undergoing constant cycling of phosphorylation and
dephosphorylation to stabilize microtubules. If tau becomes hyperphosphorylated it will
dissociate from microtubules, bind to other hyperphosphorylated species, and form higher
order structures, such as oligomers, filaments, and NFTs.
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Figure 1.4 Leptin Signaling.
Leptin binds to its receptor, initiating a phosphorylation cascade, activating the Janus
Kinase (JAK). JAK can initiate a cascade of signaling events via the PI3K/AKT and
MAPK pathways and alter gene expression by phosphorylating the Signal Transducer
and Activator of Transcription (STAT). Upon STAT phosphorylation it homodimerizes
and translocates to the nucleus where it alters gene expression, promoting increased
energy expenditure and satiety.

Copyright © Thomas L. Platt 2014
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CHAPTER 2: General Materials and Methods
2.1 – Cell Lines and Lysis Protocol
Human SH-SY5Y neuroblastoma cells were purchased from ATCC, and were
cultured in Dulbecco’s Modified Eagle Media (DMEM; Hyclone; Thermo Scientific,
Waltham, MA). Human H4 neuroglioma cells stably overexpressing APP(KM670/671NL)
mutant were grown in Opti-MEM (Invitrogen; Life Technologies, Carlsbad, CA) with
200 µg/mL hygromycin as a selective agent. HEK293 human embryonic kidney cells
with Tau(P301L) mutant, a gift from Dr. Chad Dickey, were grown in DMEM with 200
µg/mL G418 selective agent. All culture media was supplemented with 10% fetal bovine
serum (FBS; HyClone) and 1% 5,000 µg/mL Penicillin-Streptomycin (Penn-Strep; Lonza
Group, Basel, Switzerland). All cell lines were grown in a humidified incubator at 37ºC
with 5% CO2. Cells were cultured and maintained in cell culture hood. Other specific
details regarding culturing techniques will be discussed for each set of experiments.
To preserve cell lines plugs of cells were cryoprotected and frozen at a density of
approximately of 106 cells per vial. Cells were grown to ~70% confluence in T-75 flasks
(#BD353136; Falcon; Corning Inc., Corning, NY;), media was removed, cells rinsed in 5
mL phosphate-buffered saline (PBS), then incubated in 0.25% w/v trypsin (Gibco; Life
Technologies) in the incubator at 37ºC for approximately 5 minutes. Once completely
dissociated with the flask cells were transferred to a 15 mL conical tube and centrifuged
at 500 x g for 5 minutes. Trypsin was aspirated from the pellet, the cells were
resuspended in 1x PBS to rinse any remaining trypsin from the cells, and then spun again
at 500 x g for 5 minutes. The PBS was aspirated and the pellet was resuspended in 6 mLs
of a 90% FBS (HyClone) 10% DMSO cryopreservation solution. 1 mL of the resulting
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suspension was aliquoted into six cryopreservation vials to have each aliquot containing
one mL of a 1,000,000 cells/mL suspension. Vials were frozen in an isopropanol chamber
at -80ºC overnight, and then transferred to liquid nitrogen the following day.
Rat hippocampal neurons were provided to us by Irena Artiushin from Dr. Chris
Norris’ lab. Neurons were collected from E18 Sprague Dawley rat pups and plated on
poly-L-lysine coated 35 mm dishes in Minimum Essential Media (MEM) with 10% FBS
and 10% horse serum, and supplemented with 15 µg/mL 5-fluoro-2-deoxyuridine to
inhibit growth of non-neuronal cells. As with other cultures these cells were incubated in
a 37ºC incubator with 5% CO2. Cells were cultured for four weeks before they were used
in studies.
Prior to lysis, media was aspirated from wells and cells were rinsed in 1x PBS.
Cells were then incubated in chilled radio-immunoprecipitation assay (RIPA) buffer (150
mM NaCl/0.1% SDS/0.5% sodium deoxycholate/50 mM Tris-Base/1% Triton X-100; pH
8.0) with 1 x protease inhibitor cocktail (PIC; Amresco, Solon, OH), and (when
measuring phosphorylated proteins) 1 x phosphatase inhibitor cocktail (PhIC; EMD
Millipore, Billerica, MA). Plates were chilled on ice for ~10 minutes. Following lysis,
cell scapers (X) were used to remove any remaining adherent cells from each well. Cell
lysate was triturated and pipetted into 1.5 mL Eppendorf tubes and centrifuged at 20,000
x g at 4ºC for 5 minutes. The supernatant was removed for assay and the pellet discarded.
2.2 – Animal Husbandry, Metabolic Measures, and Behavioral Analysis
All husbandry and treatment procedures were conducted with prior approval of
the University of Kentucky’s Institutional Animal Care and Use Committee (IACUC;
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protocol # 2010-0673), in accordance with PHS guidelines. Leptin receptor deficient
mice were purchased from the Jackson Laboratory (B6.BKS(D)-Leprdb/J, stock # 000697,
hereafter referred to as db mice) and were housed two or three mice per cage with ab
libitum access to food and water on a 12 hour light/dark cycle. These founders were bred
to establish a colony. Approximately 10 days after birth tails snips were collected and
were used for genotyping by SNP-specific Taqman®-based qPCR using a Taqman®
genotyping kit (Applied Biosystems by Life Technologies; Grand Island, NY). All db
homozygous mice were monitored weekly, measuring each animal’s weight, coat
appearance, gait, and body condition score to identify any potential health issues. If any
adverse issue arose, the Division of Laboratory Animal Resources (DLAR) veterinary
technicians were contacted to inspect the mice and advise on treatment.
At different timepoints in each study group mice underwent metabolic testing by
performing glucose tolerance tests (GTTs) and/or insulin tolerance tests (ITTs). Six hours
before testing mice were removed from their home cages and placed into new cages
without access to food in a quiet procedure room. After a six hour fast, mice were
injected intraperitoneally with a bolus of either glucose (2g/kg body weight) or insulin
(0.75 U/kg body weight), depending on the metabolic test being performed. At 0, 15, 30,
60, and 120 minutes blood glucose was measured by taking a small drop of blood via tail
nick of each mouse. In case of adverse event, QuickStop coagulant was on hand to use in
case of excessive bleeding and a bolus of glucose (2g/kg bodyweight) was ready to
rescue any mice from the ITT. In the course of these experiments no adverse events
occurred which required rescuing. At the end of the test mice were placed into a new
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cage with a hopper of fresh food. The following day each animal was checked for any
complications related to the experiment.
Cognitive impairment was measured by performing a modified Morris Water
Maze (MWM) test. At the beginning of each test day mice were individually placed into
clean cages on heating pads to acclimate. After 20 minutes of acclimation mice were
introduced into a 134.5 cm diameter pool, and were given 60 seconds to find a
submerged 11 cm diameter circular platform. Visual cues were placed around the
platform to provide spatial reference to allow the mice to remember where the platform
was. If mice did not find the platform within the 60 seconds, they were placed on the
platform for 15 seconds to acquaint them with the platform location. Mice were given
five minutes of rest between trials. Mice were trained over a five day period using a
submerged platform running four 60-second trials each day. At the end of training on the
fifth day the platform was removed and a 60 second probe trial was performed. In the
probe trial the platform is removed and the time mice spend in the target quadrant
(quadrant where the platform was during the trials) and target zone (zone where the
platform was during the trials) as a measure of memory and learning. Additionally, after
the probe trial, a visual acuity trial was performed. In the visual acuity trial the platform
was moved to the opposite side of the pool and a small white marker placed on top of the
platform. All trials were captured using a video camera and analyzed with EthoVision XT
software (Noldus Information Technology, Leesburg, VA) to measure swim distance,
escape latency and swim velocity.
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2.3 – Tissue Collection and Processing
When mice were to be sacrificed a lethal dose of Beuthanasia-D (Schein-Plough
Animal Health, Union, NJ) was administered intraperitoneally and after signs of life were
no longer apparent animals were decapitated as a secondary means of euthanasia. The left
hemibrain was collected and drop-fixed in 10% saline-buffered formalin for
approximately a week, and then transferred to 1x PBS containing 0.05% sodium azide for
storage. The right hemibrain was immediately frozen on dry ice for future extraction.
Whole blood, attained from trunk bleeding after decapitation, was collected into EDTA
containing tubes and centrifuged at 1,500 x g for 10 minutes. After centrifugation the
plasma supernatant was pipetted off into 1.5 mL tubes and frozen on dry ice for future
analysis.
Frozen brain tissue (from mice or humans) was homogenized with an AHS200
PowerMax polytron (VWR, Radnor, PA) in 1x RIPA with PIC (Amresco) and PhIC
(EMD Millipore) at 1mL per 200µg tissue. Insoluble material was separated by
centrifugation at 13,000 x g for 15 minutes at 4°C. Supernatants were transferred to 1.5
mL tubes and frozen at -80ºC, and the pellet discarded. The protein concentrations of the
supernatants were calculated by bicinchoninic acid (BCA) assay (Pierce, Rockford,
Illinois).
2.4 – Statistical Analysis
All data were analyzed using SPSS software version 22 (IBM; Armonk, New
York) or Prism version 5 (GraphPad Software, La Jolla, CA). Group comparison data
were analyzed by general linear model ANOVA and post-hoc comparisons made using
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Tukey-HSD or Dunnett’s tests. When analyzing human data, age, gender, and PMI were
used as co-varying factors. Correlations were analyzed as Pearson’s product test for
parametric analysis or Spearman’s rank order test for non-parametric analysis. Repeated
measures were analyzed using linear mixed models with time as categorical predictors.
Specific statistical information and procedures are outlined in figure legends.

Copyright © Thomas L. Platt 2014
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CHAPTER 3: Tau and Neurodegenerative Disease
Portions of this chapter are reprinted with permission from:
Holler CJ, Davis PR, Beckett TL, Platt TL, Webb RL, Head E, Murphy MP. Bridging
Integrator 1 (BIN1) Protein Expression Increases in the Alzheimer’s Disease Brain and
Correlates with Neurofibrillary Tangle Pathology (Accepted)
Farr SA, Ripley JL, Sultana R, Zhang Z, Niehoff ML, Platt TL, Murphy MP, Morley JE,
Kumar V, Butterfield DA (2014).Antisense oligonucleotide against GSK-3β in brain of
SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement
of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med.
(2014) 67:387-95
3.1 – INTRODUCTION

Tau plays an interesting role in neurodegeneration. Tau is associated with many
forms of neurodegenerative disease and is likely the sole cause of degeneration in some
of those diseases. However, aside from genetic mutation, tau rarely initiates the disease
process and typically results from other insult. For example, dementia pugilistica is a
tauopathy which results from repeated brain injury and was first described in boxers
(Mendez 1995, Erlanger, Kutner et al. 1999). The amyloid cascade hypothesis of AD
posits that Aβ is the central insult which initiates the development of tau pathology
(Selkoe 1991, Hardy and Higgins 1992).
Though no cure for tauopathies exists, several groups suggest tauopathies can be
attenuated by inhibiting GSK3β activity. GSK3β is a proline-directed serine/threonine
protein kinase that is involved in a variety of pathways modulating cellular metabolism
and gene expression (Welsh and Proud 1993, Grimes and Jope 2001, Turenne and Price
2001). GSK3β was first discovered to inactivate glycogen synthase, and has since been
shown to play a key role in glycogen metabolism (Embi, Rylatt et al. 1980, Woodgett
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1990). GSK3β is highly expressed in the brain and is mainly found in neurons and
astrocytes (Woodgett 1990, Yao, Shaw et al. 2002, Perez-Costas, Gandy et al. 2010).
Knocking out GSK3β is embryonic lethal as shown in mice (Hoeflich, Luo et al. 2000).
This lethality is likely a result of GSK3β’s important role in development. GSK3β
signaling regulates transcriptional expression of key developmental proteins, regulates
apoptotic signals, and axonal formation (Hoeflich, Luo et al. 2000, Kim, Zhou et al.
2006, Garrido, Simon et al. 2007, Liang and Chuang 2007, Kim, Wang et al. 2009,
Mines, Beurel et al. 2011). GSK3β is constitutively active and is negatively regulated by
Wnt, insulin, and leptin signaling pathways which phosphorylate GSK3β at the serine-9
residue (Stambolic and Woodgett 1994,

Saltiel and Kahn 2001). Serine-9

phosphorylation blocks entry of primed phosphorylation substrates, preventing GSK3β
kinase activity (Harwood 2001). Phosphorylation of tyrosin-216 promotes GSK3β
activity (Hughes, Nikolakaki et al. 1993, Bijur and Jope 2001, Buescher and Phiel 2010).
Increased

GSK3β

activity

and

expression

has

been

implicated

in

neurodegenerative processes (Schaffer, Bertram et al. 2008). Inhibition of PI3K and
Wnt, key inhibitors of GSK3β, impairs learning and memory, and overexpression of
GSK3β inhibits the induction of long-term potentiation (LTP) and promotes long-term
depression (LTD) (Sanna, Cammalleri et al. 2002, Chen, Park et al. 2006, Hooper,
Markevich et al. 2007, Peineau, Taghibiglou et al. 2007).
Recent evidence suggests GSK3β plays a vital role in AD pathogenesis. Aside
from increased tau hyperphosphorylation, elevated GSK3β activity and the generation of
Aβ are tightly associated, though it is not clear if increased GSK3β activation results in
increased Aβ production or vice versa (Hernandez, Gomez de Barreda et al. 2010,
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DaRocha-Souto, Coma et al. 2012, Avrahami, Farfara et al. 2013, Reddy 2013). GSK3β
localizes with dystrophic neurites and NFTs, and displays increased activity within pretangle containing neurons and frontal cortex of AD brains, and expression of GSK3β is
elevated within the hippocampus of AD patients (Shiurba, Ishiguro et al. 1996, Pei, Braak
et al. 1999, Blalock, Geddes et al. 2004). Additionally, a polymorphism in GSK3β has
been implicated as a promoter of late onset AD (Mateo, Infante et al. 2006).
Enzymatic dysregulation of tau kinases are not the only ways in which tau
pathology can be initiated. Alternative splicing of the tau gene yields 6 tau isoforms, half
with 3 microtubule binding domains (3R) and the other half with 4 microtubule binding
domains (4R) (Goedert, Spillantini et al. 1989, Goedert, Spillantini et al. 1989). Normal
adult tissues contain an equal distribution of 3R and 4R isoforms and unequal 3R to 4R
ratios have been observed in tauopathies (Goedert, Spillantini et al. 1989, Andreadis,
Broderick et al. 1995). Unequal splicing of tau exon 10 results in an imbalance of 3R and
4R containing isoforms (Goedert, Spillantini et al. 1989, Goedert and Jakes 1990,
Andreadis, Brown et al. 1992). 4R:3R ratios are found to be elevated in several
tauopathies such as corticobasal degeneration, AD, PSP, and FTD (Flament, Delacourte
et al. 1991, Sergeant, Wattez et al. 1999, Tolnay, Sergeant et al. 2002).
The mechanism by which disruption of the equimolar ratio of 3R to 4R isoforms
promotes pathology is unknown. 4R isoforms more readily bind microtubules and it is
possible this increased binding affinity could promote tau’s ability to aggregate (Goedert
and Jakes 1990, Panda, Samuel et al. 2003). It is interesting to note that many animals
which don’t develop tauopathies, such as mice, express only 4R isoforms in the adult
brain (Lee, Cowan et al. 1988). However, when mice express all six human tau isoforms,
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both 3R and 4R, with no mutations to promote pathogenesis, tau hyperphosphorylation
and aggregation occurs (Andorfer, Kress et al. 2003). These findings suggest the presence
and interactions of both tau isoforms promote pathogenesis. In fact, a recent study
revealed equimolar concentrations of 3R and 4R tau isoforms reduces tau fibrilization,
whereas ratios with higher levels of 4R isoforms promoted tau fibrilization (Adams,
DeTure et al. 2010).
Myotonic dystrophy (DM) is a disease in which tau pathology develops due to
dysfunctional splicing events (Kiuchi, Otsuka et al. 1991, Vermersch, Sergeant et al.
1996). Type 1 DM consists of a trinucleotide repeat CUG in the 3’ untranslated region of
myotonic dystrophy protein kinase (DMPK) (Ashley and Warren 1995). Type 2 DM
consists of a similar tetranucleotide CCTG repeat in the cellular nucleic acid binding
protein (CNBP) within intron 1 of ZNF9 (Liquori, Ricker et al. 2001). Traditionally these
diseases are associated with muscle wasting but have many other associated symptoms as
a result of splicing abnormalities (Ashley and Warren 1995, Korade-Mirnics, Babitzke et
al. 1998, Day, Roelofs et al. 1999, Udd, Meola et al. 2011). The mRNA repeats in DM
act as gain of function mutations, resulting in sequestration of splicing machinery to
repeat regions, leaving other transcripts which require splicing unprocessed (Mankodi,
Logigian et al. 2000). In type 1 DM a reduction in tau exon 2 and an increase in exon 10
inclusion, and a reduction in exon 2 and 3 inclusion in type 2 DM (Sergeant, Sablonniere
et al. 2001, Maurage, Udd et al. 2005, Dhaenens, Tran et al. 2011). It is likely disruption
of normal tau isoform ratios result in tau pathogenesis.
In tauopathies, several forms of tau aggregates exist: oligomers, PHFs, NFTs, and
many intermediates. The number of NFTs and severity of phenotype are closely
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correlated,

therefore,

it

has

traditionally

been

believed

that

NFTs

induce

neurodegeneration in tauopathies (Bierer, Hof et al. 1995, Santacruz, Lewis et al. 2005).
Contrary to this belief, transgenic animal models overexpressing non-mutant human tau
do not develop NFTs yet neurodegeneration still occurs (German, Quintero et al. 2001,
Wittmann, Wszolek et al. 2001, Andorfer, Acker et al. 2005). Additionally, NFTs are
detected in healthy individuals and it has been posited that NFTs can persist for up to 30
years in neurons without inducing neurodegeneration. These data suggests NFTs may
play another role within the brain (Morsch, Simon et al. 1999).
It has been proposed that NFTs actually play a neuroprotective role and may not
be toxic to cells (Lee, Perry et al. 2005, Congdon and Duff 2008). Lee et al. propose that
NFT formation is a compensatory mechanism against reactive oxygen species, where in
response

to

oxidative

stress

tau

kinases

become

activated

and

promote

hyperphosphorylation of tau and NFT formation (Lee, Perry et al. 2005). Additionally,
some have suggested other tau species are cytotoxic whereas NFTs are benign. Tian et al.
demonstrated that 4R trimeric tau is toxic to SH-SY5Y cells while monomers and dimers
are not (Tian, Davidowitz et al. 2013). Hippocampal injections of tau monomers,
oligomers, and tau fibrils into C57BL/6 mice demonstrated that oligomer injection
impaired recognition memory, induced synaptic loss, and resulted in neurodegeneration
(Lasagna-Reeves, Castillo-Carranza et al. 2011).
In this chapter we explore some of the aforementioned mechanisms to provide a
better understanding of tau pathogenesis. Utilizing antisense oligonucleotides we
inhibited expression of GSK3β and demonstrated that this reduction lowered levels of tau
phosphorylation. We demonstrated that protein expression is altered in the human DM
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brain, which indicates splicing abnormalities may promote pathogenesis. Finally, we
show that recombinant tau oligomers are toxic to both primary rat hippocampal neurons
and SH-SY5Y cells, further supporting the role of tau oligomers in neurodegeneration.
3.2 – METHODS
3.1 – Subjects
Human tissue samples were acquired from the NICHD Brain and Tissue Bank for
Developmental Disorders at the University of Maryland, three myotonic dystrophy (DM)
cases (two DM type-1 and one DM type-2) and three controls age matched controls.
3.2 – Animals
SAMP8 mice, a model of accelerated aging with memory deficits and amyloid
deposition, were aged to 11 months of age in accordance with previously described
husbandry methods (Butterfield and Poon 2005). Husbandry of these mice was performed
by the lab of Dr. Alan Butterfield’s lab. Isofluorane (4%) anesthetized mice received
cortical stereotaxic injections of GSK antisense oligonucleotides (GAO; n = 9) or control
scrambled antisense oligonucleotides (RAO; n = 7) once a week for three weeks.
Stereotaxic injection coordinates were 0.5 mm posterior to the bregma, 1.0 mm to the
right of the sagittal suture, and a depth of 2.0 mm. Frozen cortical tissue was
homogenized in lysis buffer (320 mM sucrose, 1 mM Tris-HCl, 0.098 mM MgCl2, 0.076
mM EDTA, PIC and PhIC, pH 7.4) with a polytron. Homogenate was centrifuged at 3000
x g at 4ºC for 5 minutes. The resulting supernatant was then centrifuged at 10,000 x g at
4ºC for 10 minutes and the supernatant (cytosolic fraction) was transferred to 1.5 mL a
Eppendorf tube and frozen at -80ºC.
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3.3 – Western Blot Analysis
The protein concentrations of the supernatants were measured by BCA protein
assay (Pierce, Rockford, Illinois). SDS-PAGE samples were prepared in Laemmli sample
buffer (2% sodium dodecyl sulfate [SDS], 10% glycerol, 62.5 mM Tris-HCL pH 6.8, and
0.002% bromophenol blue) with 10% β-mercaptoethanol (BME), and heated to 65ºC for
15 minutes before loading onto a gel. Twenty-five µg protein per sample were loaded
into 4-12% Bis-Tris Criterion precast SDS-PAGE gels in MOPS running buffer (BioRad, Hercules, California). The proteins were electrically transferred to 0.2 µm
nitrocellulose membrane at 1 ampere for 60 minutes. Following transfer the membranes
were blocked overnight in 1% BSA and 2% BlockAce (AbD Serotec, Raleigh, North
Carolina) in Tris-Buffered Saline (TBS) at 4ºC.
Membranes were incubated for 1 hour in primary antibody diluted in 5% non-fat
dried milk in Tris-Buffered Saline with 0.1% Tween-20 (TBST), pH 7.4, at room
temperature. Following 1 hour incubation in primary antibody, blots were rinsed three
times in TBST buffer for 10 minutes each, then incubated in horseradish peroxidase
(HRP) conjugated rabbit anti-mouse or donkey anti-rabbit secondary antibodies
(Rockland Immunochemicals Inc.; Gilbertsville, Pennsylvania, 1:10,000) diluted in 5%
non-fat dried milk in TBST for one hour at room temperature on an orbital shaker.
Following secondary antibody incubation blots were rinsed three times in TBST for 10
minutes, followed by two rinses in TBS to remove any remaining Tween-20 from the
membranes. Membranes were then incubated with Super Signal West Dura
chemiluminescent detection substrate (Pierce, Rockford, Illinois) for 5 minutes, and then
exposed to autoradiographic film (ISC BioExpress; Fisher Scientific). Films were
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developed by Kodak X-OMAT 2000A film processor (Eastman Kodak Company,
Rochester, NY) Films were scanned, and densitometric analysis was performed using
Image J software (NIH; www.imagej.net).
Primary antibodies used were as follows: AT180 (Koike, Green et al. 2010,
Martinez-Coria, Green et al. 2010, van Eersel, Ke et al. 2010) for pThr-231 tau
(#MN1040, Pierce, 1:1000), HT7 (Koike, Green et al. 2010, Martinez-Coria, Green et al.
2010, van Eersel, Ke et al. 2010) for total tau (#MN1000, Pierce, 1:1000), monoclonal
anti-BIN1 99D (#B9428, Sigma-Aldrich, St. Louis, MO, 1:1000), rabbit monoclonal
anti-BACE1 D10E5 (5606S; Cell Signaling, Danvers, MA, 1:1000) and anti-GAPDH
(ab9385, Abcam; Cambridge, MA, 1:5000). CNBP was detected using an in-house rabbit
polyclonal antibody (1:5000) (Niedowicz, Beckett et al. 2010).
3.4 – Recombinant Tau Production and Oligomerization
Full-length recombinant tau (tau-441 2N4R) was transformed into One Shot®
Efficiency DH5α-T1R chemically competent E. coli (C6010-03; Life Technologies)
according to the manufacturer’s instructions and plated on LB agar supplemented with 50
μg/L carbenicillin (C3416; Sigma-Aldrich). Cells were grown in a shaker at 37ºC
overnight in 250 mL LB agar. This overnight culture was used to inoculate a new culture
for protein over expression. Protein expression was induced with 0.5 mM IPTG (I5502;
Sigma-Aldrich) for 3 hours and then cells were harvested by centrifugation at 2,150 x g at
4ºC for 10 minutes. The pellet was rinsed in 50 mL of 25 mM Tris-HCl, pH 8.0, and
centrifuged at 2,150 x g at 4ºC for 10 minutes, the supernatant removed, and the pellet
frozen at -20ºC.
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To purify the expressed tau-441 protein the pellet was resuspended in lysis buffer
(20 mM MES, 50 mM NaCl, 1 mM MgCl2, 2 mM EGTA, 0.1 mM EDTA, 5 mM DTT, 1
mM PMSF, 10 µg/mL leupeptin, and 10 µg/mL pepstatin). Cells were lysed by
sonication by 10 pulses, 0.5 seconds per pulse, at 100 W on ice. NaCl was added to the
lysate to a concentration of 0.5 M and heated to 95ºC for 10 minutes. The lysate was
centrifuged at 40,000 x g at 4ºC for 45 minutes. The supernatant was twice dialyzed with
a cation exchange buffer A (20 mM MES, 50 mM NaCl, 1 mM MgCl2, 2 mM EGTA, 0.1
mM EDTA, 2 mM DTT, 0.1 mM PMSF) to remove the high concentration of NaCl.
Cation exchange resin sulfopropyl sepharose 6 was activated with a high salt buffer (100
mM MES, 1M NaCl, 1 mM MgCl2, 2 mM EGTA, 1 mM EDTA) for one hour, then
equilibrated with cation exchange buffer A to remove the high concentration of salt. The
protein was then bound to the resin by rocking the resin with the supernatant at 4ºC for
one hour. The resin was then washed twice with cation exchange buffer A and loaded
into a column where it was washed with additional cation exchange buffer A. A linear
gradient was run against buffer B (20 mM MES, 50 mM NaCl, 1 mM MgCl2, 2 mM
EGTA, 0.1 mM EDTA, 2 mM DTT, 0.1 mM PMSF, 0.6 M NaCl). Fractions were
collected and tested by assaying for gel filtration. Briefly, the protein was dialyzed
against PBS and 1 mM DTT and run on a Superdex 200 gel filtration column at 1
mL/min. Purified Tau-441 was stored in 20 mM Tris, 100 mM CaCl2, 2 mM MgCl2, and
1 mM DTT, pH 7.5.
To induce tau 441 oligomerization DTT was added to purified tau-441 to a
concentration of 4 mM and incubated at 37ºC for 30 minutes. The solutions were heated
at 95ºC for 8 minutes. After cooling, DTT was added to a concentration of 1 mM, and the
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protein concentration was measured by BCA. Tau-441 was incubated in a 1:1 ratio with
HFIP at 37ºC for 1 hour. Eighty uLs of ddH2O was added to each sample to adjust to a
final concentration of 2-5 µM per samples and incubated at 37ºC for 1 hour.
Oligomerized tau samples were then incubated at RT overnight.
3.5 – Tau Oligomer Toxicity Assay
Primary rat hippocampal cultures were treated in duplicate with increasing
concentrations of tau oligomers (0, 25, 50, and 100 nM, based on total tau concentration).
Cultures were maintained in a humidified incubator at 37ºC with 5% CO2 with 1.7 mL of
culture media. 100 uL samples of media were collected at 2, 3, 7, 24, and 48 hour
timepoints. Media was centrifuged at 250 x g for 5 minutes. LDH activity levels were
measured using the Cytoscan™-LDH Cytotoxicity Assay Kit (#786‐210; G-Biosciences,
St. Louis, MO). Briefly, 50 uL of centrifuged media supernatant was added to 50 µL of
50 µL substrate mix (G-Biosciences) in a 96 well flat bottom plate (#P7366; Nunc;
Sigma-Aldrich) and incubated at room temperature on an orbital shaker for 30 minutes.
After 30 minutes stop solution (G-Biosciences) was added and the absorbance of each
well was measured at 490 nm.
SH-SY5Ys were treated similarly with some minor changes. Cells were grown in
96 well tissue culture plates in DMEM with 10% FBS and 1% PS. Once the cells reached
~70% confluence they were treated with varying concentrations of tau oligomers (0, 10,
50, 100, and 200 nM, based on total tau concentration). Six control wells containing cells
were left untreated for each timepoint. At 24, 48, and 72 hours 3 untreated wells were
lysed with Lysis Solution (G-Biosciences) to use as controls representing maximum cell
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death. The plates were centrifuged at 250 x g for 5 minutes and 50 uL of the supernatant
was transferred to a fresh 96 well plate. Fifty uL of fresh media were added to 6 empty
wells of the 96 well plate to use as spontaneous controls. Fifty uL of substrate mix (GBiosciences) was added to each well and the plate was incubated for 30 minutes at room
temperature on an orbital shaker. After 30 minutes stop solution (G-Biosciences) was
added and the absorbance of each well was measured at 490 nm. The median absorbances
from lysed wells (Maximum LDH Release) and fresh media containing wells
(Spontaneous) were used in cytotoxicity calculations. Percent cytotoxicity was
determined using the following formula: ((Experimental (OD490) – Spontaneous (OD490))
/ Maximum LDH Release (OD490)) x 100.
3.3 – RESULTS
3.3.1 – GSK3β Knock-Down Reduces Tau Phosphorylation
Many studies have tried to reduce GSK3β activity with pharmacologic inhibitors,
such as lithium (Engel, Goni-Oliver et al. 2006). Lithium and other inhibitors, however,
have many mechanisms of action; therefore we specifically knocked-down GSK3β
expression using antisense olgionucelotide technology in the cortex of SAMP8 mice
(Figure 3.1). Overall, a significant reduction of tau phosphorylation was observed at the
threonine-231 (AT180) epitope in SAMP8 mice treated with the GSK3β antisense
oligonucleotides compared to random antisense oligonucleotide treated animals (p ≤
0.05). This suggests that direct reduction in GSK3β can reduce pathological T231
hyperphosphorylation associated with tauopathies.
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3.3.2 – Protein Expression in Myotonic Dystrophy (DM)
To determine how DM mechanisms may alter expression of AD related proteins
we obtained a small set of human samples and probed them by western blot. As expected
we observed striking differences in tau protein in DM cases compared to controls, with
different banding patterns indicating differential isoform expression, likely due to
disrupted splicing mechanisms (Figure 3.2). Additionally, total levels of tau were
significantly reduces as determined by densitometric analysis (p ≤ 0.01). BACE1, which
is involved in amyloidogenic processing was significantly increased compared to controls
(p ≤ .01). Bridging Integrator 1 (BIN1), which has been implicated to be a major genetic
locus associated with AD susceptibility, trended to be expressed at higher levels
compared to controls (p ≤ 0.08)(Harold, Abraham et al. 2009, Lambert, Heath et al. 2009,
Seshadri, Fitzpatrick et al. 2010). Expression of CNBP was also significantly increased
compared to controls (p ≤ 0.01). The increase in CNBP expression is of note, as ZNF9,
the gene which codes for CNBP, is implicated in DM2, but the altered expression
observed in DM1 cases indicates it likely plays a larger role in the disease process.
3.3.3 – Tau Oligomers are Highly Cytotoxic
To determine the impact of different tau assemblies and conformational structures
on cell viability we treated SH-SY5Y neuroblastoma cells with tau monomers, fibrils,
and oligomers. Toxicity, as measured by LDH release, was only detected upon
oligomeric tau treatment (Figure 3.3A; p ≤ 0.05). Tau oligomers have been implicated as
the most toxic tau species. Primary rat neurons cultured from the hippocampus and SHSY5Y cells were treated with increasing concentrations of tau oligomers. LDH activity
was then measured as a marker of cytotoxicity from the media of these cells. Primary
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neurons were treated in duplicate as we were limited by the number of plates we could
use, but a clear rise in LDH activity was detected (Figure 3.3B). SH-SY5Y cells treated
with oligomers display significantly higher levels of LDH activity over time (p ≤ 0.001),
with 35% cytotoxicity measured with 200 nM tau oligomers at 48 hours post treatment
(Figure 3.3C; p ≤ 0.001). These data indicate that tau oligomers are highly cytotoxic to
both primary neurons and cultured cell lines.
3.3.4 – Pathology in Human Diabetic and AD Cases
As T2DM has been associated with increased risk of dementia we wanted to
determine if AD patients with T2DM developed more severe pathology than non-diabetic
AD patients. We analyzed neuropathology data from control, diabetic, AD, and diabetic
AD cases acquired from the Sanders-Brown neuropathology core (Table 3.1).
Interestingly, diabetic AD cases displayed significantly reduced tangle counts throughout
the brain (except in the occipital lobe) compared to non-diabetic AD cases (Figure 3.4;
Frontal: p ≤ 0.001, Temporal: p ≤ 0.001, Parietal: p ≤ 0.005, Amygdala: p ≤ 0.001,
Entorhinal Cortex: p ≤ 0.001, Hippocampus: p ≤ 0.001, Subiculum: p ≤ 0.001; n =
13M/16F control, 17M/12F diabetic, 9M/20F AD, 13M/15F diabetic AD). By contrast,
comparison of the occurrence of neuritic and diffuse plaques in the same cases revealed
no significant difference between brain regions (data not shown).
3.4 – DISCUSSION
To date there are approximately two dozen neurodegenerative diseases classified
as tauopathies (Delacourte and Buee 2000, Lee and Leugers 2012). Each of these
diseases presents tau pathology in different ways, some develop NFTs in specific areas of
the brain and others accumulate in different structural conformations of high order tau
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aggregates. The mechanisms which drive each of these tauopathies are similar, some of
these mechanisms are distinctive, yet many others are involved in multi-pathway
crosstalk and may occur as a result of a variety of other pathologies.
It is also interesting to note that while most discussions about tau focus on the
development of tau aggregates and disruption of the microtubule network, tau has many
other functions aside from cytoskeletal stabilization. Tau has been shown to associate
with nucleoli and polysomes, and mutations in tau may result in chromosomal
abnormalities (Loomis, Howard et al. 1990, Thurston, Zinkowski et al. 1996, Rossi,
Conconi et al. 2014). Certain phosphorylation events cause tau to interact with cellular
membranes, and tau may interact with lipid raft components involved in growth cone
function in oligodendrocytes (Maas, Eidenmuller et al. 2000, Klein, Kramer et al. 2002).
Tau may not only have a role inside the cell, but also outside; a recent study has
implicated AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor)induced synaptic release of tau (Pooler, Phillips et al. 2013). Additionally, extracellular
tau has been shown to increase intracellular calcium concentrations in primary
hippocampal and cortical neurons (Gomez-Ramos, Diaz-Hernandez et al. 2008).
In summary, the data in this chapter indicate that tau pathogenesis in tauopathies
and subsequent neurodegeneration is highly varied and there may be many mechanisms
which contribute to the development of disease. Additionally, mechanisms which
promote tauopathy are likely also involved in the development of amyloid pathology.
Subsequent chapters explore one potential mechanism associated with metabolic
dysregulation.
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Table 3.1 Human Subject Demographic Data

Control
Diabetic
AD
Diabetic
AD

Sex, M/F
(no.)
13/16
17/12
9/20
13/15

Age
PMI
(years)*
(hours)*
82.1 ± 1.1 5.0 ± 1.0
82.1 ± 1.2 4.0 ± 0.6
82.1 ± 1.2 7.4 ± 1.0
82.2 ± 1.2

3.9 ± 0.5

* Values are given as mean ± SEM

44

Braak Stage
(Median)
II
II
VI
VI
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Figure 3.1 Antisense Oligomer Knockdown of GSK Reduces Total GSK3β Levels
and Tau Phosphorylation in SAMP8 Mice.
GAO-treated

(n = 9) SAMP8 mice displayed decreased GSK3β expression (A&B) and tau

phosphorylation (C) compared to RAO-treated mice (n = 7; t-test, * = p≤0.05). Shown are
two representative western blots of samples from each group and of GAPDH (loading
control).
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Figure 3.2 Altered Protein Expression in the Frontal Cortex of Myotonic Dystrophy
Homogenates.
(A) CNBP, BACE1, and Tau (note also the different pattern of Tau isoforms in DM
cases; the two DM1 cases were essentially indistinguishable from the single DM2 case, in
the last lane) increase in the frontal cortex of DM cases relative to age-matched controls
(BIN1, 99D, Sigma; Tau, Tau46, Cell Signaling; BACE1, 5606, Cell Signaling; βActin,
AC15, Sigma); CNBP antibody, per [24]). (B) Quantification of DM cases / controls (ttest, * = p≤0.05, ** = p≤0.01, *** = p≤0.001; (*) = p≤0.08).
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Figure 3.3 Oligomeric Tau is Toxic to Primary Rat Neurons and Human SH-SY5Y
Neuroblastoma Cells.
(A) Monomeric, fibrillar, and oligomeric tau were administered to SH-SY5Y cells. Only
oligomeric tau was cytotoxic by LDH assay (ANOVA, p ≤ 0.05). (B) LDH activity (a
marker for cell death) increases in rat hippocampal neurons in a dose dependent manner
with oligomeric tau concentrations. This response can be seen from the earliest timepoint
of two hours and is sustained up to 48 hours. (C) Increasing the concentration of
oligomeric tau treatments in SH-SY5Y cells revealed concentrations of 50 nM or higher
significantly increase cytotoxicity at 48 hours (ANOVA, * p ≤ 0.01, ** = p≤0.001).
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Figure 3.4 NFT Counts are Reduced in Diabetic AD Cases Compared to NonDiabetic AD Cases.
When comparing tangle counts in human cases, diabetic AD cases displayed significantly
reduced tangle counts throughout the brain (except in the occipital lobe) compared to
non-diabetic AD cases (n = 13M/16F control, 17M/12F diabetic, 9M/20F AD, 13M/15F
diabetic AD).

Copyright © Thomas L. Platt 2014
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CHAPTER 4: Diabetes, Obesity, and Neurodegeneration
Portions of this chapter are reprinted with permission from:
Niedowicz DM, Studzinski CM, Weidner AM, Platt TL, Kingry KN, Beckett TL, BruceKeller AJ, Keller JN, Murphy MP (2013). Leptin regulates amyloid β production via the
γ-secretase complex. Biochem Biophys Acta. 2013 Mar;1832(3):439-44
Niedowicz DM, Reeves VL, Platt TL, Kohler K, Beckett TL, Powell DK, Lee TL, Sexton
TR, Song E, Brewer LD, Latimer CS, Kraner SD, Larson KL, Ozcan S, Norris CM,
Hersh LB, Porter NM, Wilcock DM, Murphy MP (2014) Obesity and Diabetes Cause
Cognitive Dysfunction in the Absence of Accelerated Beta-Amyloid Deposition in a
Novel Murine Model of Mixed or Vascular Dementia. Acta Neuropathologica
Communications. 2014 Jun; 2(64)
4.1 – INTRODUCTION
The development of AD, the most common neurodegenerative disease associated
with age, can be driven by many factors including genetic, vascular, and metabolic risks
(Peila, Rodriguez et al. 2002). While cases with direct familial contribution to disease
pathogenesis do occur, it is rare. A majority of AD cases are classified as sporadic, with
no clear insult or factor giving rise to the disease state. In the last quarter century the
scientific community has shed some light on risks which may increase the risk for AD,
including mid-life obesity, metabolic syndrome, and diabetes (Gustafson, Rothenberg et
al. 2003, Whitmer, Gunderson et al. 2005, Wolf, Beiser et al. 2007).
As obesity levels have risen to an epidemic level, there is increasing concern that
peripheral effects associated with obesity may impact the development of other
pathologies, including AD (Bray 2004). Mid-life obesity is a driving factor associated
with dementia, with one study demonstrating that obese individuals have a two-fold
increased risk of developing dementia than normal weight individuals (Kivipelto, Ngandu
et al. 2005). Interestingly, a related study with similar findings demonstrated that patterns
of fat deposition also displayed relationship with the development of dementia, as
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individuals in the top fifth distribution of skin fold thickness in the subscapular or tricep
regions has a 72% and 59% increased risk of dementia, respectively (Whitmer,
Gunderson et al. 2005). T2DM, which is highly associated with obesity, is commonly
cited as a likely cause of pathogenesis in these diseases (Luchsinger and Mayeux 2007).
Several studies have demonstrated that T2DM imparts an increased risk of developing
AD, while findings related to the severity of pathology are controversial (Janson, Laedtke
et al. 2004, Xu, Qiu et al. 2004, Haan 2006). Interestingly, most studies solely focus on
insulin-resistance as the key mechanism by which pathogenesis is initiated when studying
obesity, T2DM, and dementia. While it is undeniable that the effects of insulin-resistance
are wide reaching, there are other dysfunctional signaling events found to be associated
with chronic obesity. Impaired leptin signaling is one such mechanism.
Leptin is a peptide hormone which is secreted from adipose tissue, proportionally
with the amount of stored adipose. Leptin is secreted from adipose tissue to regulate
satiety and energy expenditure via the hypothalamus. However, the leptin receptor (ObR) is expressed throughout various other regions of the brain, which suggests it likely
plays another role outside metabolic regulation (Couce, Burguera et al. 1997, Shioda,
Funahashi et al. 1998, Burguera, Couce et al. 2000). Leptin signaling classically regulates
transcription via Janus Kinase – Signal Transducer and Activator of Transcription (JAKSTAT) pathways (Hakansson and Meister 1998, Elias, Aschkenasi et al. 1999, Munzberg,
Huo et al. 2003). However, leptin signaling also involves a variety of other signaling
cascades including the PI3K/AKT and MAPK pathways (Figure 4.1) (Banks, Davis et al.
2000, Bjorbaek, Buchholz et al. 2001, Niswender, Morton et al. 2001, Zhao, Huan et al.
2002, Rahmouni, Haynes et al. 2003, Cota, Proulx et al. 2006, Cota, Matter et al. 2008).
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Elevated leptin signaling has also been shown to improve cognition in rodents and
humans, and has been correlated with a decreased risk of dementia and AD (Harvey
2007, Lieb, Beiser et al. 2009, Greco, Bryan et al. 2010). Individuals who are obese, and
often suffer from T2DM as a result of obesity, develop resistance to leptin signaling over
a long period of time (Campfield, Smith et al. 1995, Halaas, Gajiwala et al. 1995,
Considine, Sinha et al. 1996, Ostlund, Yang et al. 1996).
In this chapter, we explore the effects of leptin signaling and leptin resistance in
cell culture and in vivo. We demonstrate that leptin signaling inhibits the generation of
Aβ and negatively regulates the expression of γ-secretase components. Furthermore, we
outline characteristics of a novel mouse line combining AD pathology (APP/PS1 knockin mice) and a leptin-resistance induced model of obesity and diabetes. We demonstrate
that while these mice develop cognitive impairments, this impairment is induced not by
increased Aβ deposition, but rather by the development of vascular pathology. Taken
together, these results indicate that leptin resistance, obesity, and diabetes are key factors
which enhance neurodegenerative properties of AD mice.
4.2 – METHODS
4.2.1 – Animals
For the initial diet study, APPKM670/671NL x PS1P264L knock-in mice (CD-1/129
background; hereafter referred to as ‘AD’ mice) were fed a control (20% fat, n = 46),
western (40% fat, n = 14), or ketogenic (80% fat, n = 47) diet ab libitum (Research Diets,
New Brunswick, NJ) for one month (n= 37 wild type, 49 heterozygotes, 21 homozygotes;
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Gender: n = 52 males, 55 females). At the end of the feeding period mice were
euthanized and brain and plasma were collected for analysis.
To generate the db/AD line the Leprdb/db mice (C57Bl/6 J background; (Jackson
Labs; Bar Harbor, Maine; referred to as db mice) were crossed with the AD mouse line.
db+/- mice (as db-/-mice are infertile) were crossed with homozygous AD mice. F1
heterozygotes (db+/- and AD+/-) were then used to generate the colony for all studies. The
majority of experiments outlined focus on four main genotypes: db+/+ x APP+/+/PS1+/+
(wt/wt), db-/- x APP+/+/PS1+/+ (db/wt), db+/+ x APPKM670/671N//PS1P264L (wt/AD), and db-/- x
APPKM670/671NL/PS1P264L (db/AD). All husbandry for this cohort was performed by the
Murphy lab.
4.2.2 – Plasma Leptin and Aβ ELISAs
Plasma was collected as previously described in chapter 2. Plasma leptin was
measured using a commercially-available ELISA kit according to manufacturer’s
methods (#EZML-82K, Millipore). For Aβ ELISAs, tissue was serially extracted in PBS,
then 2% SDS, and finally 70% formic acid (FA). All extraction buffers were
supplemented with PIC and, when looking at phospho-tau, PhIC. Briefly, extracts were
diluted in PBS homogenization buffer (1 mL buffer per 200µg sample) and homogenized
with a polytron. Homogenate was centrifuged at 20,800 x g for 30 minutes at 4ºC and
supernatants stored at -80ºC. Pellets were resuspended 0.7 mL 2%SDS, and sonicated (10
x 0.5 sec. at 100 W) followed by centrifugation at 20,800 x g for 30 minutes at 14ºC to
prevent SDS from precipitating. Supernatants were frozen at -80ºC. The remaining pellet
was then extracted with 70% FA by sonication and centrifugation at 20,800 x g for 60
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minutes at 4ºC. PBS and SDS extracts were diluted in AC buffer (0.2 M Na3PO4, 0.4 M
NaCl, 2 mM EDTA, 0.4% Block Ace, 0.4% BSA, 0.05% CHAPS, 0.05% NaN3) before
analysis used to perform a standard sandwich ELISA in 384 well plates, using Ab42.5 as
the capture antibody and biotinylated-4G8 antibody for detection. Following 4G8
incubation, plates were incubated with 0.1% NeutrAvidin-HRP (Pierce) and developed
with 3’,3’,5’,5’-tetramethylbenzidine (TMB) and stopped with 6% phosphoric-acid.
Absorbance of each well was measured at 450 nm.
4.2.3 – Immunoblots
For western blot analysis, samples were processed as described for ELISAs or by
RIPA extraction as previously described. Protein samples were run on Bis-Tris Criterion
precast SDS-PAGE (4-12% gradient) gels in MOPS running buffer (Bio-Rad). The
proteins were electrically transferred to 0.45 µm or 0.2 µm nitrocellulose membrane at 1
ampere for 60 minutes. For dot blots, 1 µg sample per well was transferred to 0.45 µm
nitrocellulose membrane by vacuum manifold. Membranes were blocked overnight in 1%
BSA and 2% BlockAce at 4ºC. The following protein-specific antibodies were used to
determine protein expression: AT8 (Hu, Waring et al. 2008, Greco, Sarkar et al. 2009,
Martinez-Coria, Green et al. 2010) for pSer-202/Thr-205 tau (#MN1020, Pierce, 1:1000),
HT7 for total tau (#MN1000, Pierce, 1:1000), CT20 for APP (1:1000), and anti-GAPDH
(ab9385, Abcam; 1:5000) and anti-Actin (A1978, Sigma; 1:5000) were used to
standardize protein expression.
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4.2.4 – qPCR
RNA was isolated from brain tissue and cultured cells by homogenization in
Trizol™ (#15596-026, Invitrogen) followed by phenol/chloroform extraction and
purification using RNeasy columns (#74106, Qiagen; Valencia, California). γ-secretase
components, BACE1, and BACE2 mRNA levels were measured by two-step qRT-PCR
with iScript (#170-8890, Bio-Rad) for reverse transcription, and PerfeCTa FastMix™
(Quanta; Gaithersburg, Maryland) for the qPCR reaction. The geometric mean of the CT
values for 18S rRNA, β-actin, and GAPDH was used as an internal control to calculate
and compare relative expression (2-∆∆CT). Gene-specific primer sets were obtained from
IDT (Coralville, IA) and the sequences are presented in Table 4.1.
4.2.5 – Histology
A set of fixed hemibrains (in 10% formalin) were processed by NeuroScience
Associates (Knoxville, Tennessee), in which hemibrains were embedded in a matrix and
cut at a thickness of 30 microns. Total Aβ was stained using the 4G8 antibody. For
Prussian Blue staining (staining of hemosiderin) another set of fixed hemibrains were
paraffin imbedded and sectioned at a thickness of eight microns and mounted to slides.
Tissue was deparaffinized, and hydrated before staining in a solution of 2% K₄[Fe(CN)₆]
and 2% hydrochloric acid. Sections were rinsed in H2O and counter-stained with neutral
red. Finally, sections were rinsed, dehydrated with ethanol, cleared with SafeClear™
(#23-314-629, Fisher Scientific), and then coverslipped.
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4.2.6 – MRI
Dr. David Powell of the UKY Magnetic Resonance Imaging and Spectroscopy
Center assisted us in acquiring MRI scans of living mouse brains. T2*-MRI was
performed by a horizontal bore Bruker Clinscan (7.0T, 30 cm, 300 MHz: Billerica, MA)
imager equipped with a triple-axis gradient (630 mT/m and 6300 T/m/s) and a heliumcooled 14K quadrature head cryo-coil, cooled to 20°K. T2*-weighted images were
acquired with a 2D GRE sequence with at 34 µm x 34 µm x 400 µm resolution, 15mm
FOV, 25 degree flip angle, 10 averages, TR 165ms, and TE 15.3ms. Mice were
anesthetized with isofluorane and temperature and respiration were constantly monitored
throughout imaging. Ten or more equally spaced images were acquired over the course of
imaging.
4.2.7 – Vascular Corrosion Casting and Scanning Electron Microscopy
Mice were anesthetized using 100 mg/kg pentobarbital and transcardially
perfused with heparinized 0.9% saline, followed by 4% para-formaldehyde. With the help
of Dr. Nada Porter and her lab, brains were perfused with a polyurethane resin (Pu4ii,
VasQtec; Zurich, Switzerland) at a rate of 4 mL per minute. The resin was allowed to
cure for two days, followed by a 48 hour incubating in 7.5% KOH at 50ºC. Brains were
then incubated for 24 hours in 5% formic acid at 50ºC. Tissue was then frozen and
lyophilized to macerate the tissue. Casted brains were sputter-coated in palladium and
imaged by scanning electron microscopy (Hitachi S-4200; Schaumburg, Illinois).
Endothelial cell density was determined by endothelial cell nuclear imprints measured
directly using Image J software. Aneurysm pathology was assessed on a 4 point scale
based on clear data break points (0 = none; 1 = 1 possible; 2 = 1-3 definite; 3 = 4+
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definite. Vascular density was determined by rank order of representative images using
three blinded, independent reviewers. Images were scored from 1 (most dense) – 26 (least
dense), and the ranks from the three reviewers averaged.
4.3 – Results
4.3.1 – Leptin Reduces Total Aβ Production
In a previous diet study, examining the impact of high fat consumption on Aβ
production in AD mice, we observed that mice with higher plasma leptin levels had
decreased levels of total Aβ in the brain (p ≤ 0.0001, n = 37 wild type, 49 heterozygotes,
21 homozygotes; Figure 4.1). Diet in this study had no effect on total Aβ production (p =
0.66) but did significantly increase plasma leptin levels (p = 0.02), suggesting that
increases in plasma leptin concentrations were the likely cause of reduced Aβ generation.
To further examine the effects observed in mice, we treated human H4
neuroglioma cells overexpressing APPKM670/671NL with 0, 10, and 50 ng/mL leptin diluted
in cell culture media. Expression of total Aβ was reduced in a dose dependent manner in
response to leptin (p = 0.024, Figure 4.2A), supporting the observations made in AD
mice. Western blot analysis of APP expression revealed an increase in αCTF expression
at higher concentrations of leptin (Figure 4.2B). This observation was indicative that the
second cleavage event of APP by the γ-secretase complex was in some way inhibited by
leptin treatment, resulting in an increase of αCTFs (Zhao, Chen et al. 1999).
To determine if reduced processing of αCTFs by the γ-secretase complex is due to
direct inhibition of the complex or by reduced expression of γ-secretase components we
measured mRNA expression of γ-secretase subunits in leptin treated APPKM670/671NL
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overexpressing H4 neuroglioma cells (Figure 4.3). The γ-secretase complex is composed
of four major subunits: presenilin (PS), nicastrin, presenilin enhancer 2 (PEN-2), and
anterior pharynx-defective 1 (APH-1) (Kaether, Haass et al. 2006). PS acts as the
catalytic subunit through its aspartyl-protease activity, nicastrin and APH-1 bind to PS
and stabilize the complex, and PEN-2 activates PS (Watanabe, Tomita et al. 2005). All of
these components are critical to the proper function of the γ-secretase complex. Leptin
treatments at a concentration of 50 ng/mL significantly reduced mRNA expression of all
γ-secretase components (p ≤ 0.03). Interestingly, the PS2 isoform displayed no alterations
in expression, and BACE2 expression increased with leptin treatment (p = 0.004).
Collectively, these data suggest leptin signaling reduces the expression of the γ-secretase
complex, therefore inhibiting γ-secretase processing of APP CTFs.
4.3.2 – Characteristics of the db/AD Mouse
In cases of chronic obesity and diabetes plasma leptin levels remain high for long
periods of time (Considine, Sinha et al. 1996). Due to these chronically high levels of
leptin, a resistance to leptin signaling develops (Bjorbaek, El-Haschimi et al. 1999).
Therefore we proposed to explore the effects of leptin resistance, obesity, and diabetes on
AD pathogenesis. We crossed the db line, which is leptin resistant due to a mutation in
the leptin receptor gene, with the AD knock-in mouse line to produce the db/AD mouse.
Mice homozygous for the db mutation (db-/-) developed morbid obesity in both females
and males (p ≤ 0.001 for all ages; Figure 4.4A-B). Heterozygotes (db+/-) did not display
any significant weight gain compared to wild type (db+/+) mice. The AD genotype did not
significantly affect body weight (p ≤ 0.3 for all ages). Glucose tolerance was significantly
impaired in mice homozygous for the db genotype (p≤0.0001 for the db genotype overall,
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n=14 WT; 13 db; 30 AD; 18 db/AD; Figure 4.4C-D). Similar results were observed in
insulin tolerance tests, where mice homozygous for the db genotype displayed significant
impairment in response to insulin (p≤0.0001 for the db genotype overall; n=14 WT; 13
db; 30 AD; 18 db/AD; Figure 4.4E-F). Together this data indicates that db homozygotes
are morbidly obese and have severe metabolic dysfunction compared to wild type and
heterozygous littermates.
4.3.3 – db/AD Mice Display Cognitive Deficits
To determine if the diabetic phenotype had any influence on cognitive function,
mice were tested by a MWM. Over the course of five days mice of the four genotypes
were trained and after the trials on the fifth day underwent a probe trial. Though no
differences were observed on the first day, as the week went on the db/AD mice had
significantly longer path lengths compared to the other genotypes (p ≤ 0.05 for days 2-5),
suggesting that these mice displayed cognitive impairment (Figure 4.5A). In the probe
trial db/AD mice spent less time in the target quadrant (p ≤ 0.04) and target zone (p ≤
0.01; Figure 4.5B). These data indicate that the convergence of the db and AD genotypes
produce a phenotype, unique from the parental lines, which results in cognitive deficit.
4.3.4 – db/AD Mice Do Not Display Increased Aβ Deposition
As previous data indicated leptin signaling inhibits γ-secretase expression, we
expected complete leptin resistance would increase expression and activity of the γsecretase complex, resulting in an increase in total Aβ. With the cognitive deficits
observed in db/AD mice, we expected increased Aβ levels. Using IHC we visualized Aβ
deposition (4G8) in the brains of mice from all four genotypes. Both AD and db/AD mice
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displayed positive staining for Aβ (Figure 4.6A). Interestingly, plaque deposition did not
seem higher in db/AD mice, as was predicted. Analysis of total Aβ levels from the brains
of young 6-7 month old and older12 month old mice indicated total Aβ levels increase
with age in AD and db/AD mice (p ≤ 0.0001, age: [6mo/12mo] n = 13/8 WT, 13/8 db, 9/8
AD, 11/7 db/AD; Figure 4.6B). However, db/AD mice did not display increased total Aβ
concentrations compared to AD mice as was expected.
4.3.5 – db/AD Mice Display Vascular Pathology
The cognitive deficits observed in db/AD mice are not due to increased plaque
burden over other genotypes. To better explore the underlying mechanisms which cause
these cognitive deficits in db/AD mice we analyzed the structure of the
cerebrovasculature. Vascular corrosion casting with a polyurethane resin was used to
create casts of the brain vasculature which were analyzed by SEM. Vasculature of WT
and db mice appeared normal (Figure 4.7A). Both AD and db/AD mice, however,
displayed extensive cerebrovascular pathology, ranging from slight blebbing of vessels
(Figure 4.7B), extensive aneurysms along individual vessels (Figure 4.7C), to highly
complex saccular aneurysms (Figure 4.7D). While this pathology was extensive it did
not explain the cognitive deficits which were only observed in db/AD mice.
To determine if the vascular pathology observed by SEM could be indicative of
stroke pathology mice were subjected to scanning by small animal MRI. Almost
exclusively db/AD mice displayed evidence of some vascular events (11/15 db/AD mice;
Figure 4.8A-C), whereas only two (2/9) AD (Figure 4.8F) mice displayed any evidence,
and no WT (0/9; Figure 4.8D) or db (0/10; Figure 4.8E) mice displayed any signs of
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vascular event (Figure 4.8). Brain sections from scanned mice were stained with Prussian
blue (which stains ferric deposits blue) with a neutral red counter-stain and regions which
tested positive for vascular event were examined for evidence of bleeding. Sections
showed no evidence of hemorrhagic event, yet dense clusters of neutral red staining
suggests these are likely ischemic strokes (Figure 4.9A-D). Extensive analysis of stained
sections did reveal some signs of microbleeds, but this was a rare occurrence (Figure
4.9E-F).
4.4 – Discussion
The combination of the db and AD genotypes imparts a unique phenotype which
is not observed in either parental line. Interestingly, though our hypothesis suggested
leptin resistance would result in increased neurodegeneration through amyloid pathology,
we did not observe increased generation or deposition of Aβ in the brains of these mice.
Instead, pathological hallmarks of vascular disease were apparent. Experiments described
in this chapter suggest metabolic dysfunction, as result of leptin resistance, obesity, and
diabetes, exacerbate cerebrovascular pathology found in AD mice, resulting in cognitive
impairment.
Our results indicate that increased plasma leptin levels inhibit the generation of
Aβ through inhibition of γ-secretase complex expression, which we also observed in cell
culture. This supports previous observations made by Lieb et al. where individuals with
higher plasma leptin concentrations were less likely to develop dementia or AD over the
course of the study (Lieb, Beiser et al. 2009). These data do not, however, provide clear
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indication as to whether or not secondary mechanisms involved in leptin signaling may or
may not impact activity of β-secretase, and requires further study.
Translation of these findings into the clinical setting, however, will be highly
challenging. Upon discovering the function of leptin, our basic understanding of energy
metabolism and weight homeostasis was greatly expanded. Scientists believed leptin
would be a breakthrough in anti-obesity therapies, and would herald in a new generation
of weight loss pharmaceuticals. Leptin therapies in humans, however, proved fruitless, as
weight loss resulting from leptin treatments was marginal at best (Heymsfield, Greenberg
et al. 1999). It was soon discovered that chronically elevated levels of circulating leptin
triggers mechanisms which result in decreased or resistant leptin signaling (Martin, Perez
et al. 2000, Banks and Farrell 2003, Munzberg, Flier et al. 2004). This realization dashed
any real hopes that leptin alone could be used as a pharmaceutical intervention for
obesity.
It is these previously encountered obstacles involved with leptin therapeutics
which led us to study the effects of leptin resistance, and resulting obesity and T2DM, on
AD pathogenesis. The Leprdb line was ideal to create a mouse model to study these
effects. The mutation in the leptin receptor gene results in a mis-spliced variant of the
mRNA product with a pre-mature stop sequence. This generates a truncated peptide
which can no longer initiate any signaling events, and because of this, it perfectly imitates
leptin resistance (Chen, Charlat et al. 1996). Additionally, the Leprdb line is inherently
sickly, and the hybrid generated by crossing it with the AD line is more robust, allowing
for better description of the aged phenotype.
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The resulting db/AD mice display the same metabolic phenotype as the parental
Leprdb line. db homozygotes weigh more than control littermates from birth and quickly
develop morbid obesity. The phenotype is so extreme that often the genotype of
homozygotes can be determined simply based upon the appearance of the mice, before
genotypic analysis. These mice are insulin intolerant and display severely impaired
glucose handling at a young age. Due to their morbid obesity, db homozygotes developed
secondary complications. With their inability to properly groom db mice often developed
dermatitis, urine scald due to excessive urination, and genital impaction of cage litter.
Because of these conditions the cage litter was changed to a soft absorbent litter and
cages were changed every other day. Interestingly, we also observed a group of db/AD
mice from each generation, primarily males, would mysteriously begin losing weight
between three and six months then spontaneously die. Overall, the obese and diabetic
phenotypes of this line were exactly what we were aiming for in developing this line.
Contrary to our hypothesis, db/AD mice developed no more extensive amyloid
deposition than AD mice. This finding was quite surprising, as other studies in our lab
have demonstrated PS1 expression was increased in db/AD mice, just as expected
(Niedowicz, Reeves et al. 2014). The same study also showed that none of the major Aβ
clearance enzymes (insulin degrading enzyme, neprilysin, and endothelin converting
enzyme) were elevated nor were peripheral or vascular Aβ levels elevated, suggesting
that clearance of excess Aβ is not a likely culprit for normal Aβ levels.
More confounding was the observation that db/AD mice display cognitive
impairment in the MWM. It is known that AD mice develop cognitive impairment at
much older ages, yet do not at the age tested in this study (Webster, Bachstetter et al.
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2013). The finding that db/AD mice were the only genotype which did display impaired
cognition suggests that crossing the db and AD produces new pathologic phenotype.
Vascular corrosion casting of the brain revealed vascular abnormalities in both AD and
db/AD genotypes, suggesting these genotypes develop severe aneurysm pathology. MRI
analysis further revealed that db/AD mice develop many small strokes, which are
predominately ischemic based on histological analysis.
While aneurysms are associated with both AD and db/AD mice, it is interesting
that crossing of the db and AD lines is required to produce stroke pathology. As no
increases in amyloid deposition or generation were observed it is unlikely that Aβ
promotes the occurrence of these ischemic events. Previously observed increases in γsecretase expression in db/AD mice could instead be the causative factor (Niedowicz,
Reeves et al. 2014). PS has been implicated to be involved in angiogenic signaling via
Notch signaling pathways (Lukiw, Gordon et al. 2001, Nakajima, Yuasa et al. 2003).
Alterations in angiogenesis in combination with cerebrovascular abnormalities observed
in mice with the AD genotype may weaken vessel walls, resulting in stroke pathology.
This, however, does not take into account the many other pathologic conditions
associated with obesity and diabetes. Intracerebroventricular injection of STZ in nontransgenic mice, a common model of brain insulin resistance and sporadic AD, causes
severe cognitive deficits, which supports the notion that dysfunctional insulin signaling
may be involved in neurodegenerative disease (Salkovic-Petrisic and Hoyer 2007, Chen,
Liang et al. 2013). STZ-induced diabetes in the hAPP AD model increases amyloid
plaque deposition, tau phosphorylation, and cognitive impairment (Jolivalt, Hurford et al.
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2010). So while altered PS expression explains the vascular pathology observed in our
model, effects resulting from metabolic dysfunction in this line warrant further study.
Overall, we have shown in this chapter that we have generated a mouse line with
leptin resistance, obesity, and diabetes in combination with AD pathology. This line
develops cognitive dysfunction due to vascular pathology and not amyloid pathology as
expected. Interestingly both AD and db/AD mice develop aneurysms, yet only in db/AD
mice are ischemic events observed in addition to aneurysm pathology. These exciting
results leave us with more questions and another aspect of the disease to explore: tau
pathology.
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Table 4.1 qPCR Primers.
Target
Gene

Direction
forward
PS1
reverse
forward
PS2
reverse
forward
PEN2
reverse
forward
Nicastrin
reverse
forward
APH1A
reverse
forward
APH1B
reverser
forward
BACE1
reverse
forward
BACE2
reverse
forward
18S
rRNA
reverse
forward
β-Actin
reverse
forward
GAPDH
reverse

Sequence
5′-AAATGGGTGCTTTGTGGTCTCTGC-3′
5′-CAGGCTGATGGCTGTTTGTGTGTT-3′
5′-ATGGACAGCTCATCTACACGCCAT-3′
5′-AGAGCACCACCAAGAAGATGGTCA-3′
5′-TCTCGCGCAAACGTCCATAACTGA-3′
5′-AATGGACACTCGCTCCAGGTTCAT-3′
5′-AGTGCCCAAATGATGGGTTTGGTG-3′
5′-TCATAAGCCAAACCATTGCCCAGC-3′
5′-ATCCGCCAGATGGCCTATGTTTCT-3′
5′-AGCAGGATAATGGCTGCTGTCAGA-3′
5′-TTATGTCTTCACCATCGCCACCGA-3′
5′-TTGCCATGAACCAAACAAGGGACG-3′
5′-ATGTTGCCACTCTGCCTCATGGTA-3′
5′-TGAGCAGGGAGATGTCATCAGCAA-3′
5′-TGAGGACCTTGTCACCATCCCAAA-3′
5′-TGGCCAAAGCAGCATAAGCAAGTC-3′
5′-TTAGAGTGTTCAAAGCAGGCCCGA-3′
5′-TTGGCAAATGCTTTCGCTCTGGTC-3′
5′-ACCAACTGGGACGACATGGAGAAA-3′
5′-TAGCACAGCCTGGATAGCAACGTA-3′
5′-TCGACAGTCAGCCGCATCTTCTTT-3′
5′-ACCAAATCCGTTGACTCCGACCTT-3′
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Figure 4.1 Plasma leptin negatively correlates with brain Aβ.
There was a strong negative correlation between plasma leptin and brain Aβ in young (2–
3 month-old) APP

KM670/671NL

× PS1P264L knock-in mice (n= 37 wild type, 49

heterozygotes, 21 homozygotes; ANOVA, p ≤ 0.0001). Experiment performed by Dr.
Dana Neidowicz (Niedowicz, Studzinski et al. 2013).
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Figure 4.2 Leptin treatment inhibits Aβ production in cell culture.
Leptin reduced the Aβ concentration in conditioned media from APP

KM670/671NL

-

overexpressing H4 neuroglioma cells after 24 h of treatment (ANOVA, * = p ≤ 0.05),
concomitant with accumulation of APP C-terminal fragments (CTFα and β: B), indicative
of reduced γ-secretase activity. Two independent experiments were performed. A is an
average of the two experiments, while B is a representative immunoblot of the results.
Experiment performed by Dr. Dana Neidowicz (Niedowicz, Studzinski et al. 2013).
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Figure 4.3 Leptin treatment reduces mRNA levels of γ-secretase components in cell
culture.
mRNA expression of the γ-secretase components PS1, PEN2, nicastrin, and APH1 were
decreased after leptin treatment in wild-type neuronal tissue culture cells. On the
contrary, there was an overall increase in the expression of BACE2 (ANOVA, p = 0.014),
one of the β-secretase enzymes. There was no change in PS2 or BACE1 mRNA
expression (ANOVA, p > 0.12). The data are an average of 2–3 independent experiments.
Experiment performed by Dr. Dana Neidowicz (Niedowicz, Studzinski et al. 2013).
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Figure 4.4 db/AD Characteristics.
The diabetic LepRdb/db mouse was crossed to the APP/PS1 knock-in model of AD to
create the db/AD line. (A - B) db HOM mice displayed significant weight-gain at an early
age, and there was no effect of the AD genotype (ANOVA, * = p≤0.01, t-test; HolmBonferroni correction; n= ~14 mice per genotype). In subsequent experiments, we
focused on the four main genotypes. For simplicity we have named them WT, db, AD,
and db/AD. (C - D) db and db/AD mice displayed impaired glucose handling by GTT
(F[2,30] = 38.2, ANOVA, p≤0.0001 for the db genotype overall, n=14 WT; 13 db ; 30
AD; 18 db/AD, * = p≤0.05, Tukey’s HSD) (E - F) db and db/AD mice were insulin
resistant (F[15,177] = 4.64, ANOVA, p≤0.0001 for the db genotype overall; n=14 WT;
13 db ; 30 AD; 18 db/AD; * = p≤0.05, ** = p≤0.01; Tukey’s HSD).
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Figure 4.5 db/AD Mice Display Impaired Cognition.
(A) db/AD mice displayed significant by MWM during the acquisition phase (ANOVA pvalue by day: 0.4, 02, 0.05, 0.001, 0.03; n = 8 WT, 6 AD, 11 db, 8 db/AD). (B) db/AD
mice displayed deficits during the probe trial, based upon the findings that they spent less
time in the target quadrant, and less time in proximity to the platform location (ANOVA,
p≤0.03; * = p≤0.05, ** = p≤0.01. Tukey’s HSD). Experiment performed by Deann
Hopkins.
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Figure 4.6 Amyloid Pathology in db/AD Mice.
(A) Aβ deposition (4G8) in 8 month old mouse neocortex (magnification: 4x). db/AD and
AD mice displayed amyloid deposition, while db and WT mice did not. (B) Mice with the
AD genotype displayed increased levels of SDS soluble total Aβ (Ab42.5/4G8) by
ELISA, and these levels increased with age in these mice (ANOVA, p≤0.0001), but the
db genotype had no significant effect (ANOVA, * = p≤0.05, compared to WT. [genotype,
age (6 mo./12 mo.): n = 13/8 WT, 13/8 db, 9/8 AD, 11/7 db/AD). Tissue sectioned and
stained by NeuroScience Associates.
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Figure 4.7 Cerebrovascular Pathology in db/AD Mice.
Vascular casts of mice were created and examined by SEM. (A) WT mice displayed
normal arterial vasculature; note the clear endothelial cell nuclear imprints and their
elongated shapes. (B) Aneurysms were observed in the brains of AD and db/AD mice.
This pathology varied from relatively minor to severe presenting with arterial blebbing
(C) or complex clusters of saccular aneurysms (D). AD and db/AD mice displayed
significantly more aneurysms compared to WT and db mice (F[1, 15] = 14.14, p < 0.002
for the AD genotype overall; N = 4-5). Casting was performed by the lab of Dr. Nada
Porter.
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Figure 4.8 Stroke Pathology in db/AD Mice.
Sequential T2*-MRI was performed on a large set of 12-14 month old mice of the four
main genotypes. Approximately 70% of db/AD mice displayed evidence of lesions
(indicated by arrowheads), which are indicative of stroke incidence. Few of these lesions
were observed in AD mice, though it was uncommon, none were observed in scans from
WT or db mice (n= 9 WT, 10 db, 11 AD, 26 db/AD). Images were acquired by Dr. David
Powell.
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Figure 4.9 db/AD Mice Display Ischemic Stroke Pathology.
(A-B) T2*-MRI was used to acquire coronal images from an older db/AD mouse. Lesions
are visible in areas indicated by arrows, which can be indicative of a vascular infarct
(~300 µm between images). (C - D) The brain from this animal was sectioned
transversely and stained with Prussian blue and a neutral red counterstain. These sections
displayed no evidence of hemorrhage, suggesting that this event was an ischemic stroke.
(E - F) Further analysis of other db/AD mice revealed some Prussian blue staining,
indicating that some mice do display signs of microhemorrhages, though this was an
uncommon finding. Staining performed by Dr. Dana Neidowicz.
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CHAPTER 5: Diabetes, Obesity, and Tau Pathology
Portions of this chapter are reprinted with permission from:
Platt TL, Reeves VL, Murphy MP (2013). Transgenic models of Alzheimer's disease:
better utilization of existing models through viral transgenesis. Biochim Biophys Acta.
2013 Apr; 1832(9):1437-48
5.1 – Introduction
We demonstrated in Chapter Four that leptin resistance induced obesity and
diabetes in the AD knock-in mouse model resulted in cognitive impairment and vascular
pathology, and yet no differences in Aβ generation were detected. While the amyloid
cascade hypothesis suggests amyloid drives the initial phases of disease, tau pathology
plays an extensive neurodegenerative role in AD (Ballatore, Lee et al. 2007). As tau
phosphorylation is closely associated with pathways disrupted by leptin resistance and
diabetes, in this chapter we explore these mechanisms and their effects on tau
hyperphosphorylation and tangle formation.
Multiple studies have demonstrated that tau pathology can be modulated by
diabetes or obesity. Streptozotocin-induced diabetes results in tau hyperphosphorylation
in mice (Planel, Tatebayashi et al. 2007). Alterations in tau splice patterns and increases
in tau phosphorylation have been observed in rodent models of T2DM (Kim, Backus et
al. 2009, Jung, Park et al. 2011). Additionally, hyperinsulinemic rats display increases in
tau hyperphosphorylation (Freude, Plum et al. 2005). These changes to tau regulation are
likely due to dysfunction within the myriad of pathways impacted by obesity and diabetes
(Virkamaki, Ueki et al. 1999, Schmelzle, Kane et al. 2006, Rains and Jain 2011). Insulin
signaling transiently modulates tau phosphorylation in primary cortical neurons when
stimulated with Insulin-like growth factor 1 (Lesort and Johnson 2000). Collectively,
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these data suggest that diabetes associated metabolic dysfunction influences tau
phosphorylation, and may promote pathogenesis via increased tau hyperphosphorylation
(Freude, Plum et al. 2005).
Insulin signaling is only one of the signaling pathways disrupted in the
chronically obese or diabetic state. Leptin is a hormone secreted from adipose tissue that
regulates satiety and energy expenditure via the hypothalamus. The leptin receptor is
expressed throughout the brain, which suggests it plays additional roles outside
hypothalamic regulation (Couce, Burguera et al. 1997, Shioda, Funahashi et al. 1998,
Burguera, Couce et al. 2000). Elevated leptin signaling has also been shown to reduce tau
phosphorylation (Greco, Sarkar et al. 2008, Marwarha, Dasari et al. 2010). Individuals
who are obese and diabetic often develop resistance to leptin signaling (Campfield, Smith
et al. 1995, Halaas, Gajiwala et al. 1995, Considine, Sinha et al. 1996, Ostlund, Yang et
al. 1996). Leptin signaling classically regulates transcription via Janus Kinase and Signal
Transducer and Activator of Transcription (JAK-STAT) pathways to modulate energy
metabolism and satiety (Hakansson and Meister 1998, Elias, Aschkenasi et al. 1999,
Munzberg, Huo et al. 2003). However, leptin signaling also involves a variety of other
signaling cascades including the PI3K/AKT, MAPK, and mTOR pathways (Banks, Davis
et al. 2000, Bjorbaek, Buchholz et al. 2001, Niswender, Morton et al. 2001, Zhao, Huan
et al. 2002, Rahmouni, Haynes et al. 2003, Cota, Proulx et al. 2006, Cota, Matter et al.
2008).

Elevated plasma leptin levels have shown to be inversely correlated with

dementia risk, and leptin treatment has been shown to increase cognition and reduce
amyloid pathology in transgenic mice (Harvey 2007, Lieb, Beiser et al. 2009, Greco,
Bryan et al. 2010). In addition, our lab has demonstrated that leptin reduces β-amyloid
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production, likely as a result of lower γ-secretase expression (Niedowicz, Studzinski et al.
2013).
No known mutations are associated with the tau protein in AD. Because of this,
most transgenic lines utilize mutations from other tauopathies, such as frontotemporal
dementia (FTD). The JNPL3 transgenic mouse was the first such line to use the FTD
mutation tauP301L, under the PrP promoter, to drive tau pathology (Hutton, Lendon et al.
1998). NFTs are first detected in these mice at approximately five months, concurrent
with observations of motor and cognitive dysfunction (Lewis, McGowan et al. 2000).
The tangles generated in these mice differ from AD tangles, with notable differences in
tangle morphology, location, and density (Lewis, McGowan et al. 2000). Some of these
differences can be explained by the fact that the tauP301L mutation generates 4R length tau
protein, where AD tangles are composed of 3R and 4R isoforms (Nasreddine, Loginov et
al. 1999). Another difference is that these animals also exhibit neuronal loss throughout
the spinal cord (Lewis, McGowan et al. 2000). Spinal cord pathology is also observed in
Tg2576 mice, which utilizes the same PrP promoter, indicating that the PrP promoter
induces significant spinal cord overexpression of the transgene.
The hTau mouse is a knock-out of endogenous rodent MAPT coupled with the
addition of a transgene expressing full length wild type human MAPT (Andorfer, Kress et
al. 2003). This line expresses the full length human MAPT gene alternative splicing
occurs, resulting in the expression all six isoforms of the human tau protein. These mice
show signs of tau hyperphosphorylation at approximately six months and NFT formation
by 15 months (Andorfer, Kress et al. 2003). NFTs in these mice are distributed
throughout the hippocampus and neocortex, roughly following the progression of tangle
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pathology seen in AD (Braak and Braak 1991). A decline in memory and cognitive
function can be observed by approximately 12 months of age, before the onset of
neurodegeneration (Polydoro, Acker et al. 2009).
Most mouse models are typically created by microinjecting complementary DNA
(cDNA), containing a transgene of interest into the pronuclei of a large number of
zygotes (Cho, Haruyama et al. 2009). Resulting embryos are then implanted into
pseudopregnant dams for normal gestation. Producing gene targeted mice is a more
involved process, although knock-out lines for many genes in the mouse are now
available (https://www.komp.org/). Though now creating a simple modification to the
mouse genome is relatively routine, generating viable animals can take many attempts
and consume a significant amount of resources. After the initial genetic modification is
made, a new mouse line can be crossed into a pre-existing line that already displays one
or more other aspects of the disease pathology. Hence, given sufficient time and funding,
one could build increasingly complex models of the disease.
Despite many concerted attempts, none of our existing mouse models are perfect
surrogates for AD. This does not mean that these models are without merit. Through the
use of mouse models, many of the underlying mechanisms that drive AD pathology and
neurodegeneration have been elucidated. Most, but not all, models overexpress proteins
involved with the disease (Duff and Suleman 2004, Hall and Roberson 2012). Some
models have predominantly amyloid pathology, others tau pathology, and a few have
both. However, for many investigators, the complex interactions between AD and other
genetic factors are becoming the main focus of their research. This creates a serious
logistical problem. Our pre-existing mouse models are already complex, and often
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involve multiple genetic modifications to reasonably mimic AD neuropathology. As a
simple example, consider a situation with a mouse line harboring mutations in three AD
associated genes, APP, PS1 and MAPT. If these genes assort independently, and wild
type littermate controls are needed for an experiment, then a basic husbandry scheme will
only generate about 3% usable animals. Although there are ways that this can be
streamlined in practice, three germline modifications represent the practical upper limit as
to what can be accommodated in a modern laboratory. Because we faced these challenges
in creating the db/AD line, we were not yet to a point where it would be feasible to create
a new transgenic line combining a tau transgenic model with the Leprdb/db model. Instead
we looked to other technologies which can allow in vivo introduction of transgenes.
Viral gene therapy was once thought to be the pinnacle for the treatment of
diseases and the future of medicine (Friedmann and Roblin 1972). Unfortunately, the
safety of such technologies was brought into question after a patient fatality in a clinical
trial using adenoviral vectors (Wilson 2009). Although the future of therapeutic gene
delivery is still debatable, the use of viral vectors to alter gene expression in animals has
expanded significantly. It is through viral transgenesis that existing AD mouse models
can be better utilized, reducing monetary cost and time investment as well as allowing
rapid, large scale screens of potentially AD related genes. Adenoviruses have been useful
tools in some fields due to their high efficiency and ease of production, but offer only
transient expression and can trigger a significant immune response, reducing their use in
brain research (Brody and Crystal 1994, Roth and Cristiano 1997, Kibbe, Murdock et al.
2000, Stephenson 2001).
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In recent years, recombinant AAVs (rAAV) have come into their own with new
technological breakthroughs, correcting many of the previous deficiencies, and
conferring greater therapeutic potential (Flotte, Trapnell et al. 2011, Bowles, McPhee et
al. 2012). AAVs are small non-enveloped parvoviruses which use single-stranded DNA
as their genetic material (Mori, Wang et al. 2004, Daya and Berns 2008). Upon infection,
viral single-stranded DNA is taken up into the nucleus, converted to double stranded
DNA, and is expressed throughout the life of the cell. These viruses are dependent on
other viruses, such as adenovirus or herpes simplex virus to achieve proper infection
(Atchison, Casto et al. 1965, Georg-Fries, Biederlack et al. 1984). Wild type AAV has
the ability to integrate into a specific site of human chromosome-19 (Kotin, Siniscalco et
al. 1990, Giraud, Winocour et al. 1994); this feature has been removed in modern rAAVs
(Huser, Gogol-Doring et al. 2010).
Currently, ten different serotypes of AAVs have been well described (Cearley and
Wolfe 2006, Zincarelli, Soltys et al. 2008). The primary difference between serotypes lies
in the capsid amino acid sequence, which alters the tropism of each serotype for different
cell types (Chiorini, Yang et al. 1997, Rutledge, Halbert et al. 1998). The first broadly
studied serotype was AAV2, which is considered to be one of the least efficient AAVs in
the CNS as it transduces far fewer cells than other serotypes (Wang, Wang et al. 2003,
Burger, Gorbatyuk et al. 2004). Serotypes 1, 4, and 5 have shown much greater levels of
transduction than AAV2 (Wang, Wang et al. 2003). Interestingly, AAV4 has shown an
affinity to transduce ependymal cells (Wang, Wang et al. 2003). Overall, analysis of each
serotype showed that AAV8 has the highest transduction efficiency in the CNS (Harding,
Dickinson et al. 2006). However, this serotype may be overly efficacious as studies have
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shown that GFP delivery via AAV8 can produce an overabundance of GFP protein,
resulting in neurotoxicity (Klein, Dayton et al. 2006). Different serotypes have a varying
degree of specificity within the CNS in regards to transduction efficiency. It has been
shown that serotype 9 transduces the hippocampus at higher levels than serotypes 7, 8
and rh10 (Cearley and Wolfe 2006, Klein, Dayton et al. 2008). Serotype 9 also holds
greater promise as it has been shown to cross the blood brain barrier in the absence of
permeabilizing reagents and it also preferentially transduces neurons and astrocytes
(Duque, Joussemet et al. 2009, Foust, Nurre et al. 2009). Similar to serotype 9, serotype
sh10 has displayed high transduction efficiencies with a small range of spread from the
site of injection (Cearley and Wolfe 2006).
These vectors have several advantages. First, rAAVs are particularly useful in
neurological studies as transgene expression occurs in dividing and quiescent cells, such
as neurons (Wu, Phillips et al. 1998). Not only do these rAAVs have the ability to
transduce non-dividing cells, but also the transgene expression in these cells is long
lasting with the appropriate promoter (McCown 2005). Second, AAVs pose little
infective risk to humans (Berns, Pinkerton et al. 1975). It is postulated that 85% of the
human population is infected by AAVs, yet no associated pathology has been observed
and does not induce a significant immune response (Muzyczka 1992, Zaiss, Liu et al.
2002). Finally, the replicative ability of these vectors has been eliminated, which reduces
the likelihood of unintended infection. After it was discovered that two inverted terminal
repeats facilitate replication of these viruses, they were excised, resulting in a replication
deficient rAAV system (Kay, Glorioso et al. 2001). rAAV production relies upon trans
expression of genes, typically packaged into plasmids, derived from adenovirus and the
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rep and cap genes from the deleted intronic regions (Samulski, Chang et al. 1989, Xiao,
Li et al. 1998).
There are disadvantages to utilizing AAVs in transgenesis. The main limitation of
AAV systems is that the packaging size is generally limited to 4.7kb (Srivastava, Lusby
et al. 1983) However, there are some exceptions to this limitation. It has been shown that
AAV5 vectors may carry up to 8.9kb (Allocca, Doria et al. 2008). This small packaging
size severely limits the practicality of using AAVs for transgenesis. Another drawback of
AAVs when compared to lentiviruses is the lack of genomic integration. Though
episomal expression can be long lasting, gene products will not replicate with the
genome, resulting in a gradual loss of expression in dividing cells. In non-dividing
neurons, however, this disadvantage is negligible.
AAVs have been used extensively in the nervous systems of rodents and nonhuman primates with high efficiency and expression. In a study by Jaworski et. al., nontransgenic mice were intracerebrally transduced with AAV vectors carrying APP.SLA
mutants, which contain the Swedish, London and Australian mutations (Jaworski,
Dewachter et al. 2009). By six months plaque deposition was observed in the cortex and
the hippocampus, yet no degeneration was observed (Jaworski, Dewachter et al. 2009). In
the same study, AAVs delivering wild-type and mutant P301L transgenes induce
neurodegeneration of pyramidal neurons of the CA1 and CA2 by 12 weeks and induce
post-mitotic neurons to activate cell-cycle machinery. Additionally, AAV serotypes 9 and
10 have been shown to effectively deliver tau mutants and to rapidly induce
neurodegeneration of dopaminergic neurons of the striatum (Klein, Dayton et al. 2008).
Gene knock-down has also been achieved within the CNS via delivery of siRNAs.
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Delivery of mTOR siRNA via AAV5 reduced mTOR levels by 80% within the CNS (Xu,
Chou et al. 2012). A significant reduction of CDK5 was observed in 3xTgAD mice
transduced with AAV CDK5-miRNA, which resulted in a five-fold decrease in tau
phosphorylation (Piedrahita, Hernandez et al. 2010). A mouse model of amyloid
pathology (TASPM; APPK670N/M671L x PS-1M146V) transduced with pathogenic tau
mutations AAV6 TauP301S or AAV6 3PO displayed increased tau phosphorylation, tau
aggregation, amyloid plaque deposition, neuronal loss and cognitive impairment (Dassie,
Andrews et al. 2013).
Therefore, instead of crossing one of the existing tau transgenic models with the
Leprdb/db line we transduced the brains of Leprdb/db pups with AAV tauP301L mutant to
generate model of tauopathy, leptin resistance, obesity, and T2DM. This method saved a
significant amount of time and financial investment, something we were not prepared to
do after the generation of the db/AD line. In this chapter we carried out a series of
experiments exploring the effects of leptin resistance, obesity, and T2DM on the
development of tau pathology. Additionally, we outline potential mechanisms which may
influence the development and/or exacerbation of pathology.
5.2 – MATERIALS AND METHODS
5.2.1 – Adeno-Associated Virus (AAV) Generation
For this study we utilized an AAV1 construct as this serotype is known to produce
robust expression in the brain and maintain expression for up to nine months (Zincarelli,
Soltys et al. 2008). The tauP301 expression construct containing the chicken β-actin
promoter and the 3’ enhancer woodchuck hepatitis virus post-transcriptional regulatory
element (WPRE), was a kind gift from Dr. Ronald Klein (Louisiana State University in
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Shreveport, Shreveport, LA). The tauP301L mutation was discovered as familial mutation
which promotes the development of pathology and induces neurodegeneration and
dementia in patients with frontotemporal dementia and parkinsonism linked to
chromosome-17 (FTDP-17), and is commonly used in studying tauopathies (Poorkaj,
Bird et al. 1998, Spillantini and Goedert 2000, Morris, Khan et al. 2001, Lin, Lewis et al.
2003). The tauP301L plasmid (pcDNA3), adeno-helper plasmid (pZac2.1), and rep/cap
(AAV1) plasmids (pZac2.1) were co-transfected into HEK293A cells (ATCC; Manassas,
VA) (Klein, Lin et al. 2004, Klein, Lin et al. 2004). After 72 hours, the cells were
harvested and the resulting virus purified by iodixanol gradient, and reconstituted in PBS.
The AAV vector was then titered for copies of vector genomes with WPRE inclusion by
quantitative

real-time

PCR

using

WPRE-specific

primers

(Forward:

GGCTGTTGGGCACTGACAAT, Reverse: CCGAAGGGACGTAGCAGAAG) and RT²
SYBR Green/ROX qPCR Master Mix (#PA-012-12 SABiosciences; Frederick, MA). The
AAV copy numbers were between 1 x 1012 and 1x1013 genomes/mL. These vectors were
created both in Murphy lab and by the UK Viral Core following the same protocol. A
control non-expressing AAV1 (CAG.Flex.eGFP.WPRE.bGH) was purchased from the
University of Pennsylvania Vector Core (AAV-1-ALL854).
5.2.2 – Viral Transduction in vivo
Viral transduction in each mouse brain was conducted as previously described
(Levites, Jansen et al. 2006). Briefly, newborn mice, postnatal day 0-2 (P0-P2), were
gently placed in an aluminum foil envelope and cryoanesthetized on wet ice for
approximately 5 minutes. AAVs (2 µL/ injection) were injected bilaterally into the
intracerebroventricular space using a 5 µL syringe (Hamilton; Reno, NV) with a 26
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gauge needle. Immediately after injection, the pups were warmed under a heat lamp until
fully recovered before returning them to their home cage. The pups were monitored for
three days following injection, then weekly for the remainder of the study. A small
number of mice were left uninjected to use as controls (62 AAV1 tauP301L injected, 28
control AAV1 injected, and 58 uninjected controls).
5.2.3 – Glucose Tolerance Test (GTT)
GTTs were performed two weeks before the end of the study. Mice were fasted
for 6 hours and fasting blood glucose was taken via tail prick using a hand held
glucometer (Breeze2, Bayer HealthCare, LLC; Tarrytown, NY). Immediately after the
baseline glucose measure was taken, the mice were administered an intraperitoneal
injection of glucose (Hospira; Lake Forest, IL) at a dose of 2g/kg body weight. Blood
glucose levels were then measured at 15, 30, 60 and 120 minutes after the injection. Any
reading of ‘HI’ (above the detectable range) was recorded as 700 mg/dL for data analysis.
5.2.4 – Behavioral Testing
One week before the end of the study, mice were tested in the Morris water maze
(MWM) to gauge cognitive function. Mice were trained over five days to locate a
submerged platform (11 cm) using external cues. The platform was in the northeast
quadrant of a 134.5 cm diameter pool filled with opaque water (25ºC) containing
nontoxic white tempura paint. Mice were given 60 seconds to find the platform, and if
they did not find it within this time period, they were placed on the platform for 15
seconds to acquaint them with its location. Mice were trained over four 60-second trials
each day (starting from a different quadrant on each trial), with a minimum five-minute
interval between trials. At the end of training on the fifth day the platform was removed

98

and a probe trial was performed. Additionally, after the probe trial a single visual acuity
test was performed during which the platform was moved from its training location to the
opposite side of the pool and cued with a small white flag. All trials were recorded using
a video camera and analyzed with EthoVision XT software (Noldus Information
Technology; Leesburg, VA) to measure swim distance, escape latency, and velocity.
5.2.5 – Cell Culture
HEK293 cells stably expressing the tauP301L mutation (a kind gift from Dr. Chad
Dickey, University of South Florida) were grown in DMEM (Invitrogen) with 10% fetal
bovine serum (HyClone; Logan, UT), 1% penicillin-streptomycin (Cellgro; Manassas,
VA) and 120 ng/mL G418 (HyClone) for selective pressure. Cells were treated with
various concentrations (0, 10, 50, and 100 ng/mL) of recombinant human leptin (SigmaAldrich; St. Louis, MO) for 48 hours and lysed in RIPA buffer (1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50mM Tris, and 150 mM sodium
chloride, pH = 8.0) supplemented with protease inhibitor cocktail (Amresco; Solon, OH)
and phosphatase inhibitor (EMD Millipore; Billerica, MA).
5.2.6 – Western Blotting and ELISAs
Frozen brain tissue was homogenized with an AHS200 PowerMax polytron
(VWR; Radnor, PA) in Tris-buffered saline (50mM Tris, 274mM NaCl, and 5mM KCl,
pH = 7.4) with protease (Amresco) and phosphatase inhibitors (EMD Millipore) at 1mL
per 100 mg tissue. The homogenate was centrifuged at 13,000 x g for 15 minutes at 4°C
and the supernatant separated and stored at -80ºC. The protein concentrations of the
supernatants were determined by bicinchoninic acid assay (Pierce; Rockford, IL).
Extracts (25 µg) were separated by SDS-PAGE on 4-12% Bis-Tris Criterion gels in
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MOPS running buffer (Bio-Rad; Hercules, CA) and transferred to a 0.2 µm nitrocellulose
membrane (Bio-Rad). Following transfer, the membranes were blocked overnight in PBS
with 1% bovine serum albumin and 2% BlockAce (AbD Serotec, Raleigh, NC). Blots
were then probed with AT8 (Greco, Bryan et al. 2010, Koike, Green et al. 2010,
Martinez-Coria, Green et al. 2010, van Eersel, Ke et al. 2010) for pSer202/pThr205 tau
(#MN1020, Pierce; 1:500), AT180 (Koike, Green et al. 2010, Martinez-Coria, Green et
al. 2010) for pThr231 tau (#MN1040, Pierce, 1:100), PHF-1 (Martinez-Coria, Green et al.
2010) for pSer396/pS404 (courtesy of Dr. Peter Davies, Albert Einstein College of
Medicine, Bronx, NY 1:1000), HT7 (Koike, Green et al. 2010, Martinez-Coria, Green et
al. 2010, van Eersel, Ke et al. 2010) for total tau (#MN1000, Pierce, 1:1000), and antiGAPDH (ab9385, Abcam; Cambridge, MA, 1:5000) antibodies then probed with HRPconjugated rabbit anti-mouse secondary antibody (Rockland Immunochemicals;
Gilbertsville, PA, 1:10,000). Membranes were then incubated with SuperSignal West
Dura chemiluminescent substrate (Pierce), and then exposed to film. Films were scanned,
and

densitometric

analysis

was

performed

using

Image

J

software

(NIH;

www.imagej.net). Total tau (KHB0041, LifeTechnologies), pSer199 tau (KHB7041,
LifeTechnologies), and pThr181 tau (#80062, Fujirebio; Malvern, PA) were measured by
sandwich ELISA using commercially available kits according to manufacturer’s
instructions. Absorbance was measured at 450 nm using a multiwell plate reader
(BioTek, Winooski, VT).
5.2.7 – Immunohistochemistry
Formalin-fixed

hemibrains

were

serially

cryoprotected

in

sucrose

(at

concentrations of 10%, 20%, and 30% sucrose for 24 hours each). Brains were sectioned
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at 25 µm on a freezing sliding microtome and stored in PBS with 0.05% NaN3.
Immunohistochemistry was performed using PHF-1 (courtesy of Dr. Peter Davies, 1:100)
to stain for neurofibrillary tangles, and a mouse on mouse (M.O.M) peroxidase kit
(Vector Laboratories; Burlingame, CA) with 3,3’diaminobenzidine (DAB; Vector
Laboratories) for development. Fluorescent double-labeling was also performed for PHF1 to stain for neurofibrillary tangles with Alexa Fluor® 568 secondary antibody
(#A10037, Life Technologies, 1:200), and astrocytes were labeled with Rabbit anti-glial
fibrillary acidic protein (GFAP) antibody (#PA1-10019, Pierce, 1:1000) and Alexa
Fluor® 488 secondary antibody (#A11070, Life Technologies,1:200). Slides were cover
slipped with VECTASHIELD® Mounting Media with DAPI (#H-1500, Vector
Laboratories). Images were taken using an Olympus BX51 microscope (Olympus;
Melville, NY) and an Olympus Q-Color5 digital camera (Olympus). Images were
processed using Image J software (NIH) to perform densitometric analysis.
5.3 – RESULTS
5.3.1 – Tau Phosphorylation in Leprdb/db Mice
To determine if tau phosphorylation was altered in the db/AD mice we performed
dotblot analysis. We observed that mice homozygous for the db mutation displayed
significantly increased levels of tau phosphorylation (p = 0.03, n = 22 Lepr+/+, 50
Lepr+/db, 24 Leprdb/db) (Figure 5.1). Though this increase in tau phosphorylation is
interesting, rodent tau does not naturally form (PHFs) or NFTs. It is, thus, not possible to
study the effect of diabetes on tangle pathology in this model. We, therefore, turned to
AAV technology, which facilitates rapid production of a large number of dual transgenic
animals (Platt, Reeves et al. 2013).
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5.3.2 – Leptin Regulates Tau Phosphorylation in vitro
The key characteristic which drives pathology in Leprdb/db mice is the abolishment
of leptin signaling. If the lack of leptin signaling promotes the development of pathology,
then it stands to reason that leptin itself may act as an inhibitor towards the development
of tau pathology. Previous studies have shown leptin treatments reduce tau
phosphorylation in vitro (Greco, Sarkar et al. 2008, Marwarha, Dasari et al. 2010). To
determine if the increase in tau phosphorylation in Leprdb/db mice is directly related the
leptin signaling axis, we tested how increased leptin signaling would affect tau
phosphorylation in vitro. TauP301L expressing HEK293 cells were treated within a 0 to
100 ng/mL range of recombinant human leptin. Leptin treatment induced a dosedependent reduction in tau phosphorylation at the pSer202/Thr205 (AT8) and pThr231
(AT180) epitopes as shown via Western blot (Figure 5.2A-B). Additionally, we
incubated SH-SY5Y cells with varying concentrations of oligomeric tau, which we
showed in chapter 3 is cytotoxic to cells, and treated half the cells with 100 ng/mL leptin
to determine if leptin’s reported neuroprotective effects may reduce oligomeric tau
cytotoxicity. Leptin treatment had no effect on reducing the cytotoxicity of oligomeric
tau (Figure 5.2C; p = 0.191). These results indicate that leptin inhibits tau
phosphorylation, and suggest that this may be the mechanism for the increase tau
phosphorylation observed in the Leprdb/db mice.
5.3.3 – Characteristics of the Leprdb/db Mouse Model
In order to better explore the impact diabetes and obesity may have on the
development of tangle pathology, independent of amyloid pathology, we transduced the
brains of Leprdb/db mice with a tau mutant, tauP301L. Though the tauopathy observed in
AD does not occur due to a genetic defect, tau mutations are found in other tauopathies.
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This mutation is commonly used to produce tangle pathology in rodent models (Lewis,
McGowan et al. 2000, Gotz, Chen et al. 2001). The tauP301L mutation was discovered as
familial mutation which promotes the development of pathology and induces
neurodegeneration and dementia in patients with frontotemporal dementia and
parkinsonism linked to chromosome-17 (FTDP-17) (Hutton, Lendon et al. 1998, Poorkaj,
Bird et al. 1998, Spillantini, Murrell et al. 1998, Morris, Khan et al. 2001). This mutation
is commonly used and is known to produce tangle pathology in rodent models (Lewis,
McGowan et al. 2000, Gotz, Chen et al. 2001).
Characterization of these mice revealed that mice homozygous for the db
mutation (Leprdb/db) weighed significantly more than wild-type (Lepr+/+) or heterozygous
(Lepr+/db) littermates (p = 0.001, n = 18 Lepr+/+, 42 Lepr+/db, 30 Leprdb/db ), and displayed
accelerated weight gain from weaning (Figure 5.3A-B). No weight differences were
observed between genders until five and six months where males of all genotypes
weighed significantly more than their female counterparts (data not shown; 5 months: p <
0.001, 6 months: p < 0.001; n = 7F/11M, Lepr+/+, 18F/24M Lepr+/db, 14F/16M Leprdb/db).
Additionally, GTT analysis showed that mice homozygous for the db mutation displayed
impaired glucose handling compared to wild-type and heterozygous littermates (Figure
5.3C-D: p < 0.001, n = 18 Lepr+/+, 45 Lepr+/db, 25 Leprdb/db). Males displayed an even
greater impairment in glucose handling compared to females (data not shown; p < 0.01, n
= 8F/10M, Lepr+/+, 18F/27M Lepr+/db, 14F/13M Leprdb/db). AAV injection with either the
control or tauP301L constructs had no effect on glucose handling (Figure 5.3E-F: p =
0.001, n = 26 uninjected, 27 control AAV1, 35 AAV1 tauP301L). These data indicate that
mice homozygous for the db mutation have metabolic dysfunction, consistent with
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previous reports (Chua, Chung et al. 1996, Koch, Augustine et al. 2010), and that
expression of mutant tau had no impact on this phenotype
5.3.4 – Mice Transduced with TauP301L Express Higher Levels of the Tau Protein
At six months of age, mice were euthanized and their tissues harvested. Mice
transduced with AAV1 tauP301L expressed significantly higher levels of tau than
uninjected animals (Figure 5.4A-B: p < 0.005, n = 13 uninjected [5 Lepr+/+, 3 Lepr+/db, 5
Leprdb/db] / 11 tauP301L [5 Lepr+/+, 3 Lepr+/db, 3 Leprdb/db]). It is also interesting to note that
some AAV1 tauP301L samples display large protein smears on Western blot (Figure 5.4A)
indicating that large amounts of tau aggregates are present in the homogenate, indicative
of tangle pathology. Total tau levels were not significantly different between genotypes
(Figure 5.4C: p = 0.172, n = 10 Lepr+/+, 23 Lepr+/db, 10 Leprdb/db) though there was a
slight trend towards a reduction of total tau in homozygous db mice (p = 0.172). The
amount of tau phosphorylation was significantly higher in homozygous db mice
compared to the other genotypes (Figure 5.4D-E: pSer 199 tau p < 0.05, pThr 181 tau p
< 0.05, n = 10 Lepr+/+, 23 Lepr+/db, 10 Leprdb/db). As only the AAV tauP301L injected mice
display increased tau expression uninjected and non-expressing AAV injected mice will
collectively be referred to as the ‘control’ group henceforth. These data support the
hypothesis that leptin resistance, obesity, and diabetes increase tau phosphorylation in
vivo.
To determine if NFT pathology was exacerbated by diabetes, we examined brain
sections from injected mice by IHC (Figure 5.5). AAV1 tauP301L-injected mice
developed tangle pathology in the neocortex and hippocampus (Figure 5.5A), typically
present in large pyramidal neurons (Figure 5.5B). Direct comparison of AAV1 tauP301L104

injected mice (Figure 5.5C & E) to control mice (Figure 5.5D & F), illustrated the
dramatic extent of tangle pathology which developed in mice expressing the tauP301L
mutation. To determine the interaction between genotype and tangle burden, five sections
from 15 mice, five of each genotype, were labeled with PHF-1 (Figure 5.6A-C).
Consistent with the observed increase in tau phosphorylation, db homozygotes displayed
more extensive tangle pathology than their wild-type or heterozygous littermates (Figure
5.6D). Interestingly, other tangle-like structures, which resembled astrocytes, were also
observed throughout the brain (Figure 5.7A). Fluorescent co-labeling with PHF1 and
anti-GFAP antibodies indicated that tangles were indeed present in a small subset of
astrocytes (Figure 5.7B).
5.3.5 – Cognitive Function
Finally, in order to determine if the observed tangle pathology induced cognitive
deficits we performed a basic Morris Water Maze test. Previous studies using AAV1
vectors to transduce the tauP301L mutation indicate extensive tangle pathology develops by
6 months of age, therefore one week before the 6 month endpoint mice were tested for
cognitive deficits (Klein, Lin et al. 2004). For all training days, swim distance was not
significantly different between the three genotypes (Figure 5.8A: p = 0.959, n = 18
Lepr+/+, 45 Lepr+/db, 26 Leprdb/db). Escape latency for db homozygous animals was
significantly higher, a finding likely explained by the slight reduction in observed swim
speed (data not shown, p < 0.001). There was no difference in swim distance between
AAV control and AAV1 tauP301L injected animals (Figure 5.8B: p = 0.862, n = 54
control, 35 AAV1 tauP301L). After the fifth day of acquisition trials, a probe trial was
performed to test spatial memory. Interestingly, db heterozygotes spent significantly
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more time in the target quadrant than the other genotypes (p = 0.044 compared to
Lepr+/+), whereas AAV1 tauP301L injection had no effect (p = 0.992; Figure 5.8C:
genotype: n = 18 Lepr+/+, 45 Lepr+/db, 26 Leprdb/db; treatment: p = 0.473, n = 35 AAV1
tauP301L, 54 control).
Diabetic retinopathy is a common secondary complication of diabetes and has
previously been reported in Leprdb/db mice as early as 22 weeks of age (Midena, Segato et
al. 1989, Clements, Robison et al. 1998, Cheung, Fung et al. 2005). Therefore, in order to
determine if there was a visual impairment in db homozygotes that could potentially
affect MWM performance, we performed a visual acuity test. In this test all mice
displayed similar swim distances to the platform (Figure 5.8D: genotype: p = 0.118, n =
18 Lepr+/+, 45 Lepr+/db, 26 Leprdb/db; treatment: p = 0.59, n = 35 AAV1 tauP301L, 54
control) regardless of genotype or treatment, indicating that there were no significant
visual deficits.
5.3.6 – Signaling Mechanisms
To explore some of the mechanisms which may drive tau pathology we probed
various regulatory phosphor-epitopes of GSK3β, AMPK, MAPK, and AKT (Figure 5.9).
Phosphorylation of GSK3β at serine 9 inhibits GSK3β activity (Cai, Wang et al. 2007).
Leprdb/db mice display decreased phosphorylation of at this epitope (p ≤ 0.05), suggesting
an increase in GSK3β activity and potentially tau phosphorylation (Figure 5.9A).
Additionally, phosphorylation of AMPK at threonine 172 is increased in these mice,
indicated AMPK activity is elevated, which can result in increased tau phosphorylation (p
≤ 0.05; Figure 5.9B) (Hardie and Carling 1997). A reduction in phosphorylation at
threonine 202 of MAPK is observed in Leprdb/db mice (Figure 5.9C), but is not quite
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significant (p = 0.086) (Chuenkova and Pereira 2001). Though total AKT levels are
significantly elevated in Leprdb/db mice (data not shown; p ≤ 0.05) activation of AKT is
not elevated by phosphorylation of serine 473 (p = 0.752; Figure 5.9D). Representations
of the western blots can be observed in Figure 5.9E.
5.4 – CONCLUSIONS
The influence of leptin resistance, obesity, and diabetes on tau pathology in
neurodegeneration remains unclear, largely due to the complex metabolic state of these
conditions. Leptin has been shown to be protective against stroke, excitotoxicity, and
neuropathy (Dicou, Attoub et al. 2001, Zhang, Wang et al. 2007, Guo, Jiang et al. 2008,
Lieb, Beiser et al. 2009, Perez-Gonzalez, Antequera et al. 2011). Reports have also
indicated that leptin may improve cognition and modulate hippocampal synaptic
plasticity (Shanley, Irving et al. 2001, Wayner, Armstrong et al. 2004, Farr, Banks et al.
2006, Oomura, Hori et al. 2006, Paz-Filho, Babikian et al. 2008). Similarly, several
studies have demonstrated that deficient leptin signaling, as a result of mutation or
resistance, can impair cognition (Li, Aou et al. 2002, Harvey and Ashford 2003,
Winocur, Greenwood et al. 2005). In this study, we demonstrate that leptin induced
obesity and diabetes modulate tau phosphorylation pathways, resulting in increased tau
phosphorylation, and that this in turn leads to accelerated development of tangle
pathology.
Leptin functions through JAK/STAT signaling pathways, activating downstream
regulatory kinases such as MAPK, AKT, and mTOR, all of which play key roles in many
global pathways, but also in regulating tau’s phosphorylation state (Augustinack,
Schneider et al. 2002, Cavallini, Brewerton et al. 2013). It is also interesting to note that
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these three regulatory pathways inhibit glycogen synthase kinase-3β (GSK3β), thought to
be the primary kinase involved in pathologic tau hyperphosphorylation (Frame and
Cohen 2001, Lee 2011). Leptin-mediated inhibition of GSK3β activity has been reported,
and it is logical to deduce that GSK3β activity would be increased in the absence of leptin
signaling, leading to increased tau phosphorylation (Valerio, Ghisi et al. 2006).
What is perhaps most interesting, is that AMPK activity was found to be elevated
in the brains of Leprdb/db mice. This was an unexpected finding as AMPK activity is
typically found to be low in the muscles of T2DM patients (Viollet, Lantier et al. 2009).
AMPK can be activated by increased adenosine monophosphate (AMP) concentrations, a
hallmark of low cellular metabolism. In addition to elevated levels of AMP, a secondary
phosphorylation of AMPK’s by AMPK kinases (AMPKKs) like liver kinase B1,
transforming growth factor-β-activated kinase 1, and Ca2+-calmodulin-dependent kinase
β can activate AMPK activity (Wang, Jiang et al. 2010). It is possible that these findings
are unique to this particular stage of insulin resistance at this age in the Leprdb/db mice.
This could suggest that AMP levels suddenly fall off around 6 months, while AMPK
phosphorylation is high, resulting in the increased activity we observed. The increased
AMPK activity found in the brains of these mice is counter-intuitive and warrants further
investigation in regards to its increased activity and ability to hyperphosphorylate tau.
Despite increases in tangle pathology, these mice displayed no impairments in
learning or memory, as tested by the MWM. The absence of any observed deficits in
learning or memory were not entirely surprising. Other traditional transgenic models,
which utilize the tauP301L mutation, display cognitive deficits at around 16 months of age
(Harris, Koyama et al. 2012). Our model has more diffuse expression than the tau models
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used in those studies and may display significant cognitive deficits at ages beyond 6
months. It is quite possible that neurodegeneration is minimal at this age though
pathology is developing in the brains of these mice. One barrier we encountered when
using the Leprdb/db model previously is that these mice have a substantially decreased
lifespan (~10-12 months) and can develop quite severe complications associated with
obesity and metabolic dysfunction. While the Leprdb/db line has proven to be an excellent
model of obesity and diabetes, any future studies with these mice will need to delicately
balance possible age requirements needed to read a neurodegenerative state with the
innate morbidity and mortality of these mice.
In addition to future studies in aged mice, altering the AAV vector itself could
provide some benefit. This study utilized an AAV serotype 1 vector. While injected mice
displayed extensive tangle pathology, utilizing another serotype could provide slightly
better results. Other AAV serotypes, such as 8 and 9 have been shown to have the highest
transduction efficiencies within the CNS, are able to provide robust expression within the
hippocampus, and cross the blood-brain barrier more easily than other serotypes (Cearley
and Wolfe 2006, Harding, Dickinson et al. 2006, Klein, Dayton et al. 2008, Duque,
Joussemet et al. 2009). Using a different AAV serotype may allow for higher
transduction efficiencies and more advanced pathology, though further experiments
would be required to determine if they would yield better results than our current AAV
serotype. Though the CBA promoter of the virus should transduce all cell types, it is
possible other promoters could enhance transgene expression. Studies indicate that the
human synapsin promoter, which selectively transduces neurons, can induce more potent
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transgene expression than other promoters, including the CBA promoter (Shevtsova,
Malik et al. 2005).
In conclusion, we have demonstrated that a model of dysfunctional leptin
signaling, obesity, and uncontrolled T2DM has increased tau phosphorylation and tangle
pathology. This study establishes a connection between metabolic dysfunction and
tauopathies. This study also paves way for the development of potential therapeutic
interventions, which could involve modulation of kinase activity with compounds such as
lithium, rapamycin, or T2DM therapeutics. These studies would help determine which
pathways directly impact pathology in this model. Additional studies into the activity
states of important tau kinases also warrant investigation in this model.
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Figure 5.1 Tau Phosphorylation is Increased in db Homozygous Mice.
(A) Homozygous db mice showed an increase in tau phosphorylation (shown: phospo-tau
[AT8]; total tau [HT7] and β-actin [AC15]; ANOVA, F[2,97]=2.917, p < 0.02, n = 22
Lepr+/+, 50 Lepr+/db, 24 Leprdb/db). The increase was also significant when not
standardized to total tau (p < 0.03, not shown). No difference between sexes was
observed (p = 0.182, n = 45 female, 51 male). (B) The AD genotype did not affect tau
phosphorylation (p = 0.647).
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Figure 5.2 Leptin Treatment Reduces Tau Phosphorylation but not Oligomeric Tau
Cytotoxicity.
(A-B HEK293 cells stably transfected with tauP301L display a dose dependent reduction in
tau phosphorylation when treated with recombinant human leptin (ANOVA,
F[3,8]=0.016; AT180: p ≤ 0.05; AT8 p = 0.108). (C) Leptin treatment (100 ng/mL) did
not reduce oligomeric tau cytotoxicity (ANOVA, F[5,42]=11.208; p = 0.191).
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Figure 5.3 Phenotypic Characteristics of Leprdb/db Mice.
Mice homozygous for the db genotype were obese, whereas wild-type and heterozygous
mice maintained a normal body weight (A-B) (4 month old littermates, right: Lepr+/db;
middle: Leprdb/db ; left: Lepr+/+. ANOVA, p < 0.001, n =18 Lepr+/+, 45 Lepr+/db 25
Leprdb/db). At five and six months males of all genotypes weighed more than female
counterparts (data not shown; 5 months: p < 0.001, 6 months: p < 0.001; n = 7F/11M,
Lepr+/+, 18F/24M Lepr+/db, 14F/16M Leprdb/db). Mice homozygous for the db genotype
had impaired glucose handling as determined by glucose tolerance test (C–D) (Repeated
measures ANOVA, F[2,85]=11.046; * = p < 0.001, n = 18 Lepr+/+, 45 Lepr+/db, 25
Leprdb/db). Males displayed a greater impairment in glucose tolerance (data not shown; p
< 0.01, n = 8F/10M, Lepr+/+, 18F/27M Lepr+/db, 14F/13M Leprdb/db). AAV injection had
no effect on glucose handling (E–F) (ANOVA, F[2,85]=0.074; p < 0.879, n = 26
uninjected, 27 control AAV1 injected, 35 tauP301L injected).
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Figure 5.4 AAV1 TauP301L Expression in db Mice. (A-B)
A cohort of mice were injected with AAV1 tauP301L at P0-P2 and expression levels of
total tau (HT7) were evaluated by Western blot after six months (ANOVA,
F[2,40]=2.641, p < 0.05; n = 13 uninjected [5 Lepr+/+, 3 Lepr+/db, 5 Leprdb/db] / 11 tauP301L
[5 Lepr+/+, 3 Lepr+/db, 3 Leprdb/db]). (C) Leprdb/db mice did not displayed significantly
different levels of total tau, as measured by sandwich ELISA, though they did appear to
have slightly less total tau (p = 0.172, n = 10 Lepr+/+, 23 Lepr+/db, 10 Leprdb/db) (D-E)
Phospho-tau Ser199 and Thr181 levels were also measured by ELISA. Both epitopes
showed a significant increase in the percentage of tau phosphorylation, standardized to
total tau, in db homozygotes compared to other genotypes (p181 Tau: ANOVA,
F[2,40]=3.199, p199 Tau: ANOVA, F[2,40]=3.0.92, * = p < 0.05; n = 10 Lepr+/+, 23
Lepr+/db, 10 Leprdb/db).

118

119

Figure 5.5 Tangle expression in AAV1 TauP301L injected mice.
(A) AAV1 tauP301L injected brain section of a db homozygous mouse stained with PHF-1
primary antibody. Extensive tangle pathology developed in the hippocampus of these
mice at 6 months of age. (B) Large neurofibrillary tangles could also be observed in the
cortex. (C – F) TauP301L injected mice displayed extensive PHF1 immunoreactivity
compared to uninjected controls (Top: PHF-1, Bottom: Nuclei stained with DAPI for
anatomical reference). Note that no PHF1 immunoreactivity is observed in mice not
injected with AAV1 tauP301L.
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Figure 5.6 Leprdb/db Mice Display Tangle Pathology Within the Hippocampus.
(A-C) AAV1 tauP301L injected hemibrains were sectioned and stained for PHF-1 to
determine the extent of tangle pathology in the hippocampus (A: Lepr+/+ B: Lepr+/db, C:
Leprdb/db). (D) Densitometric analysis of these sections indicated that db homozygotes
displayed increased PHF1 immunoreactivity than the wild-types or heterozygotes (
ANOVA, F[2,12]=4.604, p < 0.05, n = 5 Lepr+/+, 5 Lepr+/db, 5 Leprdb/db).
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Figure 5.7 Astrocytic Tangles are Present in AAV1 TauP301L Mice.
(A) In addition to tangles in pyramidal neurons, tangles were present in astrocytes
(arrows). (B) Co-labeling with PHF1 and anti-GFAP antibodies revealed co-localization
of NFTs within a subset of astrocytes (arrows).
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Figure 5.8 Mice Have No Deficits in Memory or Learning Based on Morris Water
Maze Analysis.
(A - B) There were no significant differences by genotype or treatment (Repeated
Measures ANOVA, F[2,2]=.042, genotype: p = 0.837, n = 18 Lepr+/+, 45 Lepr+/db, 26
Leprdb/db, treatment: Repeated Measures ANOVA, F[2,1]=.031, p = 0.633, n = 54 control,
35 AAV1 tauP301L injected). (C) On the last day of training after the final trial, the
platform was removed and mice underwent a probe trial. Heterozygotes performed
significantly better at this trial than their counterparts, and treatment had no effect
(genotype: ANOVA, F[2,86]=6.285, p < 0.05, n = 18 Lepr+/+, 45 Lepr+/db, 26 Leprdb/db;
treatment: ANOVA, F[2,87]=0.923, p = 0.473, n = 54 control, 35 AAV1 tauP301L
injected) (D) After the probe trial the platform was placed in the tank within the
southwest quadrant and flagged to make the platform visible. Neither genotype nor
treatment had any significant effect (genotype: ANOVA, F[2,86]=2.858, p = 0.118, n =
18 Lepr+/+, 45 Lepr+/db, 26 Leprdb/db, treatment: ANOVA, F[2,87]=2.988, p = 0.59, n = 54
control, 35 AAV1 tauP301L injected).
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Figure 5.9 GSK3β and AMPK are activated in Leprdb/db mice.
Leprdb/db mice display decreased phosphorylation at the serine 9 epitope of GSK3β is
reduced (ANOVA, F[2,12]=3.562, p ≤ 0.05; A). Increased phosphorylation at threonine
172 of AMPK is also increased in these mice (ANOVA, F[2,12]=6.942, p ≤ 0.05; B). A
reduction in phosphorylation at threonine 202 of MAPK is observed in Leprdb/db mice
(C), but is not quite significant (ANOVA, F[2,12]=3.581, p = 0.086). Phosphorylation at
serine 473 of AKT is not different between any of the genotypes (ANOVA,
F[2,12]=4.018, p = 0.752; D). GAPDH expression was not significant between any
genotypes and was used as a loading control (ANOVA, F[2,12]=2.241, p = 0.58; E).
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS
6.1 – SUMMARY
In chapter three, we evaluated mechanisms by which tau pathology can develop
and how pathology may lead to neurodegeneration. First we evaluated the effects of
knocking-down GSK3β expression using anti-sense oligonucleotide technology in
SAMP8 mice. GSK3β is believed to be a major kinase involved in tau pathogenesis.
Inhibiting the expression of this kinase is thought to be a key therapeutic intervention for
treating tauopathies. Knock-down of GSK3β revealed a significant reduction in
phosphorylated tau (pThr231), as was expected (Figure 3.1).
Tau pathology is not only initiated by aberrant phosphorylation events.
Alternative splicing of tau can result in unequal inclusion of microtubule binding
domains (3R:4R ratio) which can result in pathogenesis. We evaluated this effect in
myotonic dystrophy cases. Myotonic dystrophy is a splicing disease in which expansions
in either DMPK (Type I DM) or ZNF9 (Type II DM) sequester splicing machinery,
leaving other transcripts without proper processing by the spliceosome. Individuals with
DM develop muscle wasting, but also develop a series of other pathologies including
tauopathy. Western blot analysis of DM cases revealed that expression of tau isoforms
were altered, with DM case samples expressing lower molecular weight tau isoforms not
seen in control cases. Additionally, expression of other proteins associated with
neurodegenerative disease, such as BACE1 and BIN1, are found to be expressed at
higher levels in DM cases.
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Next, we tested which tau structures (monomers, fibrils, and oligomers) were
most cytotoxic. Initial studies revealed tau oligomers were cytotoxic to SH-SY5Y cells,
whereas monomers and fibrils were not (Figure 3.3A). To explore the toxic
characteristics of oligomeric tau both primary rat hippocampal neurons and SH-SY5Ys
were treated with varying concentrations of tau oligomers (Figure 3.3B-C). Cytotoxicity
of oligomers was significant at concentrations of 50 nM and higher. These findings were
important to verify which tau species is most cytotoxic to both immortalized cell lines
and primary neuronal culture.
Finally, we wanted to determine if T2DM may influence the development of
pathology in AD patients. To do so, we compared pathologic data from normal, diabetic,
AD, and diabetic AD patients. Interestingly, diabetic AD patients displayed significant
reductions in tangle counts in all brain regions except the occipital lobe, which is likely
due to the fact that the occipital lobe is relatively unaffected in AD (Figure 3.4). These
effects were restricted to tau pathology as diffuse and neuritic plaque counts were no
different between AD and diabetic AD cases.
In chapter four, we presented evidence that suggests leptin resistance induced
obesity and diabetes may influence the development of neurodegenerative disease. The
initial phases of this project began with a high-fat diet study in APP/PS1 mice. Neither
ketogenic diet nor high-fat western diet resulted in increased amyloid pathology.
However, this study did reveal that total Aβ levels were negatively correlated with
plasma leptin levels (Figure 4.1). To further investigate this finding, overexpressing
human APP in H4 neuroglioma cells were treated with leptin, and we observed a dose
dependent decrease in Aβ generation related to leptin concentration (Figure 4.2). This
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reduction in Aβ generation is due to a reduction in γ-secretase expression. The first sign
of this reduced γ-secretase expression was found in an APP western blot which showed
that leptin treated cells accumulated α-CTFs. RT-qPCR analysis revealed that mRNA
levels of all γ-secretase subunits was reduced in cells treated with leptin (Figure 4.3).
Interestingly, BACE1 expression was not altered by leptin treatment, but BACE2
expression was increased.
Leptin is an adipokine which signals satiety and increased energy metabolism via
the hypothalamus. However, a chronically high level of circulating leptin results in
desensitization of the hypothalamus to leptin signaling, resulting in leptin resistance. This
condition is common in obesity and T2DM. To explore the impact leptin resistance may
have on amyloid pathology, we crossed leptin-resistant db mice with the APP/PS1 (AD)
line. This line developed obesity and diabetes as a result of leptin resistance (Figure 4.4)
and MWM testing revealed that db/AD mice develop severe cognitive impairment
(Figure 4.5). Interestingly, we observed no increase in plaque deposition within the
brains of db/AD mice when compared to AD mice (Figure 4.6).
To determine how the db/AD mice develop cognitive impairment without
increased amyloid deposition, we turned to the brain’s vasculature for answers. Using
vascular corrosion casting to isolate the structure of the brain’s vasculature we were able
to visualize vascular events within the brain using SEM. While wild type and db
displayed no vascular abnormalities, AD and db/AD mice presented with varying degrees
of pathology ranging from small blebbing of vessels to large complex saccular aneurysms
(Figure 4.7). This finding did not explain, however, why cognitive deficits were only
observed in db/AD mice and not AD mice, as they had the same vascular pathology by
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SEM analysis. Following up this experiment with small animal MRI revealed that db/AD
mice developed ischemic strokes, which was supported by histological evidence (Figures
4.8 and 4.9). These findings suggest that a mechanism unique to the db/AD mouse line
produces cognitive impairment, not due to amyloid, but from extensive cerebrovascular
pathology.
In chapter five, we went beyond amyloid to determine how leptin resistance
induced obesity and diabetes might affect tau pathology. In db/AD mice we observed a
significant increase in tau phosphorylation in mice homozygous for the db mutation,
regardless of the AD genotype (Figure 5.1). To verify this observation in cell culture we
treated HEK293 cells expressing tau mutant P301L with varying concentrations of leptin.
We observed a significant reduction in tau phosphorylation (Figure 5.2), indicating that
leptin signaling reduces tau phosphorylation, and the observations in db/AD mice in
which leptin resistance resulted in increased tau phosphorylation. To further explore these
mechanisms we created a mouse model of tauopathy and leptin resistance.
Instead of crossing the Leprdb/db line with a tau transgenic line, as we did in the
db/AD line in regards to amyloidogenic mutations, we utilized AAV technology to
introduce the tau mutant P301L into the brains of Leprdb/db mice. Mice with the Leprdb/db
mutation displayed significant increases in weight gain and impaired glucose handling
(Figure 5.3). AAV tauP301L injected Leprdb/db mice display significantly elevated levels of
phosphorylated tau (Figure 5.4) compared to other genotypes also transduced with
tauP301L. We demonstrated that AAV tauP301L injected Leprdb/db mice develop significantly
more tangle pathology within the hippocampus (Figure 5.6). In addition, AAV tauP301L
transduced brains displayed a large number of astrocytic tangles, verified by fluorescent
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co-labeling for PHF-1 and GFAP (Figure 5.7). Though these astrocytic tangles were
observed in many brains, their presence was not consistent enough to draw any
conclusions and is likely a result of variable viral transduction efficiency. Finally, these
mice did not display any cognitive deficits, despite extensive tangle pathology in all
genotypes (Figure 5.8). It is likely that the mice had not reached an appropriately
advanced age for pathology to initiate any cognitive deficit.
To determine potential underlying mechanisms involved in this acceleration of tau
pathology in Leprdb/db mice we used western blot to determine if key enzymes known to
be involved in tau phosphorylation were activated or inhibited. We determined inhibitory
phosphorylation of GSK3β at serine 9 was significantly reduced in Leprdb/db mice (Figure
5.9). Additionally, activation of AMPK by phosphorylation at threonine 172 was
significantly elevated in Leprdb/db mice. AKT and MAPK, however, showed no
significant alterations in activation by phosphorylation.
Interestingly, observations from chapter 5 were different than what we observed
from human case data from chapter 3. Based upon data observed in the db/tauP301L mouse
model we would have expected NFT counts to be elevated in diabetic AD cases
compared to AD cases. However, diabetic AD cases displayed significant reduction in
NFT counts compared to AD cases (Figure 3.4). We suspect that these differences are a
result of diabetic therapeutics taken by all the human diabetic cases. It is possible that
diabetes medications counter the effects of diabetes and inhibit the development of
pathology.
The ultimate goal of this project was to discern whether or not leptin and leptin
resistance induced obesity and diabetes might play a role in the development of
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neurodegenerative disease. Collectively, these results indicate that this metabolic
dysfunction does indeed play a role in the development of pathology, in relation to both
amyloidogenic models and tau models of disease, though with very different outcomes.
Leptin resistance induced obesity and diabetes generate vascular pathology in an
amyloidogenic model of neurodegenerative disease while tau pathology is exacerbated by
metabolic dysfunction. Despite many interesting observations, the etiology of
pathogenesis remains unclear and warrants further investigation.
6.2 – CONCLUSIONS and FUTURE DIRECTIONS
Here we have created new models of leptin resistance induced obesity and
diabetes with either amyloid or tau pathology. The db model expressing amyloidogenic
mutations, surprisingly, does not generate more amyloid pathology, but presented with
cerebrovascular pathology. The db model expressing tauP301L developed increased tau
phosphorylation and NFT pathology. While these two models provide exciting new
evidence, suggesting that metabolic dysfunction can result in neurodegenerative disease,
we are left with more questions than answers.
One key drawback to this model is that whole body leptin resistance initiates a
cascade of events which results in severe metabolic disease, disrupting many systems in
the brain. To better explore our original hypothesis, that leptin resistance alone might
promote pathology, we need to develop a better model where leptin resistance is found in
all regions of the brain, except for the hypothalamus. This would prevent the
development of obesity and diabetes, while still allowing leptin resistance to influence
the development of pathology in areas like the hippocampus and cortex.
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There are several such ways a modified model could be created. Perhaps the most
direct model would be to stereotaxically reintroduce the full length leptin receptor into
the hypothalamus of newborn Leprdb/db pups using an adeno-associated virus. This would
restore normal leptin signaling along the metabolic axis, but retain leptin resistance in
other areas of the brain. With this model the only influence on pathogenesis would be
leptin resistance, and any factors associated with obesity and diabetes we detected in the
other models would be removed. Unfortunately, the impact of the leptin resistance in the
prenatal pups may still play a role in pathogenesis. At this point we have no evidence that
epigenetic or physiological factors associated with leptin resistance in utero may play a
role in pathogenesis, but more evidence is needed before any conclusions may be drawn.
Another option would be to utilize a Lepr flox line in combination with the AD
line or AAV tauP301L models. Leptin resistance could be induced in specific areas of the
brain by using an AAV Cre recombinase vector to remove the Lepr gene. This method
would also allow us to initiate leptin resistance at different ages in mice, to study the
effects it may have in different stages of amyloid or tau pathogenesis. This model could
also be beneficial in that normal breeding paradigms associated with breeding the Leprdb
line could be avoided (only heterozygotes may be bred together, and only a quarter of the
offspring are homozygous for the db mutation).
Another factor to consider is the signaling effects of different leptin receptor
isoforms. Multiple leptin receptor isoforms have been identified and are differentially
expressed throughout the brain (Guan, Hess et al. 1997). While only the long form of the
leptin receptor has been shown to initiate intracellular signaling events, the function of
other isoforms is largely unknown (Wang, Zhou et al. 1996, Bjorbaek, Uotani et al.
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1997). By knocking-out endogenous leptin signaling, then restoring individual isoforms
in cell culture we could explore the effects of leptin signaling through each isoform and
determine how Aβ production and/or tau phosphorylation are impacted by each type.
Aside from isolating the effects of leptin signaling on pathology, there are several
other avenues that can be investigated to better understand the pathogenic mechanisms
observed in our disease models. Over time these Leprdb/db mice become gradually more
insensitive to insulin and develop severe impairment in glucose handling, all of which are
characteristics of T2DM. Most human T2DM patients with access to healthcare take
measures to control their disease, including exercise, diet, and pharmaceutical
interventions. Our current model, however, represents an untreated form of diabetes.
We briefly ran a controlled exercise trial, where mice were loaded into small
wheels on a mechanized platform and were forced to run at a certain speed for a specific
period of time. This brief trial revealed Leprdb/db mice are too obese to perform this basic
trial, even at an extremely slow speed of one meter per minute. Because of this we ended
the trial after only a few weeks to avoid any adverse events. Despite the short duration of
exercise intervention, GTTs completed after the exercise trial ended showed that
exercised mice had better glucose handling when compared to baseline GTTs performed
prior to the exercise trial. It was surprising to see such a stark effect with such a short and
mild treatment.
To expand on these studies we need to develop a better exercise paradigm in
which the Leprdb/db mice can perform the exercise over a longer period of time. During
the initial exercise trial the youngest Leprdb/db mice were four months old, and the oldest
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were over seven months. By this stage, mice are severely obese (weighing between 65
and 80 grams) and have difficulty even moving around their cages. By weaning Leprdb/db
mice weigh roughly 25 to 30 grams. This may be a much more reasonable age to begin
mice on an exercise regimen. Perhaps by starting mice at this age we can attenuate weight
gain, and inhibit the development or reduce the severity of the diabetic phenotype
(Figure 6.2).
Forced exercise is not our only avenue of treatment. Previous studies have used
swim training to restrict weight gain. Two hours a day for six weeks significantly reduces
weight of Leprdb/db animals by 15 to 20 percent (Oh, Kim et al. 2007). By utilizing this
same exercise paradigm over the lifespan of these mice we should be able to restrict
weight gain, eliminate or reduce the effects of diabetes, and perhaps better understand
how pathogenesis can be attenuated.
There have always been two traditional avenues of treating obesity and diabetes.
In addition to exercise, dietary modifications are commonly prescribed by physicians to
diabetic patients. The obesity and diabetic phenotypes associated with the Leprdb/db mice
could be completely removed by caloric restriction. An experiment of this nature would
provide interesting insights into this model. For one, we could determine how obesity and
diabetes influence the development of pathology based on which aspects of pathology are
removed when compared to untreated Leprdb/db/AD or Leprdb/db/tauP301L mice. Similarly,
we could determine how leptin resistance may influence the development of pathology.
Despite the fact that a healthy diet and moderate exercise have always been
known to be beneficial, funding agencies are looking for more pharmaceutical therapy
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driven studies. It may be more feasible to use pharmaceutical interventions to treat the
metabolic dysfunction observed in Leprdb/db mice. Treating these mice with common
diabetes medications, like insulin, metformin, glipizide, or pioglitazone could provide
better insights into what we see in the human condition. Most human diabetic patients are
on several medications to control their blood glucose levels, and by treating Leprdb/db
mice with the same medications we will have a better model of the current human disease
state. We showed that diabetic AD patients display significantly less tangle pathology
than non-diabetic AD patients (Figure 3.4). If we can show similar reductions in
pathology in Leprdb/db mice by treating with diabetic therapies, then we may find new
ways to use the medications in treating non-diabetic AD patients (Figure 6.2).
Throughout the 20th century, T2DM became and increasingly common concern
and in the last 25 years has risen to epidemic levels (Amos, McCarty et al. 1997, King,
Aubert et al. 1998). The industrial revolution led to some of the greatest changes in
lifestyles seen throughout all of human history. Decreased necessity for manual labor,
increased ease of transportation and communication, an ever abundant and increasingly
processed and preservative-containing food supply, and better medical treatment which
have all culminated in better long lives. These benefits, however, also have their
downsides. We’ve become a society of excess, and this has resulted in increased disease.
The studies presented in this dissertation aid in advancing our understanding of these
diseases and how they are connected. By building upon these findings, we may uncover
potential therapeutics to treat neurodegenerative disease associated with metabolic
dysfunction.
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Figure 6.1 Model of Leptin Signaling with Amyloid and Tau Pathology.
In this general model, leptin signaling directly influences the development of pathological
changes associated with AD. Leptin initiates JAK/STAT signaling pathways which
inhibit the expression of γ-secretase complex proteins, therefore reducing APP processing
and Aβ generation. Additionally, leptin signaling inhibits the phosphorylation of tau,
likely through enzymatic pathways inhibiting tau kinases or activating tau phosphatases.

140

141

Figure 6.2 Model of Leptin Resistance Induced Pathology and Future Interventions.
This model outlines the mechanisms involved in leptin resistance induced obesity and
diabetes and associated neuropathological development. Leptin resistance induces obesity
and diabetes. These factors drive an increase in tau phosphorylation and NFT formation,
in addition to cerebrovascular pathology. By intervening with diet, exercise of
pharmaceutical therapies we should be able to alter the pathogenesis of these features and
better understand mechanisms underlying their development.
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APPENDIX 1: List of Abbreviations
AAV

Adeno-associated virus

AD

Alzheimer’s disease

APP

Amyloid Precursor Protein

APPswe

APP Swedish mutation (ΔNL)

AICD

APP intracellular domain

APOE

Apolipoprotein E

Aβ

Amyloid-beta

BACE(1/2)

β-site APP cleaving enzyme (1/2)

BCA

Bicinchoninic acid

BIN1

Bridging integrator 1

BME

β-mercaptoethanol

BSA

Bovine serum albumin

CNBP

Cellular Nucleic Acid Binding Protein

DM1

Myotonic Dystrophy type 1

DM2

Myotonic Dystrophy type 2

DMEM

Dulbecco’s modified eagle medium
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APPENDIX ONE continued
DMPK

Protein Kinase

DTT

Dithiolthreitol

EDTA

Ethylenediaminetetraacetic acid

ELISA

Enzyme-linked immunosorbent assay

FBS

Fetal bovine serum

FTD

Frontotemporal dementia

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

HRP

Horseradish peroxidase

IPTG

Isopropylthio-β-galactoside

MAPT

Microtubule associate protein tau

MEM

Minimum essential medium

MCI

Mild cognitive impairment

MMSE

Mini-mental state examination

MOI

Multiplicity of infection

MOPS

3-(N-morpholino)propanesulfonic acid

mRNA

Messenger RNA
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APPENDIX ONE continued
NFT

Neurofibrillary Tangle

PAGE

Polyacrylamide gel electrophoresis

PCR

Polymerase chain reaction

PHF

Paired Helical Filament

PMI

Postmortem interval

qPCR

Quantitative real-time PCR

RIPA

Radioimmunoprecipitation assay

RNA

Ribonucleic acid

RT-PCR

Reverse transcription PCR

sAPP(α/β)

Soluble APP (α/β)

SDS

Sodium dodecyl sulfate

SMTG

Superior middle temporal gyri

TBS

Tris-buffered saline

TBST

Tris-buffered saline (+ Tween)

ZNF9

Zinc-finger protein 9
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Symbols
α

Alpha α

β

Beta β

γ

Gamma γ

μ

Mu μ

Copyright © Thomas L. Platt 2014
146

REFERENCES
Abdullah, A., A. Peeters, M. de Courten and J. Stoelwinder (2010). "The magnitude of
association between overweight and obesity and the risk of diabetes: a meta-analysis of
prospective cohort studies." Diabetes Res Clin Pract 89(3): 309-319.
Accardi, G., C. Caruso, G. Colonna-Romano, C. Camarda, R. Monastero and G. Candore
(2012). "Can Alzheimer disease be a form of type 3 diabetes?" Rejuvenation research
15(2): 217-221.
Adams, S. J., M. A. DeTure, M. McBride, D. W. Dickson and L. Petrucelli (2010).
"Three repeat isoforms of tau inhibit assembly of four repeat tau filaments." PLoS One
5(5): e10810.
Adeghate, E., P. Schattner and E. Dunn (2006). "An update on the etiology and
epidemiology of diabetes mellitus." Annals of the New York Academy of Sciences 1084:
1-29.
Ahima, R. S., D. Prabakaran, C. Mantzoros, D. Qu, B. Lowell, E. Maratos-Flier and J. S.
Flier (1996). "Role of leptin in the neuroendocrine response to fasting." Nature
382(6588): 250-252.
Ahmed, R. R., C. J. Holler, R. L. Webb, F. Li, T. L. Beckett and M. P. Murphy (2010).
"BACE1 and BACE2 enzymatic activities in Alzheimer's disease." J Neurochem 112(4):
1045-1053.
Allocca, M., M. Doria, M. Petrillo, P. Colella, M. Garcia-Hoyos, D. Gibbs, S. R. Kim, A.
Maguire, T. S. Rex, U. Di Vicino, L. Cutillo, J. R. Sparrow, D. S. Williams, J. Bennett
and A. Auricchio (2008). "Serotype-dependent packaging of large genes in adenoassociated viral vectors results in effective gene delivery in mice." The Journal of clinical
investigation 118(5): 1955-1964.
Alonso, A., T. Zaidi, M. Novak, I. Grundke-Iqbal and K. Iqbal (2001).
"Hyperphosphorylation induces self-assembly of tau into tangles of paired helical
filaments/straight filaments." Proc Natl Acad Sci U S A 98(12): 6923-6928.
Amos, A. F., D. J. McCarty and P. Zimmet (1997). "The rising global burden of diabetes
and its complications: estimates and projections to the year 2010." Diabet Med 14 Suppl
5: S1-85.
Andorfer, C., C. M. Acker, Y. Kress, P. R. Hof, K. Duff and P. Davies (2005). "Cellcycle reentry and cell death in transgenic mice expressing nonmutant human tau
isoforms." J Neurosci 25(22): 5446-5454.

147

Andorfer, C., Y. Kress, M. Espinoza, R. de Silva, K. L. Tucker, Y. A. Barde, K. Duff and
P. Davies (2003). "Hyperphosphorylation and aggregation of tau in mice expressing
normal human tau isoforms." Journal of neurochemistry 86(3): 582-590.
Andorfer, C., Y. Kress, M. Espinoza, R. de Silva, K. L. Tucker, Y. A. Barde, K. Duff and
P. Davies (2003). "Hyperphosphorylation and aggregation of tau in mice expressing
normal human tau isoforms." J Neurochem 86(3): 582-590.
Andreadis, A., J. A. Broderick and K. S. Kosik (1995). "Relative exon affinities and
suboptimal splice site signals lead to non-equivalence of two cassette exons." Nucleic
Acids Res 23(17): 3585-3593.
Andreadis, A., W. M. Brown and K. S. Kosik (1992). "Structure and novel exons of the
human tau gene." Biochemistry 31(43): 10626-10633.
Arriagada, P. V., K. Marzloff and B. T. Hyman (1992). "Distribution of Alzheimer-type
pathologic changes in nondemented elderly individuals matches the pattern in
Alzheimer's disease." Neurology 42(9): 1681-1688.
Ashley, C. T., Jr. and S. T. Warren (1995). "Trinucleotide repeat expansion and human
disease." Annu Rev Genet 29: 703-728.
Association, A. D. (2013). Prevention and Management of Diabetes Complications.
Alexandria, Va, USA, American Diabetes Association.
Atchison, R. W., B. C. Casto and W. M. Hammon (1965). "Adenovirus-Associated
Defective Virus Particles." Science 149(3685): 754-756.
Augustinack, J. C., A. Schneider, E. M. Mandelkow and B. T. Hyman (2002). "Specific
tau phosphorylation sites correlate with severity of neuronal cytopathology in
Alzheimer's disease." Acta neuropathologica 103(1): 26-35.
Avrahami, L., D. Farfara, M. Shaham-Kol, R. Vassar, D. Frenkel and H. EldarFinkelman (2013). "Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid
pathology and restores lysosomal acidification and mammalian target of rapamycin
activity in the Alzheimer disease mouse model: in vivo and in vitro studies." J Biol Chem
288(2): 1295-1306.
Baker, L. D., D. J. Cross, S. Minoshima, D. Belongia, G. S. Watson and S. Craft (2011).
"Insulin resistance and Alzheimer-like reductions in regional cerebral glucose
metabolism for cognitively normal adults with prediabetes or early type 2 diabetes."
Archives of neurology 68(1): 51-57.

148

Ballatore, C., V. M. Lee and J. Q. Trojanowski (2007). "Tau-mediated neurodegeneration
in Alzheimer's disease and related disorders." Nat Rev Neurosci 8(9): 663-672.
Banks, A. S., S. M. Davis, S. H. Bates and M. G. Myers, Jr. (2000). "Activation of
downstream signals by the long form of the leptin receptor." The Journal of biological
chemistry 275(19): 14563-14572.
Banks, W. A. and C. L. Farrell (2003). "Impaired transport of leptin across the bloodbrain barrier in obesity is acquired and reversible." Am J Physiol Endocrinol Metab
285(1): E10-15.
Barsottini, O. G., A. C. Felicio, C. C. Aquino and J. L. Pedroso (2010). "Progressive
supranuclear palsy: new concepts." Arq Neuropsiquiatr 68(6): 938-946.
Bates, S. H., W. H. Stearns, T. A. Dundon, M. Schubert, A. W. Tso, Y. Wang, A. S.
Banks, H. J. Lavery, A. K. Haq, E. Maratos-Flier, B. G. Neel, M. W. Schwartz and M. G.
Myers, Jr. (2003). "STAT3 signalling is required for leptin regulation of energy balance
but not reproduction." Nature 421(6925): 856-859.
Beckman, J. A., M. A. Creager and P. Libby (2002). "Diabetes and atherosclerosis:
epidemiology, pathophysiology, and management." JAMA 287(19): 2570-2581.
Bellamy, L., J. P. Casas, A. D. Hingorani and D. Williams (2009). "Type 2 diabetes
mellitus after gestational diabetes: a systematic review and meta-analysis." Lancet
373(9677): 1773-1779.
Bergman, M. (2013). "Pathophysiology of prediabetes and treatment implications for the
prevention of type 2 diabetes mellitus." Endocrine 43(3): 504-513.
Berns, K. I., T. C. Pinkerton, G. F. Thomas and M. D. Hoggan (1975). "Detection of
adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from
latently infected Detroit 6 cells." Virology 68(2): 556-560.
Bierer, L. M., P. R. Hof, D. P. Purohit, L. Carlin, J. Schmeidler, K. L. Davis and D. P.
Perl (1995). "Neocortical neurofibrillary tangles correlate with dementia severity in
Alzheimer's disease." Arch Neurol 52(1): 81-88.
Bijur, G. N. and R. S. Jope (2001). "Proapoptotic stimuli induce nuclear accumulation of
glycogen synthase kinase-3 beta." J Biol Chem 276(40): 37436-37442.
Bjorbaek, C., R. M. Buchholz, S. M. Davis, S. H. Bates, D. D. Pierroz, H. Gu, B. G.
Neel, M. G. Myers, Jr. and J. S. Flier (2001). "Divergent roles of SHP-2 in ERK
activation by leptin receptors." The Journal of biological chemistry 276(7): 4747-4755.
149

Bjorbaek, C., K. El-Haschimi, J. D. Frantz and J. S. Flier (1999). "The role of SOCS-3 in
leptin signaling and leptin resistance." J Biol Chem 274(42): 30059-30065.
Bjorbaek, C., S. Uotani, B. da Silva and J. S. Flier (1997). "Divergent signaling capacities
of the long and short isoforms of the leptin receptor." J Biol Chem 272(51): 3268632695.
Blalock, E. M., J. W. Geddes, K. C. Chen, N. M. Porter, W. R. Markesbery and P. W.
Landfield (2004). "Incipient Alzheimer's disease: microarray correlation analyses reveal
major transcriptional and tumor suppressor responses." Proc Natl Acad Sci U S A 101(7):
2173-2178.
Bowles, D. E., S. W. McPhee, C. Li, S. J. Gray, J. J. Samulski, A. S. Camp, J. Li, B.
Wang, P. E. Monahan, J. E. Rabinowitz, J. C. Grieger, L. Govindasamy, M. AgbandjeMcKenna, X. Xiao and R. J. Samulski (2012). "Phase 1 gene therapy for Duchenne
muscular dystrophy using a translational optimized AAV vector." Molecular therapy : the
journal of the American Society of Gene Therapy 20(2): 443-455.
Braak, H. and E. Braak (1991). "Neuropathological stageing of Alzheimer-related
changes." Acta neuropathologica 82(4): 239-259.
Bray, G. A. (2004). "Obesity is a chronic, relapsing neurochemical disease." Int J Obes
Relat Metab Disord 28(1): 34-38.
Brenner, B. M., M. E. Cooper, D. de Zeeuw, W. F. Keane, W. E. Mitch, H. H. Parving,
G. Remuzzi, S. M. Snapinn, Z. Zhang, S. Shahinfar and R. S. Investigators (2001).
"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy." N Engl J Med 345(12): 861-869.
Brody, S. L. and R. G. Crystal (1994). "Adenovirus-mediated in vivo gene transfer."
Annals of the New York Academy of Sciences 716: 90-101; discussion 101-103.
Buescher, J. L. and C. J. Phiel (2010). "A noncatalytic domain of glycogen synthase
kinase-3 (GSK-3) is essential for activity." J Biol Chem 285(11): 7957-7963.
Burger, C., O. S. Gorbatyuk, M. J. Velardo, C. S. Peden, P. Williams, S. Zolotukhin, P. J.
Reier, R. J. Mandel and N. Muzyczka (2004). "Recombinant AAV viral vectors
pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency
and cell tropism after delivery to different regions of the central nervous system."
Molecular therapy : the journal of the American Society of Gene Therapy 10(2): 302-317.

150

Burguera, B., M. E. Couce, J. Long, J. Lamsam, K. Laakso, M. D. Jensen, J. E. Parisi and
R. V. Lloyd (2000). "The long form of the leptin receptor (OB-Rb) is widely expressed in
the human brain." Neuroendocrinology 71(3): 187-195.
Butterfield, D. A. and H. F. Poon (2005). "The senescence-accelerated prone mouse
(SAMP8): a model of age-related cognitive decline with relevance to alterations of the
gene expression and protein abnormalities in Alzheimer's disease." Exp Gerontol 40(10):
774-783.
Caballero, B. (2007). "The global epidemic of obesity: an overview." Epidemiol Rev 29:
1-5.
Cade, W. T. (2008). "Diabetes-related microvascular and macrovascular diseases in the
physical therapy setting." Phys Ther 88(11): 1322-1335.
Cai, G., J. Wang, X. Xin, Z. Ke and J. Luo (2007). "Phosphorylation of glycogen
synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells." Int
J Oncol 31(3): 657-662.
Campfield, L. A., F. J. Smith, Y. Guisez, R. Devos and P. Burn (1995). "Recombinant
mouse OB protein: evidence for a peripheral signal linking adiposity and central neural
networks." Science 269(5223): 546-549.
Cavallini, A., S. Brewerton, A. Bell, S. Sargent, S. Glover, C. Hardy, R. Moore, J. Calley,
D. Ramachandran, M. Poidinger, E. Karran, P. Davies, M. Hutton, P. Szekeres and S.
Bose (2013). "An unbiased approach to identifying tau kinases that phosphorylate tau at
sites associated with Alzheimer disease." The Journal of biological chemistry 288(32):
23331-23347.
Cearley, C. N. and J. H. Wolfe (2006). "Transduction characteristics of adeno-associated
virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain." Molecular
therapy : the journal of the American Society of Gene Therapy 13(3): 528-537.
Chang, S. H., C. R. Stoll, J. Song, J. E. Varela, C. J. Eagon and G. A. Colditz (2014).
"The effectiveness and risks of bariatric surgery: an updated systematic review and metaanalysis, 2003-2012." JAMA Surg 149(3): 275-287.
Chau, M. F., M. J. Radeke, C. de Ines, I. Barasoain, L. A. Kohlstaedt and S. C. Feinstein
(1998). "The microtubule-associated protein tau cross-links to two distinct sites on each
alpha and beta tubulin monomer via separate domains." Biochemistry 37(51): 1769217703.

151

Chen, F., H. Hasegawa, G. Schmitt-Ulms, T. Kawarai, C. Bohm, T. Katayama, Y. Gu, N.
Sanjo, M. Glista, E. Rogaeva, Y. Wakutani, R. Pardossi-Piquard, X. Ruan, A. Tandon, F.
Checler, P. Marambaud, K. Hansen, D. Westaway, P. St George-Hyslop and P. Fraser
(2006). "TMP21 is a presenilin complex component that modulates gamma-secretase but
not epsilon-secretase activity." Nature 440(7088): 1208-1212.
Chen, H., O. Charlat, L. A. Tartaglia, E. A. Woolf, X. Weng, S. J. Ellis, N. D. Lakey, J.
Culpepper, K. J. Moore, R. E. Breitbart, G. M. Duyk, R. I. Tepper and J. P. Morgenstern
(1996). "Evidence that the diabetes gene encodes the leptin receptor: identification of a
mutation in the leptin receptor gene in db/db mice." Cell 84(3): 491-495.
Chen, J., C. S. Park and S. J. Tang (2006). "Activity-dependent synaptic Wnt release
regulates hippocampal long term potentiation." J Biol Chem 281(17): 11910-11916.
Chen, S., S. W. Hong, M. C. Iglesias-de la Cruz, M. Isono, A. Casaretto and F. N.
Ziyadeh (2001). "The key role of the transforming growth factor-beta system in the
pathogenesis of diabetic nephropathy." Ren Fail 23(3-4): 471-481.
Chen, Y., Z. Liang, J. Blanchard, C. L. Dai, S. Sun, M. H. Lee, I. Grundke-Iqbal, K.
Iqbal, F. Liu and C. X. Gong (2013). "A non-transgenic mouse model (icv-STZ mouse)
of Alzheimer's disease: similarities to and differences from the transgenic model (3xTgAD mouse)." Mol Neurobiol 47(2): 711-725.
Cheung, A. K., M. K. Fung, A. C. Lo, T. T. Lam, K. F. So, S. S. Chung and S. K. Chung
(2005). "Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier
breakdown, apoptosis, and glial reactivation in the retina of db/db mice." Diabetes
54(11): 3119-3125.
Chiorini, J. A., L. Yang, Y. Liu, B. Safer and R. M. Kotin (1997). "Cloning of adenoassociated virus type 4 (AAV4) and generation of recombinant AAV4 particles." Journal
of virology 71(9): 6823-6833.
Cho, A., N. Haruyama and A. B. Kulkarni (2009). "Generation of transgenic mice."
Current protocols in cell biology / editorial board, Juan S. Bonifacino ... [et al.] Chapter
19: Unit 19 11.
Chua, S. C., Jr., W. K. Chung, X. S. Wu-Peng, Y. Zhang, S. M. Liu, L. Tartaglia and R.
L. Leibel (1996). "Phenotypes of mouse diabetes and rat fatty due to mutations in the OB
(leptin) receptor." Science 271(5251): 994-996.
Chuenkova, M. V. and M. A. Pereira (2001). "The T. cruzi trans-sialidase induces PC12
cell differentiation via MAPK/ERK pathway." Neuroreport 12(17): 3715-3718.

152

Cioffi, J. A., A. W. Shafer, T. J. Zupancic, J. Smith-Gbur, A. Mikhail, D. Platika and H.
R. Snodgrass (1996). "Novel B219/OB receptor isoforms: possible role of leptin in
hematopoiesis and reproduction." Nat Med 2(5): 585-589.
Clark, C. M., Jr. and D. A. Lee (1995). "Prevention and treatment of the complications of
diabetes mellitus." N Engl J Med 332(18): 1210-1217.
Clements, R. S., Jr., W. G. Robison, Jr. and M. P. Cohen (1998). "Anti-glycated albumin
therapy ameliorates early retinal microvascular pathology in db/db mice." Journal of
diabetes and its complications 12(1): 28-33.
Coleman, D. L. (1978). "Obese and diabetes: two mutant genes causing diabetes-obesity
syndromes in mice." Diabetologia 14(3): 141-148.
Colquitt, J. L., J. Picot, E. Loveman and A. J. Clegg (2009). "Surgery for obesity."
Cochrane Database Syst Rev(2): CD003641.
Congdon, E. E. and K. E. Duff (2008). "Is tau aggregation toxic or protective?" J
Alzheimers Dis 14(4): 453-457.
Considine, R. V., M. K. Sinha, M. L. Heiman, A. Kriauciunas, T. W. Stephens, M. R.
Nyce, J. P. Ohannesian, C. C. Marco, L. J. McKee, T. L. Bauer and et al. (1996). "Serum
immunoreactive-leptin concentrations in normal-weight and obese humans." N Engl J
Med 334(5): 292-295.
Considine, R. V., M. K. Sinha, M. L. Heiman, A. Kriauciunas, T. W. Stephens, M. R.
Nyce, J. P. Ohannesian, C. C. Marco, L. J. McKee, T. L. Bauer and et al. (1996). "Serum
immunoreactive-leptin concentrations in normal-weight and obese humans." The New
England journal of medicine 334(5): 292-295.
Cooper, M. E., F. Bonnet, M. Oldfield and K. Jandeleit-Dahm (2001). "Mechanisms of
diabetic vasculopathy: an overview." Am J Hypertens 14(5 Pt 1): 475-486.
Corder, E. H., A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W.
Small, A. D. Roses, J. L. Haines and M. A. Pericak-Vance (1993). "Gene dose of
apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families."
Science 261(5123): 921-923.
Cota, D., E. K. Matter, S. C. Woods and R. J. Seeley (2008). "The role of hypothalamic
mammalian target of rapamycin complex 1 signaling in diet-induced obesity." The
Journal of neuroscience : the official journal of the Society for Neuroscience 28(28):
7202-7208.

153

Cota, D., K. Proulx, K. A. Smith, S. C. Kozma, G. Thomas, S. C. Woods and R. J. Seeley
(2006). "Hypothalamic mTOR signaling regulates food intake." Science 312(5775): 927930.
Couce, M. E., B. Burguera, J. E. Parisi, M. D. Jensen and R. V. Lloyd (1997).
"Localization of leptin receptor in the human brain." Neuroendocrinology 66(3): 145150.
Cuchillo-Ibanez, I., A. Seereeram, H. L. Byers, K. Y. Leung, M. A. Ward, B. H.
Anderton and D. P. Hanger (2008). "Phosphorylation of tau regulates its axonal transport
by controlling its binding to kinesin." FASEB J 22(9): 3186-3195.
D'Alessio, D. (2011). "The role of dysregulated glucagon secretion in type 2 diabetes."
Diabetes Obes Metab 13 Suppl 1: 126-132.
D'Souza, I., P. Poorkaj, M. Hong, D. Nochlin, V. M. Lee, T. D. Bird and G. D.
Schellenberg (1999). "Missense and silent tau gene mutations cause frontotemporal
dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA
splicing regulatory elements." Proc Natl Acad Sci U S A 96(10): 5598-5603.
DaRocha-Souto, B., M. Coma, B. G. Perez-Nievas, T. C. Scotton, M. Siao, P. SanchezFerrer, T. Hashimoto, Z. Fan, E. Hudry, I. Barroeta, L. Sereno, M. Rodriguez, M. B.
Sanchez, B. T. Hyman and T. Gomez-Isla (2012). "Activation of glycogen synthase
kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease."
Neurobiol Dis 45(1): 425-437.
Dassie, E., M. R. Andrews, J. C. Bensadoun, M. Cacquevel, B. L. Schneider, P.
Aebischer, F. S. Wouters, J. C. Richardson, I. Hussain, D. R. Howlett, M. G. Spillantini
and J. W. Fawcett (2013). "Focal expression of adeno-associated viral-mutant tau induces
widespread impairment in an APP mouse model." Neurobiology of aging 34(5): 13551368.
Day, J. W., R. Roelofs, B. Leroy, I. Pech, K. Benzow and L. P. Ranum (1999). "Clinical
and genetic characteristics of a five-generation family with a novel form of myotonic
dystrophy (DM2)." Neuromuscul Disord 9(1): 19-27.
Daya, S. and K. I. Berns (2008). "Gene therapy using adeno-associated virus vectors."
Clinical microbiology reviews 21(4): 583-593.
Delacourte, A. and L. Buee (2000). "Tau pathology: a marker of neurodegenerative
disorders." Curr Opin Neurol 13(4): 371-376.

154

Demuro, A., E. Mina, R. Kayed, S. C. Milton, I. Parker and C. G. Glabe (2005).
"Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism
of soluble amyloid oligomers." J Biol Chem 280(17): 17294-17300.
Deshpande, A., K. M. Win and J. Busciglio (2008). "Tau isoform expression and
regulation in human cortical neurons." FASEB J 22(7): 2357-2367.
Dhaenens, C. M., H. Tran, M. L. Frandemiche, C. Carpentier, S. Schraen-Maschke, A.
Sistiaga, M. Goicoechea, S. Eddarkaoui, E. Van Brussels, H. Obriot, A. Labudeck, M. H.
Gevaert, F. Fernandez-Gomez, N. Charlet-Berguerand, V. Deramecourt, C. A. Maurage,
L. Buee, A. L. de Munain, B. Sablonniere, M. L. Caillet-Boudin and N. Sergeant (2011).
"Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by
overexpression of CELF2 but not by MBNL1 silencing." Biochim Biophys Acta 1812(7):
732-742.
Dicou, E., S. Attoub and P. Gressens (2001). "Neuroprotective effects of leptin in vivo
and in vitro." Neuroreport 12(18): 3947-3951.
Dornhorst, A. and M. Rossi (1998). "Risk and prevention of type 2 diabetes in women
with gestational diabetes." Diabetes Care 21 Suppl 2: B43-49.
Drewes, G., B. Trinczek, S. Illenberger, J. Biernat, G. Schmitt-Ulms, H. E. Meyer, E. M.
Mandelkow and E. Mandelkow (1995). "Microtubule-associated protein/microtubule
affinity-regulating kinase (p110mark). A novel protein kinase that regulates taumicrotubule interactions and dynamic instability by phosphorylation at the Alzheimerspecific site serine 262." J Biol Chem 270(13): 7679-7688.
Drummond, K., M. Mauer and G. International Diabetic Nephropathy Study (2002). "The
early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes
in type 1 diabetes." Diabetes 51(5): 1580-1587.
Duff, K., H. Knight, L. M. Refolo, S. Sanders, X. Yu, M. Picciano, B. Malester, M.
Hutton, J. Adamson, M. Goedert, K. Burki and P. Davies (2000). "Characterization of
pathology in transgenic mice over-expressing human genomic and cDNA tau
transgenes." Neurobiol Dis 7(2): 87-98.
Duff, K. and F. Suleman (2004). "Transgenic mouse models of Alzheimer's disease: how
useful have they been for therapeutic development?" Briefings in functional genomics &
proteomics 3(1): 47-59.
Duque, S., B. Joussemet, C. Riviere, T. Marais, L. Dubreil, A. M. Douar, J. Fyfe, P.
Moullier, M. A. Colle and M. Barkats (2009). "Intravenous administration of selfcomplementary AAV9 enables transgene delivery to adult motor neurons." Molecular
therapy : the journal of the American Society of Gene Therapy 17(7): 1187-1196.
155

Elias, C. F., C. Aschkenasi, C. Lee, J. Kelly, R. S. Ahima, C. Bjorbaek, J. S. Flier, C. B.
Saper and J. K. Elmquist (1999). "Leptin differentially regulates NPY and POMC
neurons projecting to the lateral hypothalamic area." Neuron 23(4): 775-786.
Elmquist, J. K., C. Bjorbaek, R. S. Ahima, J. S. Flier and C. B. Saper (1998).
"Distributions of leptin receptor mRNA isoforms in the rat brain." J Comp Neurol 395(4):
535-547.
Elneihoum, A. M., M. Goransson, P. Falke and L. Janzon (1998). "Three-year survival
and recurrence after stroke in Malmo, Sweden: an analysis of stroke registry data." Stroke
29(10): 2114-2117.
Embi, N., D. B. Rylatt and P. Cohen (1980). "Glycogen synthase kinase-3 from rabbit
skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and
phosphorylase kinase." Eur J Biochem 107(2): 519-527.
Engel, T., P. Goni-Oliver, J. J. Lucas, J. Avila and F. Hernandez (2006). "Chronic lithium
administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau
hyperphosphorylation and neurofibrillary tangle formation, but pre-formed
neurofibrillary tangles do not revert." J Neurochem 99(6): 1445-1455.
Erlanger, D. M., K. C. Kutner, J. T. Barth and R. Barnes (1999). "Neuropsychology of
sports-related head injury: Dementia Pugilistica to Post Concussion Syndrome." Clin
Neuropsychol 13(2): 193-209.
Evangelisti, E., D. Wright, M. Zampagni, R. Cascella, C. Fiorillo, S. Bagnoli, A. Relini,
D. Nichino, T. Scartabelli, B. Nacmias, S. Sorbi and C. Cecchi (2013). "Lipid rafts
mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer's
disease." Curr Alzheimer Res 10(2): 143-153.
Facchini, F. S., N. Hua, F. Abbasi and G. M. Reaven (2001). "Insulin resistance as a
predictor of age-related diseases." J Clin Endocrinol Metab 86(8): 3574-3578.
Farr, S. A., W. A. Banks and J. E. Morley (2006). "Effects of leptin on memory
processing." Peptides 27(6): 1420-1425.
Fewlass, D. C., K. Noboa, F. X. Pi-Sunyer, J. M. Johnston, S. D. Yan and N. Tezapsidis
(2004). "Obesity-related leptin regulates Alzheimer's Abeta." FASEB J 18(15): 18701878.
Figlewicz, D. P., S. B. Evans, J. Murphy, M. Hoen and D. G. Baskin (2003). "Expression
of receptors for insulin and leptin in the ventral tegmental area/substantia nigra
(VTA/SN) of the rat." Brain Res 964(1): 107-115.
156

Flament, S., A. Delacourte, M. Verny, J. J. Hauw and F. Javoy-Agid (1991). "Abnormal
Tau proteins in progressive supranuclear palsy. Similarities and differences with the
neurofibrillary degeneration of the Alzheimer type." Acta Neuropathol 81(6): 591-596.
Flotte, T. R., B. C. Trapnell, M. Humphries, B. Carey, R. Calcedo, F. Rouhani, M.
Campbell-Thompson, A. T. Yachnis, R. A. Sandhaus, N. G. McElvaney, C. Mueller, L.
M. Messina, J. M. Wilson, M. Brantly, D. R. Knop, G. J. Ye and J. D. Chulay (2011).
"Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1antitrypsin: interim results." Human gene therapy 22(10): 1239-1247.
Ford, E. S., D. F. Williamson and S. Liu (1997). "Weight change and diabetes incidence:
findings from a national cohort of US adults." American journal of epidemiology 146(3):
214-222.
Forman, M. S., V. M. Lee and J. Q. Trojanowski (2000). "New insights into genetic and
molecular mechanisms of brain degeneration in tauopathies." J Chem Neuroanat 20(3-4):
225-244.
Foust, K. D., E. Nurre, C. L. Montgomery, A. Hernandez, C. M. Chan and B. K. Kaspar
(2009). "Intravascular AAV9 preferentially targets neonatal neurons and adult
astrocytes." Nature biotechnology 27(1): 59-65.
Frame, S. and P. Cohen (2001). "GSK3 takes centre stage more than 20 years after its
discovery." The Biochemical journal 359(Pt 1): 1-16.
Freude, S., L. Plum, J. Schnitker, U. Leeser, M. Udelhoven, W. Krone, J. C. Bruning and
M. Schubert (2005). "Peripheral hyperinsulinemia promotes tau phosphorylation in vivo."
Diabetes 54(12): 3343-3348.
Friedmann, T. and R. Roblin (1972). "Gene therapy for human genetic disease?" Science
175(4025): 949-955.
Fukumoto, H., B. S. Cheung, B. T. Hyman and M. C. Irizarry (2002). "Beta-secretase
protein and activity are increased in the neocortex in Alzheimer disease." Arch Neurol
59(9): 1381-1389.
Garrido, J. J., D. Simon, O. Varea and F. Wandosell (2007). "GSK3 alpha and GSK3 beta
are necessary for axon formation." FEBS Lett 581(8): 1579-1586.
Georg-Fries, B., S. Biederlack, J. Wolf and H. zur Hausen (1984). "Analysis of proteins,
helper dependence, and seroepidemiology of a new human parvovirus." Virology 134(1):
64-71.

157

German, D. C., E. M. Quintero, C. L. Liang, B. Ng, S. Punia, C. Xie and J. M. Dietschy
(2001). "Selective neurodegeneration, without neurofibrillary tangles, in a mouse model
of Niemann-Pick C disease." J Comp Neurol 433(3): 415-425.
Geschwind, D. H. (2003). "Tau phosphorylation, tangles, and neurodegeneration: the
chicken or the egg?" Neuron 40(3): 457-460.
Giraud, C., E. Winocour and K. I. Berns (1994). "Site-specific integration by adenoassociated virus is directed by a cellular DNA sequence." Proceedings of the National
Academy of Sciences of the United States of America 91(21): 10039-10043.
Glabe, C. G. (2006). "Common mechanisms of amyloid oligomer pathogenesis in
degenerative disease." Neurobiol Aging 27(4): 570-575.
Goedert, M. and R. Jakes (1990). "Expression of separate isoforms of human tau protein:
correlation with the tau pattern in brain and effects on tubulin polymerization." EMBO J
9(13): 4225-4230.
Goedert, M. and R. Jakes (2005). "Mutations causing neurodegenerative tauopathies."
Biochim Biophys Acta 1739(2-3): 240-250.
Goedert, M., M. G. Spillantini, R. Jakes, D. Rutherford and R. A. Crowther (1989).
"Multiple isoforms of human microtubule-associated protein tau: sequences and
localization in neurofibrillary tangles of Alzheimer's disease." Neuron 3(4): 519-526.
Goedert, M., M. G. Spillantini, M. C. Potier, J. Ulrich and R. A. Crowther (1989).
"Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated
protein tau containing four tandem repeats: differential expression of tau protein mRNAs
in human brain." EMBO J 8(2): 393-399.
Gomez-Isla, T., R. Hollister, H. West, S. Mui, J. H. Growdon, R. C. Petersen, J. E. Parisi
and B. T. Hyman (1997). "Neuronal loss correlates with but exceeds neurofibrillary
tangles in Alzheimer's disease." Ann Neurol 41(1): 17-24.
Gomez-Ramos, A., M. Diaz-Hernandez, A. Rubio, M. T. Miras-Portugal and J. Avila
(2008). "Extracellular tau promotes intracellular calcium increase through M1 and M3
muscarinic receptors in neuronal cells." Mol Cell Neurosci 37(4): 673-681.
Gotz, J., F. Chen, R. Barmettler and R. M. Nitsch (2001). "Tau filament formation in
transgenic mice expressing P301L tau." The Journal of biological chemistry 276(1): 529534.

158

Gotz, J., F. Chen, J. van Dorpe and R. M. Nitsch (2001). "Formation of neurofibrillary
tangles in P301l tau transgenic mice induced by Abeta 42 fibrils." Science 293(5534):
1491-1495.
Greco, S. J., K. J. Bryan, S. Sarkar, X. Zhu, M. A. Smith, J. W. Ashford, J. M. Johnston,
N. Tezapsidis and G. Casadesus (2009). "Chronic Leptin Supplementation Ameliorates
Pathology and Improves Cognitive Performance in a Transgenic Mouse Model of
Alzheimer's Disease." J Alzheimers Dis.
Greco, S. J., K. J. Bryan, S. Sarkar, X. Zhu, M. A. Smith, J. W. Ashford, J. M. Johnston,
N. Tezapsidis and G. Casadesus (2010). "Leptin reduces pathology and improves
memory in a transgenic mouse model of Alzheimer's disease." Journal of Alzheimer's
disease : JAD 19(4): 1155-1167.
Greco, S. J., K. J. Bryan, S. Sarkar, X. Zhu, M. A. Smith, J. W. Ashford, J. M. Johnston,
N. Tezapsidis and G. Casadesus (2010). "Leptin reduces pathology and improves
memory in a transgenic mouse model of Alzheimer's disease." J Alzheimers Dis 19(4):
1155-1167.
Greco, S. J., S. Sarkar, J. M. Johnston and N. Tezapsidis (2009). "Leptin regulates tau
phosphorylation and amyloid through AMPK in neuronal cells." Biochem Biophys Res
Commun 380(1): 98-104.
Greco, S. J., S. Sarkar, J. M. Johnston, X. Zhu, B. Su, G. Casadesus, J. W. Ashford, M.
A. Smith and N. Tezapsidis (2008). "Leptin reduces Alzheimer's disease-related tau
phosphorylation in neuronal cells." Biochemical and biophysical research
communications 376(3): 536-541.
Greco, S. J., S. Sarkar, J. M. Johnston, X. Zhu, B. Su, G. Casadesus, J. W. Ashford, M.
A. Smith and N. Tezapsidis (2008). "Leptin reduces Alzheimer's disease-related tau
phosphorylation in neuronal cells." Biochem Biophys Res Commun 376(3): 536-541.
Griffin, W. S., J. G. Sheng, M. C. Royston, S. M. Gentleman, J. E. McKenzie, D. I.
Graham, G. W. Roberts and R. E. Mrak (1998). "Glial-neuronal interactions in
Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression." Brain
Pathol 8(1): 65-72.
Grimes, C. A. and R. S. Jope (2001). "The multifaceted roles of glycogen synthase kinase
3beta in cellular signaling." Prog Neurobiol 65(4): 391-426.
Grover, A., H. Houlden, M. Baker, J. Adamson, J. Lewis, G. Prihar, S. Pickering-Brown,
K. Duff and M. Hutton (1999). "5' splice site mutations in tau associated with the
inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative
splicing of exon 10." J Biol Chem 274(21): 15134-15143.
159

Guan, X. M., J. F. Hess, H. Yu, P. J. Hey and L. H. van der Ploeg (1997). "Differential
expression of mRNA for leptin receptor isoforms in the rat brain." Mol Cell Endocrinol
133(1): 1-7.
Guo, Z., H. Jiang, X. Xu, W. Duan and M. P. Mattson (2008). "Leptin-mediated cell
survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial
stabilization." The Journal of biological chemistry 283(3): 1754-1763.
Gustafson, D., E. Rothenberg, K. Blennow, B. Steen and I. Skoog (2003). "An 18-year
follow-up of overweight and risk of Alzheimer disease." Arch Intern Med 163(13): 15241528.
Haan, M. N. (2006). "Therapy Insight: type 2 diabetes mellitus and the risk of late-onset
Alzheimer's disease." Nat Clin Pract Neurol 2(3): 159-166.
Haheim, L. L., I. Holme, I. Hjermann and P. Leren (1995). "Nonfasting serum glucose
and the risk of fatal stroke in diabetic and nondiabetic subjects. 18-year follow-up of the
Oslo Study." Stroke 26(5): 774-777.
Hakansson, M. L. and B. Meister (1998). "Transcription factor STAT3 in leptin target
neurons of the rat hypothalamus." Neuroendocrinology 68(6): 420-427.
Halaas, J. L., K. S. Gajiwala, M. Maffei, S. L. Cohen, B. T. Chait, D. Rabinowitz, R. L.
Lallone, S. K. Burley and J. M. Friedman (1995). "Weight-reducing effects of the plasma
protein encoded by the obese gene." Science 269(5223): 543-546.
Hall, A. M. and E. D. Roberson (2012). "Mouse models of Alzheimer's disease." Brain
research bulletin 88(1): 3-12.
Hanger, D. P., B. H. Anderton and W. Noble (2009). "Tau phosphorylation: the
therapeutic challenge for neurodegenerative disease." Trends Mol Med 15(3): 112-119.
Hardie, D. G. and D. Carling (1997). "The AMP-activated protein kinase--fuel gauge of
the mammalian cell?" Eur J Biochem 246(2): 259-273.
Harding, T. C., P. J. Dickinson, B. N. Roberts, S. Yendluri, M. Gonzalez-Edick, R. A.
Lecouteur and K. U. Jooss (2006). "Enhanced gene transfer efficiency in the murine
striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8pseudotyped vectors." Human gene therapy 17(8): 807-820.
Hardy, J. and D. Allsop (1991). "Amyloid deposition as the central event in the aetiology
of Alzheimer's disease." Trends Pharmacol Sci 12(10): 383-388.

160

Hardy, J. A. and G. A. Higgins (1992). "Alzheimer's disease: the amyloid cascade
hypothesis." Science 256(5054): 184-185.
Harold, D., R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, M. L. Hamshere, J. S.
Pahwa, V. Moskvina, K. Dowzell, A. Williams, N. Jones, C. Thomas, A. Stretton, A. R.
Morgan, S. Lovestone, J. Powell, P. Proitsi, M. K. Lupton, C. Brayne, D. C. Rubinsztein,
M. Gill, B. Lawlor, A. Lynch, K. Morgan, K. S. Brown, P. A. Passmore, D. Craig, B.
McGuinness, S. Todd, C. Holmes, D. Mann, A. D. Smith, S. Love, P. G. Kehoe, J.
Hardy, S. Mead, N. Fox, M. Rossor, J. Collinge, W. Maier, F. Jessen, B. Schurmann, H.
van den Bussche, I. Heuser, J. Kornhuber, J. Wiltfang, M. Dichgans, L. Frolich, H.
Hampel, M. Hull, D. Rujescu, A. M. Goate, J. S. Kauwe, C. Cruchaga, P. Nowotny, J. C.
Morris, K. Mayo, K. Sleegers, K. Bettens, S. Engelborghs, P. P. De Deyn, C. Van
Broeckhoven, G. Livingston, N. J. Bass, H. Gurling, A. McQuillin, R. Gwilliam, P.
Deloukas, A. Al-Chalabi, C. E. Shaw, M. Tsolaki, A. B. Singleton, R. Guerreiro, T. W.
Muhleisen, M. M. Nothen, S. Moebus, K. H. Jockel, N. Klopp, H. E. Wichmann, M. M.
Carrasquillo, V. S. Pankratz, S. G. Younkin, P. A. Holmans, M. O'Donovan, M. J. Owen
and J. Williams (2009). "Genome-wide association study identifies variants at CLU and
PICALM associated with Alzheimer's disease." Nat Genet 41(10): 1088-1093.
Harris, J. A., A. Koyama, S. Maeda, K. Ho, N. Devidze, D. B. Dubal, G. Q. Yu, E.
Masliah and L. Mucke (2012). "Human P301L-mutant tau expression in mouse
entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no
cognitive deficits." PloS one 7(9): e45881.
Harvey, J. (2007). "Leptin regulation of neuronal excitability and cognitive function."
Current opinion in pharmacology 7(6): 643-647.
Harvey, J. and M. L. Ashford (2003). "Leptin in the CNS: much more than a satiety
signal." Neuropharmacology 44(7): 845-854.
Harwood, A. J. (2001). "Regulation of GSK-3: a cellular multiprocessor." Cell 105(7):
821-824.
Hasegawa, M., M. Morishima-Kawashima, K. Takio, M. Suzuki, K. Titani and Y. Ihara
(1992). "Protein sequence and mass spectrometric analyses of tau in the Alzheimer's
disease brain." J Biol Chem 267(24): 17047-17054.
Haslam, D. W. and W. P. James (2005). "Obesity." Lancet 366(9492): 1197-1209.
Hernandez, F. and J. Avila (2007). "Tauopathies." Cell Mol Life Sci 64(17): 2219-2233.
Hernandez, F., E. Gomez de Barreda, A. Fuster-Matanzo, J. J. Lucas and J. Avila (2010).
"GSK3: a possible link between beta amyloid peptide and tau protein." Exp Neurol
223(2): 322-325.
161

Heymsfield, S. B., A. S. Greenberg, K. Fujioka, R. M. Dixon, R. Kushner, T. Hunt, J. A.
Lubina, J. Patane, B. Self, P. Hunt and M. McCamish (1999). "Recombinant leptin for
weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial."
JAMA 282(16): 1568-1575.
Hoeflich, K. P., J. Luo, E. A. Rubie, M. S. Tsao, O. Jin and J. R. Woodgett (2000).
"Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB
activation." Nature 406(6791): 86-90.
Holler, C. J., R. L. Webb, A. L. Laux, T. L. Beckett, D. M. Niedowicz, R. R. Ahmed, Y.
Liu, C. R. Simmons, A. L. Dowling, A. Spinelli, M. Khurgel, S. Estus, E. Head, L. B.
Hersh and M. P. Murphy (2012). "BACE2 expression increases in human
neurodegenerative disease." Am J Pathol 180(1): 337-350.
Hong, M., V. Zhukareva, V. Vogelsberg-Ragaglia, Z. Wszolek, L. Reed, B. I. Miller, D.
H. Geschwind, T. D. Bird, D. McKeel, A. Goate, J. C. Morris, K. C. Wilhelmsen, G. D.
Schellenberg, J. Q. Trojanowski and V. M. Lee (1998). "Mutation-specific functional
impairments in distinct tau isoforms of hereditary FTDP-17." Science 282(5395): 19141917.
Hooper, C., V. Markevich, F. Plattner, R. Killick, E. Schofield, T. Engel, F. Hernandez,
B. Anderton, K. Rosenblum, T. Bliss, S. F. Cooke, J. Avila, J. J. Lucas, K. P. Giese, J.
Stephenson and S. Lovestone (2007). "Glycogen synthase kinase-3 inhibition is integral
to long-term potentiation." Eur J Neurosci 25(1): 81-86.
Hu, J. and L. J. Van Eldik (1999). "Glial-derived proteins activate cultured astrocytes and
enhance beta amyloid-induced glial activation." Brain Res 842(1): 46-54.
Hu, M., J. F. Waring, M. Gopalakrishnan and J. Li (2008). "Role of GSK-3beta activation
and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells." J
Neurochem 106(3): 1371-1377.
Hughes, K., E. Nikolakaki, S. E. Plyte, N. F. Totty and J. R. Woodgett (1993).
"Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation."
EMBO J 12(2): 803-808.
Hummel, K. P., M. M. Dickie and D. L. Coleman (1966). "Diabetes, a new mutation in
the mouse." Science 153(3740): 1127-1128.
Huser, D., A. Gogol-Doring, T. Lutter, S. Weger, K. Winter, E. M. Hammer, T.
Cathomen, K. Reinert and R. Heilbronn (2010). "Integration preferences of wildtype
AAV-2 for consensus rep-binding sites at numerous loci in the human genome." PLoS
pathogens 6(7): e1000985.
162

Hutton, M., C. L. Lendon, P. Rizzu, M. Baker, S. Froelich, H. Houlden, S. PickeringBrown, S. Chakraverty, A. Isaacs, A. Grover, J. Hackett, J. Adamson, S. Lincoln, D.
Dickson, P. Davies, R. C. Petersen, M. Stevens, E. de Graaff, E. Wauters, J. van Baren,
M. Hillebrand, M. Joosse, J. M. Kwon, P. Nowotny, L. K. Che, J. Norton, J. C. Morris, L.
A. Reed, J. Trojanowski, H. Basun, L. Lannfelt, M. Neystat, S. Fahn, F. Dark, T.
Tannenberg, P. R. Dodd, N. Hayward, J. B. Kwok, P. R. Schofield, A. Andreadis, J.
Snowden, D. Craufurd, D. Neary, F. Owen, B. A. Oostra, J. Hardy, A. Goate, J. van
Swieten, D. Mann, T. Lynch and P. Heutink (1998). "Association of missense and 5'splice-site mutations in tau with the inherited dementia FTDP-17." Nature 393(6686):
702-705.
Ibrahim, S., N. D. Harris, M. Radatz, F. Selmi, S. Rajbhandari, L. Brady, J. Jakubowski
and J. D. Ward (1999). "A new minimally invasive technique to show nerve ischaemia in
diabetic neuropathy." Diabetologia 42(6): 737-742.
Ingalls, A. M., M. M. Dickie and G. D. Snell (1950). "Obese, a new mutation in the
house mouse." J Hered 41(12): 317-318.
Iqbal, K., C. Alonso Adel, S. Chen, M. O. Chohan, E. El-Akkad, C. X. Gong, S.
Khatoon, B. Li, F. Liu, A. Rahman, H. Tanimukai and I. Grundke-Iqbal (2005). "Tau
pathology in Alzheimer disease and other tauopathies." Biochim Biophys Acta 1739(23): 198-210.
Ittner, L. M. and J. Gotz (2011). "Amyloid-beta and tau--a toxic pas de deux in
Alzheimer's disease." Nat Rev Neurosci 12(2): 65-72.
Jankowsky, J. L., D. J. Fadale, J. Anderson, G. M. Xu, V. Gonzales, N. A. Jenkins, N. G.
Copeland, M. K. Lee, L. H. Younkin, S. L. Wagner, S. G. Younkin and D. R. Borchelt
(2004). "Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid
peptide in vivo: evidence for augmentation of a 42-specific gamma secretase." Hum Mol
Genet 13(2): 159-170.
Janson, J., T. Laedtke, J. E. Parisi, P. O'Brien, R. C. Petersen and P. C. Butler (2004).
"Increased risk of type 2 diabetes in Alzheimer disease." Diabetes 53(2): 474-481.
Jaworski, T., I. Dewachter, B. Lechat, S. Croes, A. Termont, D. Demedts, P. Borghgraef,
H. Devijver, R. K. Filipkowski, L. Kaczmarek, S. Kugler and F. Van Leuven (2009).
"AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without
neurofibrillary tangle formation in wild-type mice." PloS one 4(10): e7280.
Johnston, J. M., W. T. Hu, D. W. Fardo, S. J. Greco, G. Perry, T. J. Montine, J. Q.
Trojanowski, L. M. Shaw, J. W. Ashford, N. Tezapsidis and I. Alzheimer's Disease
Neuroimaging (2014). "Low plasma leptin in cognitively impaired ADNI subjects:

163

gender differences and diagnostic and therapeutic potential." Curr Alzheimer Res 11(2):
165-174.
Jolivalt, C. G., R. Hurford, C. A. Lee, W. Dumaop, E. Rockenstein and E. Masliah
(2010). "Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic
mice." Exp Neurol 223(2): 422-431.
Jung, H. J., S. S. Park, J. O. Mok, T. K. Lee, C. S. Park and S. A. Park (2011). "Increased
expression of three-repeat isoforms of tau contributes to tau pathology in a rat model of
chronic type 2 diabetes." Experimental neurology 228(2): 232-241.
Kaether, C., C. Haass and H. Steiner (2006). "Assembly, trafficking and function of
gamma-secretase." Neurodegener Dis 3(4-5): 275-283.
Karran, E., M. Mercken and B. De Strooper (2011). "The amyloid cascade hypothesis for
Alzheimer's disease: an appraisal for the development of therapeutics." Nat Rev Drug
Discov 10(9): 698-712.
Kay, M. A., J. C. Glorioso and L. Naldini (2001). "Viral vectors for gene therapy: the art
of turning infectious agents into vehicles of therapeutics." Nature medicine 7(1): 33-40.
Kibbe, M. R., A. Murdock, T. Wickham, A. Lizonova, I. Kovesdi, S. Nie, L. Shears, T.
R. Billiar and E. Tzeng (2000). "Optimizing cardiovascular gene therapy: increased
vascular gene transfer with modified adenoviral vectors." Archives of Surgery 135(2):
191-197.
Kim, B., C. Backus, S. Oh, J. M. Hayes and E. L. Feldman (2009). "Increased tau
phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes."
Endocrinology 150(12): 5294-5301.
Kim, W. Y., X. Wang, Y. Wu, B. W. Doble, S. Patel, J. R. Woodgett and W. D. Snider
(2009). "GSK-3 is a master regulator of neural progenitor homeostasis." Nat Neurosci
12(11): 1390-1397.
Kim, W. Y., F. Q. Zhou, J. Zhou, Y. Yokota, Y. M. Wang, T. Yoshimura, K. Kaibuchi, J.
R. Woodgett, E. S. Anton and W. D. Snider (2006). "Essential roles for GSK-3s and
GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth."
Neuron 52(6): 981-996.
King, H., R. E. Aubert and W. H. Herman (1998). "Global burden of diabetes, 19952025: prevalence, numerical estimates, and projections." Diabetes Care 21(9): 14141431.

164

Kiuchi, A., N. Otsuka, Y. Namba, I. Nakano and M. Tomonaga (1991). "Presenile
appearance of abundant Alzheimer's neurofibrillary tangles without senile plaques in the
brain in myotonic dystrophy." Acta Neuropathol 82(1): 1-5.
Kivipelto, M., T. Ngandu, L. Fratiglioni, M. Viitanen, I. Kareholt, B. Winblad, E. L.
Helkala, J. Tuomilehto, H. Soininen and A. Nissinen (2005). "Obesity and vascular risk
factors at midlife and the risk of dementia and Alzheimer disease." Arch Neurol 62(10):
1556-1560.
Klein, C., E. M. Kramer, A. M. Cardine, B. Schraven, R. Brandt and J. Trotter (2002).
"Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the
cytoskeletal protein tau." J Neurosci 22(3): 698-707.
Klein, R. L., R. D. Dayton, N. J. Leidenheimer, K. Jansen, T. E. Golde and R. M. Zweig
(2006). "Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or
green fluorescent proteins." Molecular therapy : the journal of the American Society of
Gene Therapy 13(3): 517-527.
Klein, R. L., R. D. Dayton, J. B. Tatom, C. G. Diaczynsky and M. F. Salvatore (2008).
"Tau expression levels from various adeno-associated virus vector serotypes produce
graded neurodegenerative disease states." The European journal of neuroscience 27(7):
1615-1625.
Klein, R. L., R. D. Dayton, J. B. Tatom, K. M. Henderson and P. P. Henning (2008).
"AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter
and purification method." Molecular therapy : the journal of the American Society of
Gene Therapy 16(1): 89-96.
Klein, R. L., W. L. Lin, D. W. Dickson, J. Lewis, M. Hutton, K. Duff, E. M. Meyer and
M. A. King (2004). "Rapid neurofibrillary tangle formation after localized gene transfer
of mutated tau." The American journal of pathology 164(1): 347-353.
Klein, R. L., W. L. Lin, D. W. Dickson, J. Lewis, M. Hutton, K. Duff, E. M. Meyer and
M. A. King (2004). "Rapid neurofibrillary tangle formation after localized gene transfer
of mutated tau." Am J Pathol 164(1): 347-353.
Koch, C., R. A. Augustine, J. Steger, G. K. Ganjam, J. Benzler, C. Pracht, C. Lowe, M.
W. Schwartz, P. R. Shepherd, G. M. Anderson, D. R. Grattan and A. Tups (2010).
"Leptin rapidly improves glucose homeostasis in obese mice by increasing hypothalamic
insulin sensitivity." J Neurosci 30(48): 16180-16187.
Koike, M. A., K. N. Green, M. Blurton-Jones and F. M. Laferla (2010). "Oligemic
hypoperfusion differentially affects tau and amyloid-{beta}." The American journal of
pathology 177(1): 300-310.
165

Kokmen, E., J. P. Whisnant, W. M. O'Fallon, C. P. Chu and C. M. Beard (1996).
"Dementia after ischemic stroke: a population-based study in Rochester, Minnesota
(1960-1984)." Neurology 46(1): 154-159.
Korade-Mirnics, Z., P. Babitzke and E. Hoffman (1998). "Myotonic dystrophy:
molecular windows on a complex etiology." Nucleic Acids Res 26(6): 1363-1368.
Korade, Z. and A. K. Kenworthy (2008). "Lipid rafts, cholesterol, and the brain."
Neuropharmacology 55(8): 1265-1273.
Kotin, R. M., M. Siniscalco, R. J. Samulski, X. D. Zhu, L. Hunter, C. A. Laughlin, S.
McLaughlin, N. Muzyczka, M. Rocchi and K. I. Berns (1990). "Site-specific integration
by adeno-associated virus." Proceedings of the National Academy of Sciences of the
United States of America 87(6): 2211-2215.
Ksiezak-Reding, H., H. K. Pyo, B. Feinstein and G. M. Pasinetti (2003). "Akt/PKB
kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro." Biochim
Biophys Acta 1639(3): 159-168.
Laakso, M. (1999). "Hyperglycemia and cardiovascular disease in type 2 diabetes."
Diabetes 48(5): 937-942.
Lambert, J. C. and P. Amouyel (2011). "Genetics of Alzheimer's disease: new evidences
for an old hypothesis?" Curr Opin Genet Dev 21(3): 295-301.
Lambert, J. C., S. Heath, G. Even, D. Campion, K. Sleegers, M. Hiltunen, O. Combarros,
D. Zelenika, M. J. Bullido, B. Tavernier, L. Letenneur, K. Bettens, C. Berr, F. Pasquier,
N. Fievet, P. Barberger-Gateau, S. Engelborghs, P. De Deyn, I. Mateo, A. Franck, S.
Helisalmi, E. Porcellini, O. Hanon, M. M. de Pancorbo, C. Lendon, C. Dufouil, C.
Jaillard, T. Leveillard, V. Alvarez, P. Bosco, M. Mancuso, F. Panza, B. Nacmias, P.
Bossu, P. Piccardi, G. Annoni, D. Seripa, D. Galimberti, D. Hannequin, F. Licastro, H.
Soininen, K. Ritchie, H. Blanche, J. F. Dartigues, C. Tzourio, I. Gut, C. Van
Broeckhoven, A. Alperovitch, M. Lathrop and P. Amouyel (2009). "Genome-wide
association study identifies variants at CLU and CR1 associated with Alzheimer's
disease." Nat Genet 41(10): 1094-1099.
Lasagna-Reeves, C. A., D. L. Castillo-Carranza, U. Sengupta, A. L. Clos, G. R. Jackson
and R. Kayed (2011). "Tau oligomers impair memory and induce synaptic and
mitochondrial dysfunction in wild-type mice." Mol Neurodegener 6: 39.
Lee, E. B. (2011). "Obesity, leptin, and Alzheimer's disease." Annals of the New York
Academy of Sciences 1243: 15-29.

166

Lee, G., N. Cowan and M. Kirschner (1988). "The primary structure and heterogeneity of
tau protein from mouse brain." Science 239(4837): 285-288.
Lee, G. and C. J. Leugers (2012). "Tau and tauopathies." Prog Mol Biol Transl Sci 107:
263-293.
Lee, G. H., R. Proenca, J. M. Montez, K. M. Carroll, J. G. Darvishzadeh, J. I. Lee and J.
M. Friedman (1996). "Abnormal splicing of the leptin receptor in diabetic mice." Nature
379(6566): 632-635.
Lee, H. G., G. Perry, P. I. Moreira, M. R. Garrett, Q. Liu, X. Zhu, A. Takeda, A.
Nunomura and M. A. Smith (2005). "Tau phosphorylation in Alzheimer's disease:
pathogen or protector?" Trends Mol Med 11(4): 164-169.
Lee, I. M., E. J. Shiroma, F. Lobelo, P. Puska, S. N. Blair, P. T. Katzmarzyk and G.
Lancet Physical Activity Series Working (2012). "Effect of physical inactivity on major
non-communicable diseases worldwide: an analysis of burden of disease and life
expectancy." Lancet 380(9838): 219-229.
Lee, V. M., M. Goedert and J. Q. Trojanowski (2001). "Neurodegenerative tauopathies."
Annu Rev Neurosci 24: 1121-1159.
Lehto, S., T. Ronnemaa, S. M. Haffner, K. Pyorala, V. Kallio and M. Laakso (1997).
"Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged
patients with NIDDM." Diabetes 46(8): 1354-1359.
Lesort, M. and G. V. Johnson (2000). "Insulin-like growth factor-1 and insulin mediate
transient site-selective increases in tau phosphorylation in primary cortical neurons."
Neuroscience 99(2): 305-316.
Lesort, M., R. S. Jope and G. V. Johnson (1999). "Insulin transiently increases tau
phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine
kinase." J Neurochem 72(2): 576-584.
Levites, Y., K. Jansen, L. A. Smithson, R. Dakin, V. M. Holloway, P. Das and T. E.
Golde (2006). "Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid
beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates
plaque pathology in amyloid precursor protein mice." The Journal of neuroscience : the
official journal of the Society for Neuroscience 26(46): 11923-11928.
Lewis, J., D. W. Dickson, W. L. Lin, L. Chisholm, A. Corral, G. Jones, S. H. Yen, N.
Sahara, L. Skipper, D. Yager, C. Eckman, J. Hardy, M. Hutton and E. McGowan (2001).

167

"Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and
APP." Science 293(5534): 1487-1491.
Lewis, J., E. McGowan, J. Rockwood, H. Melrose, P. Nacharaju, M. Van Slegtenhorst,
K. Gwinn-Hardy, M. Paul Murphy, M. Baker, X. Yu, K. Duff, J. Hardy, A. Corral, W. L.
Lin, S. H. Yen, D. W. Dickson, P. Davies and M. Hutton (2000). "Neurofibrillary tangles,
amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau
protein." Nature genetics 25(4): 402-405.
Li, X. L., S. Aou, Y. Oomura, N. Hori, K. Fukunaga and T. Hori (2002). "Impairment of
long-term potentiation and spatial memory in leptin receptor-deficient rodents."
Neuroscience 113(3): 607-615.
Liang, M. H. and D. M. Chuang (2007). "Regulation and function of glycogen synthase
kinase-3 isoforms in neuronal survival." J Biol Chem 282(6): 3904-3917.
Licinio, J., C. Mantzoros, A. B. Negrao, G. Cizza, M. L. Wong, P. B. Bongiorno, G. P.
Chrousos, B. Karp, C. Allen, J. S. Flier and P. W. Gold (1997). "Human leptin levels are
pulsatile and inversely related to pituitary-adrenal function." Nat Med 3(5): 575-579.
Lieb, W., A. S. Beiser, R. S. Vasan, Z. S. Tan, R. Au, T. B. Harris, R. Roubenoff, S.
Auerbach, C. DeCarli, P. A. Wolf and S. Seshadri (2009). "Association of plasma leptin
levels with incident Alzheimer disease and MRI measures of brain aging." JAMA
302(23): 2565-2572.
Lieb, W., A. S. Beiser, R. S. Vasan, Z. S. Tan, R. Au, T. B. Harris, R. Roubenoff, S.
Auerbach, C. DeCarli, P. A. Wolf and S. Seshadri (2009). "Association of plasma leptin
levels with incident Alzheimer disease and MRI measures of brain aging." JAMA : the
journal of the American Medical Association 302(23): 2565-2572.
Lin, W. L., J. Lewis, S. H. Yen, M. Hutton and D. W. Dickson (2003). "Filamentous tau
in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform
with the P301L mutation." The American journal of pathology 162(1): 213-218.
Liquori, C. L., K. Ricker, M. L. Moseley, J. F. Jacobsen, W. Kress, S. L. Naylor, J. W.
Day and L. P. Ranum (2001). "Myotonic dystrophy type 2 caused by a CCTG expansion
in intron 1 of ZNF9." Science 293(5531): 864-867.
Loomis, P. A., T. H. Howard, R. P. Castleberry and L. I. Binder (1990). "Identification of
nuclear tau isoforms in human neuroblastoma cells." Proc Natl Acad Sci U S A 87(21):
8422-8426.

168

Louis, E. D., R. Babij, K. Ma, E. Cortes and J. P. Vonsattel (2013). "Essential tremor
followed by progressive supranuclear palsy: postmortem reports of 11 patients." J
Neuropathol Exp Neurol 72(1): 8-17.
Luchsinger, J. A. and R. Mayeux (2007). "Adiposity and Alzheimer's disease." Curr
Alzheimer Res 4(2): 127-134.
Lukiw, W. J., W. C. Gordon, E. I. Rogaev, H. Thompson and N. G. Bazan (2001).
"Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and
pathoangiogenesis." Neuroreport 12(1): 53-57.
Lund, E. T., R. McKenna, D. B. Evans, S. K. Sharma and W. R. Mathews (2001).
"Characterization of the in vitro phosphorylation of human tau by tau protein kinase II
(cdk5/p20) using mass spectrometry." J Neurochem 76(4): 1221-1232.
Lyn-Cook, L. E., Jr., M. Lawton, M. Tong, E. Silbermann, L. Longato, P. Jiao, P. Mark,
J. R. Wands, H. Xu and S. M. de la Monte (2009). "Hepatic ceramide may mediate brain
insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic
steatohepatitis." J Alzheimers Dis 16(4): 715-729.
Maas, T., J. Eidenmuller and R. Brandt (2000). "Interaction of tau with the neural
membrane cortex is regulated by phosphorylation at sites that are modified in paired
helical filaments." J Biol Chem 275(21): 15733-15740.
Malecki, M. T. (2005). "Genetics of type 2 diabetes mellitus." Diabetes Res Clin Pract 68
Suppl1: S10-21.
Malik, V. S., B. M. Popkin, G. A. Bray, J. P. Despres and F. B. Hu (2010). "Sugarsweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk."
Circulation 121(11): 1356-1364.
Mandelkow, E. M., O. Schweers, G. Drewes, J. Biernat, N. Gustke, B. Trinczek and E.
Mandelkow (1996). "Structure, microtubule interactions, and phosphorylation of tau
protein." Ann N Y Acad Sci 777: 96-106.
Mankodi, A., E. Logigian, L. Callahan, C. McClain, R. White, D. Henderson, M. Krym
and C. A. Thornton (2000). "Myotonic dystrophy in transgenic mice expressing an
expanded CUG repeat." Science 289(5485): 1769-1773.
Martin, L., X. Latypova, C. M. Wilson, A. Magnaudeix, M. L. Perrin, C. Yardin and F.
Terro (2013). "Tau protein kinases: involvement in Alzheimer's disease." Ageing Res
Rev 12(1): 289-309.

169

Martin, R. L., E. Perez, Y. J. He, R. Dawson, Jr. and W. J. Millard (2000). "Leptin
resistance is associated with hypothalamic leptin receptor mRNA and protein
downregulation." Metabolism 49(11): 1479-1484.
Martinez-Coria, H., K. N. Green, L. M. Billings, M. Kitazawa, M. Albrecht, G. Rammes,
C. G. Parsons, S. Gupta, P. Banerjee and F. M. LaFerla (2010). "Memantine improves
cognition and reduces Alzheimer's-like neuropathology in transgenic mice." Am J Pathol
176(2): 870-880.
Martinez-Coria, H., K. N. Green, L. M. Billings, M. Kitazawa, M. Albrecht, G. Rammes,
C. G. Parsons, S. Gupta, P. Banerjee and F. M. LaFerla (2010). "Memantine improves
cognition and reduces Alzheimer's-like neuropathology in transgenic mice." The
American journal of pathology 176(2): 870-880.
Marwarha, G., B. Dasari, J. R. Prasanthi, J. Schommer and O. Ghribi (2010). "Leptin
reduces the accumulation of Abeta and phosphorylated tau induced by 27hydroxycholesterol in rabbit organotypic slices." Journal of Alzheimer's disease : JAD
19(3): 1007-1019.
Mateo, I., J. Infante, J. Llorca, E. Rodriguez, J. Berciano and O. Combarros (2006).
"Association between glycogen synthase kinase-3beta genetic polymorphism and lateonset Alzheimer's disease." Dement Geriatr Cogn Disord 21(4): 228-232.
Mattson, M. P., W. Duan, W. A. Pedersen and C. Culmsee (2001). "Neurodegenerative
disorders and ischemic brain diseases." Apoptosis 6(1-2): 69-81.
Maurage, C. A., B. Udd, M. M. Ruchoux, P. Vermersch, H. Kalimo, R. Krahe, A.
Delacourte and N. Sergeant (2005). "Similar brain tau pathology in DM2/PROMM and
DM1/Steinert disease." Neurology 65(10): 1636-1638.
McCown, T. J. (2005). "Adeno-associated virus (AAV) vectors in the CNS." Current
gene therapy 5(3): 333-338.
Meda, L., P. Baron and G. Scarlato (2001). "Glial activation in Alzheimer's disease: the
role of Abeta and its associated proteins." Neurobiol Aging 22(6): 885-893.
Megherbi, S. E., C. Milan, D. Minier, G. Couvreur, G. V. Osseby, K. Tilling, A. Di
Carlo, D. Inzitari, C. D. Wolfe, T. Moreau, M. Giroud and B. S. o. S. C. G. European
(2003). "Association between diabetes and stroke subtype on survival and functional
outcome 3 months after stroke: data from the European BIOMED Stroke Project." Stroke
34(3): 688-694.

170

Mendez, M. F. (1995). "The neuropsychiatric aspects of boxing." Int J Psychiatry Med
25(3): 249-262.
Michel, G., M. Mercken, M. Murayama, K. Noguchi, K. Ishiguro, K. Imahori and A.
Takashima (1998). "Characterization of tau phosphorylation in glycogen synthase kinase3beta and cyclin dependent kinase-5 activator (p23) transfected cells." Biochim Biophys
Acta 1380(2): 177-182.
Midena, E., T. Segato, S. Radin, G. di Giorgio, F. Meneghini, S. Piermarocchi and A. S.
Belloni (1989). "Studies on the retina of the diabetic db/db mouse. I. Endothelial cellpericyte ratio." Ophthalmic research 21(2): 106-111.
Mines, M. A., E. Beurel and R. S. Jope (2011). "Regulation of cell survival mechanisms
in Alzheimer's disease by glycogen synthase kinase-3." Int J Alzheimers Dis 2011:
861072.
Mirra, S. S., J. R. Murrell, M. Gearing, M. G. Spillantini, M. Goedert, R. A. Crowther, A.
I. Levey, R. Jones, J. Green, J. M. Shoffner, B. H. Wainer, M. L. Schmidt, J. Q.
Trojanowski and B. Ghetti (1999). "Tau pathology in a family with dementia and a
P301L mutation in tau." J Neuropathol Exp Neurol 58(4): 335-345.
Mokdad, A. H., E. S. Ford, B. A. Bowman, W. H. Dietz, F. Vinicor, V. S. Bales and J. S.
Marks (2003). "Prevalence of obesity, diabetes, and obesity-related health risk factors,
2001." JAMA : the journal of the American Medical Association 289(1): 76-79.
Mokdad, A. H., M. K. Serdula, W. H. Dietz, B. A. Bowman, J. S. Marks and J. P. Koplan
(1999). "The spread of the obesity epidemic in the United States, 1991-1998." JAMA
282(16): 1519-1522.
Mori, S., L. Wang, T. Takeuchi and T. Kanda (2004). "Two novel adeno-associated
viruses from cynomolgus monkey: pseudotyping characterization of capsid protein."
Virology 330(2): 375-383.
Morishima-Kawashima, M., M. Hasegawa, K. Takio, M. Suzuki, H. Yoshida, K. Titani
and Y. Ihara (1995). "Proline-directed and non-proline-directed phosphorylation of PHFtau." J Biol Chem 270(2): 823-829.
Morris, H. R., M. N. Khan, J. C. Janssen, J. M. Brown, J. Perez-Tur, M. Baker, M.
Ozansoy, J. Hardy, M. Hutton, N. W. Wood, A. J. Lees, T. Revesz, P. Lantos and M. N.
Rossor (2001). "The genetic and pathological classification of familial frontotemporal
dementia." Arch Neurol 58(11): 1813-1816.

171

Morris, H. R., M. N. Khan, J. C. Janssen, J. M. Brown, J. Perez-Tur, M. Baker, M.
Ozansoy, J. Hardy, M. Hutton, N. W. Wood, A. J. Lees, T. Revesz, P. Lantos and M. N.
Rossor (2001). "The genetic and pathological classification of familial frontotemporal
dementia." Archives of neurology 58(11): 1813-1816.
Morris, M., S. Maeda, K. Vossel and L. Mucke (2011). "The many faces of tau." Neuron
70(3): 410-426.
Morrison, C. D. (2009). "Leptin signaling in brain: A link between nutrition and
cognition?" Biochim Biophys Acta 1792(5): 401-408.
Morsch, R., W. Simon and P. D. Coleman (1999). "Neurons may live for decades with
neurofibrillary tangles." J Neuropathol Exp Neurol 58(2): 188-197.
Munch, G., R. Schinzel, C. Loske, A. Wong, N. Durany, J. J. Li, H. Vlassara, M. A.
Smith, G. Perry and P. Riederer (1998). "Alzheimer's disease--synergistic effects of
glucose deficit, oxidative stress and advanced glycation endproducts." J Neural Transm
105(4-5): 439-461.
Muntean, C., A. Mitrea, M. Mota and V. Tudorica (2012). "TYPE 2 DIABETES AND
ITS IMPLICATIONS IN CEREBROVASCULAR DISEASE " Rom J Diabetes Nutr
Metab Dis. 19(1): 81-88.
Munzberg, H., J. S. Flier and C. Bjorbaek (2004). "Region-specific leptin resistance
within the hypothalamus of diet-induced obese mice." Endocrinology 145(11): 48804889.
Munzberg, H., L. Huo, E. A. Nillni, A. N. Hollenberg and C. Bjorbaek (2003). "Role of
signal transducer and activator of transcription 3 in regulation of hypothalamic
proopiomelanocortin gene expression by leptin." Endocrinology 144(5): 2121-2131.
Muzyczka, N. (1992). "Use of adeno-associated virus as a general transduction vector for
mammalian cells." Current topics in microbiology and immunology 158: 97-129.
Myers, M. G., M. A. Cowley and H. Munzberg (2008). "Mechanisms of leptin action and
leptin resistance." Annu Rev Physiol 70: 537-556.
Nakajima, M., S. Yuasa, M. Ueno, N. Takakura, H. Koseki and T. Shirasawa (2003).
"Abnormal blood vessel development in mice lacking presenilin-1." Mech Dev 120(6):
657-667.
Nasreddine, Z. S., M. Loginov, L. N. Clark, J. Lamarche, B. L. Miller, A. Lamontagne,
V. Zhukareva, V. M. Lee, K. C. Wilhelmsen and D. H. Geschwind (1999). "From
172

genotype to phenotype: a clinical pathological, and biochemical investigation of
frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau
mutation." Annals of neurology 45(6): 704-715.
Nazimek-Siewniak, B., D. Moczulski and W. Grzeszczak (2002). "Risk of macrovascular
and microvascular complications in Type 2 diabetes: results of longitudinal study
design." J Diabetes Complications 16(4): 271-276.
Niedowicz, D. M., T. L. Beckett, C. J. Holler, A. M. Weidner and M. P. Murphy (2010).
"APP(DeltaNL695) expression in murine tissue downregulates CNBP expression."
Neuroscience letters 482(1): 57-61.
Niedowicz, D. M., V. L. Reeves, T. L. Platt, K. Kohler, T. L. Beckett, D. K. Powell, T. L.
Lee, T. R. Sexton, E. S. Song, L. D. Brewer, C. S. Latimer, S. D. Kraner, K. L. Larson, S.
Ozcan, C. M. Norris, L. B. Hersh, N. M. Porter, D. M. Wilcock and M. P. Murphy
(2014). "Obesity and diabetes cause cognitive dysfunction in the absence of accelerated
beta-amyloid deposition in a novel murine model of mixed or vascular dementia." Acta
Neuropathol Commun 2(1): 64.
Niedowicz, D. M., C. M. Studzinski, A. M. Weidner, T. L. Platt, K. N. Kingry, T. L.
Beckett, A. J. Bruce-Keller, J. N. Keller and M. P. Murphy (2013). "Leptin regulates
amyloid beta production via the gamma-secretase complex." Biochim Biophys Acta
1832(3): 439-444.
Niswender, K. D., G. J. Morton, W. H. Stearns, C. J. Rhodes, M. G. Myers, Jr. and M. W.
Schwartz (2001). "Intracellular signalling. Key enzyme in leptin-induced anorexia."
Nature 413(6858): 794-795.
O'Donnell, M. J., D. Xavier, L. Liu, H. Zhang, S. L. Chin, P. Rao-Melacini, S.
Rangarajan, S. Islam, P. Pais, M. J. McQueen, C. Mondo, A. Damasceno, P. LopezJaramillo, G. J. Hankey, A. L. Dans, K. Yusoff, T. Truelsen, H. C. Diener, R. L. Sacco,
D. Ryglewicz, A. Czlonkowska, C. Weimar, X. Wang, S. Yusuf and I. investigators
(2010). "Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries
(the INTERSTROKE study): a case-control study." Lancet 376(9735): 112-123.
Oba, H., A. Yagishita, H. Terada, A. J. Barkovich, K. Kutomi, T. Yamauchi, S. Furui, T.
Shimizu, M. Uchigata, K. Matsumura, M. Sonoo, M. Sakai, K. Takada, A. Harasawa, K.
Takeshita, H. Kohtake, H. Tanaka and S. Suzuki (2005). "New and reliable MRI
diagnosis for progressive supranuclear palsy." Neurology 64(12): 2050-2055.
Oddo, S., A. Caccamo, J. D. Shepherd, M. P. Murphy, T. E. Golde, R. Kayed, R.
Metherate, M. P. Mattson, Y. Akbari and F. M. LaFerla (2003). "Triple-transgenic model
of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic
dysfunction." Neuron 39(3): 409-421.
173

Oh, K. S., E. Y. Kim, M. Yoon and C. M. Lee (2007). "Swim training improves leptin
receptor deficiency-induced obesity and lipid disorder by activating uncoupling proteins."
Exp Mol Med 39(3): 385-394.
Ohnishi, S. and K. Takano (2004). "Amyloid fibrils from the viewpoint of protein
folding." Cell Mol Life Sci 61(5): 511-524.
Oomura, Y., N. Hori, T. Shiraishi, K. Fukunaga, H. Takeda, M. Tsuji, T. Matsumiya, M.
Ishibashi, S. Aou, X. L. Li, D. Kohno, K. Uramura, H. Sougawa, T. Yada, M. J. Wayner
and K. Sasaki (2006). "Leptin facilitates learning and memory performance and enhances
hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats." Peptides
27(11): 2738-2749.
Orchard, T. J., J. S. Dorman, R. E. Maser, D. J. Becker, A. L. Drash, D. Ellis, R. E.
LaPorte and L. H. Kuller (1990). "Prevalence of complications in IDDM by sex and
duration. Pittsburgh Epidemiology of Diabetes Complications Study II." Diabetes 39(9):
1116-1124.
Ostlund, R. E., Jr., J. W. Yang, S. Klein and R. Gingerich (1996). "Relation between
plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates."
The Journal of clinical endocrinology and metabolism 81(11): 3909-3913.
Ott, A., R. P. Stolk, F. van Harskamp, H. A. Pols, A. Hofman and M. M. Breteler (1999).
"Diabetes mellitus and the risk of dementia: The Rotterdam Study." Neurology 53(9):
1937-1942.
Panda, D., J. C. Samuel, M. Massie, S. C. Feinstein and L. Wilson (2003). "Differential
regulation of microtubule dynamics by three- and four-repeat tau: implications for the
onset of neurodegenerative disease." Proc Natl Acad Sci U S A 100(16): 9548-9553.
Paz-Filho, G. J., T. Babikian, R. Asarnow, T. Delibasi, K. Esposito, H. K. Erol, M. L.
Wong and J. Licinio (2008). "Leptin replacement improves cognitive development." PloS
one 3(8): e3098.
Pei, J. J., E. Braak, H. Braak, I. Grundke-Iqbal, K. Iqbal, B. Winblad and R. F. Cowburn
(1999). "Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains
staged for Alzheimer disease neurofibrillary changes." J Neuropathol Exp Neurol 58(9):
1010-1019.
Peila, R., B. L. Rodriguez, L. J. Launer and S. Honolulu-Asia Aging (2002). "Type 2
diabetes, APOE gene, and the risk for dementia and related pathologies: The HonoluluAsia Aging Study." Diabetes 51(4): 1256-1262.

174

Peineau, S., C. Taghibiglou, C. Bradley, T. P. Wong, L. Liu, J. Lu, E. Lo, D. Wu, E.
Saule, T. Bouschet, P. Matthews, J. T. Isaac, Z. A. Bortolotto, Y. T. Wang and G. L.
Collingridge (2007). "LTP inhibits LTD in the hippocampus via regulation of
GSK3beta." Neuron 53(5): 703-717.
Perez-Costas, E., J. C. Gandy, M. Melendez-Ferro, R. C. Roberts and G. N. Bijur (2010).
"Light and electron microscopy study of glycogen synthase kinase-3beta in the mouse
brain." PLoS One 5(1): e8911.
Perez-Gonzalez, R., D. Antequera, T. Vargas, C. Spuch, M. Bolos and E. Carro (2011).
"Leptin induces proliferation of neuronal progenitors and neuroprotection in a mouse
model of Alzheimer's disease." Journal of Alzheimer's disease : JAD 24 Suppl 2: 17-25.
Piedrahita, D., I. Hernandez, A. Lopez-Tobon, D. Fedorov, B. Obara, B. S. Manjunath, R.
L. Boudreau, B. Davidson, F. Laferla, J. C. Gallego-Gomez, K. S. Kosik and G. P.
Cardona-Gomez (2010). "Silencing of CDK5 reduces neurofibrillary tangles in
transgenic alzheimer's mice." The Journal of neuroscience : the official journal of the
Society for Neuroscience 30(42): 13966-13976.
Planel, E., Y. Tatebayashi, T. Miyasaka, L. Liu, L. Wang, M. Herman, W. H. Yu, J. A.
Luchsinger, B. Wadzinski, K. E. Duff and A. Takashima (2007). "Insulin dysfunction
induces in vivo tau hyperphosphorylation through distinct mechanisms." The Journal of
neuroscience : the official journal of the Society for Neuroscience 27(50): 13635-13648.
Planel, E., Y. Tatebayashi, T. Miyasaka, L. Liu, L. Wang, M. Herman, W. H. Yu, J. A.
Luchsinger, B. Wadzinski, K. E. Duff and A. Takashima (2007). "Insulin dysfunction
induces in vivo tau hyperphosphorylation through distinct mechanisms." J Neurosci
27(50): 13635-13648.
Platt, T. L., V. L. Reeves and M. P. Murphy (2013). "Transgenic models of Alzheimer's
disease: better utilization of existing models through viral transgenesis." Biochimica et
biophysica acta 1832(9): 1437-1448.
Polydoro, M., C. M. Acker, K. Duff, P. E. Castillo and P. Davies (2009). "Age-dependent
impairment of cognitive and synaptic function in the htau mouse model of tau
pathology." The Journal of neuroscience : the official journal of the Society for
Neuroscience 29(34): 10741-10749.
Pooler, A. M., E. C. Phillips, D. H. Lau, W. Noble and D. P. Hanger (2013).
"Physiological release of endogenous tau is stimulated by neuronal activity." EMBO Rep
14(4): 389-394.
Poorkaj, P., T. D. Bird, E. Wijsman, E. Nemens, R. M. Garruto, L. Anderson, A.
Andreadis, W. C. Wiederholt, M. Raskind and G. D. Schellenberg (1998). "Tau is a
175

candidate gene for chromosome 17 frontotemporal dementia." Annals of neurology
43(6): 815-825.
Poorkaj, P., T. D. Bird, E. Wijsman, E. Nemens, R. M. Garruto, L. Anderson, A.
Andreadis, W. C. Wiederholt, M. Raskind and G. D. Schellenberg (1998). "Tau is a
candidate gene for chromosome 17 frontotemporal dementia." Ann Neurol 43(6): 815825.
Poulain, M., M. Doucet, G. C. Major, V. Drapeau, F. Series, L. P. Boulet, A. Tremblay
and F. Maltais (2006). "The effect of obesity on chronic respiratory diseases:
pathophysiology and therapeutic strategies." CMAJ 174(9): 1293-1299.
Prevention, C. o. D. C. a. (2011). Diabetes Fact Sheet: national estimates and general
information on diabetes and prediabetes in the United States, 2011. Atlanta, GA, U.S.
Department of Health and Human Services.
Rahman, S., T. Rahman, A. A. Ismail and A. R. Rashid (2007). "Diabetes-associated
macrovasculopathy: pathophysiology and pathogenesis." Diabetes Obes Metab 9(6): 767780.
Rahmouni, K., W. G. Haynes, D. A. Morgan and A. L. Mark (2003). "Intracellular
mechanisms involved in leptin regulation of sympathetic outflow." Hypertension 41(3 Pt
2): 763-767.
Rains, J. L. and S. K. Jain (2011). "Oxidative stress, insulin signaling, and diabetes." Free
radical biology & medicine 50(5): 567-575.
Reddy, P. H. (2013). "Amyloid beta-induced glycogen synthase kinase 3beta
phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction
and neuronal damage." Biochim Biophys Acta 1832(12): 1913-1921.
Resnick, H. E., P. Valsania, J. B. Halter and X. Lin (2000). "Relation of weight gain and
weight loss on subsequent diabetes risk in overweight adults." Journal of epidemiology
and community health 54(8): 596-602.
Reusch, J. E. and B. B. Draznin (2007). "Atherosclerosis in diabetes and insulin
resistance." Diabetes Obes Metab 9(4): 455-463.
Rewers, M., D. Zaccaro, R. D'Agostino, S. Haffner, M. F. Saad, J. V. Selby, R. Bergman
and P. Savage (2004). "Insulin sensitivity, insulinemia, and coronary artery disease: the
Insulin Resistance Atherosclerosis Study." Diabetes care 27(3): 781-787.

176

Reynolds, M. R., J. F. Reyes, Y. Fu, E. H. Bigio, A. L. Guillozet-Bongaarts, R. W. Berry
and L. I. Binder (2006). "Tau nitration occurs at tyrosine 29 in the fibrillar lesions of
Alzheimer's disease and other tauopathies." J Neurosci 26(42): 10636-10645.
Ribo, M., C. Molina, J. Montaner, M. Rubiera, R. Delgado-Mederos, J. F. Arenillas, M.
Quintana and J. Alvarez-Sabin (2005). "Acute hyperglycemia state is associated with
lower tPA-induced recanalization rates in stroke patients." Stroke 36(8): 1705-1709.
Riserus, U., W. C. Willett and F. B. Hu (2009). "Dietary fats and prevention of type 2
diabetes." Prog Lipid Res 48(1): 44-51.
Rizzu, P., M. Joosse, R. Ravid, A. Hoogeveen, W. Kamphorst, J. C. van Swieten, R.
Willemsen and P. Heutink (2000). "Mutation-dependent aggregation of tau protein and its
selective depletion from the soluble fraction in brain of P301L FTDP-17 patients." Hum
Mol Genet 9(20): 3075-3082.
Robertson, L. A., K. L. Moya and K. C. Breen (2004). "The potential role of tau protein
O-glycosylation in Alzheimer's disease." J Alzheimers Dis 6(5): 489-495.
Robinson, J. L., F. Geser, M. M. Corrada, D. J. Berlau, S. E. Arnold, V. M. Lee, C. H.
Kawas and J. Q. Trojanowski (2011). "Neocortical and hippocampal amyloid-beta and
tau measures associate with dementia in the oldest-old." Brain 134(Pt 12): 3708-3715.
Roman, G. (2003). "Vascular dementia: a historical background." Int Psychogeriatr 15
Suppl 1: 11-13.
Rossi, G., D. Conconi, E. Panzeri, L. Paoletta, E. Piccoli, M. G. Ferretti, M. Mangieri, M.
Ruggerone, L. Dalpra and F. Tagliavini (2014). "Mutations in MAPT give rise to
aneuploidy in animal models of tauopathy." Neurogenetics 15(1): 31-40.
Rosso, S. M., L. Donker Kaat, T. Baks, M. Joosse, I. de Koning, Y. Pijnenburg, D. de
Jong, D. Dooijes, W. Kamphorst, R. Ravid, M. F. Niermeijer, F. Verheij, H. P. Kremer,
P. Scheltens, C. M. van Duijn, P. Heutink and J. C. van Swieten (2003). "Frontotemporal
dementia in The Netherlands: patient characteristics and prevalence estimates from a
population-based study." Brain 126(Pt 9): 2016-2022.
Roth, J. A. and R. J. Cristiano (1997). "Gene therapy for cancer: what have we done and
where are we going?" Journal of the National Cancer Institute 89(1): 21-39.
Rushworth, J. V. and N. M. Hooper (2010). "Lipid Rafts: Linking Alzheimer's Amyloidbeta Production, Aggregation, and Toxicity at Neuronal Membranes." Int J Alzheimers
Dis 2011: 603052.

177

Rutledge, E. A., C. L. Halbert and D. W. Russell (1998). "Infectious clones and vectors
derived from adeno-associated virus (AAV) serotypes other than AAV type 2." Journal of
virology 72(1): 309-319.
Salkovic-Petrisic, M. and S. Hoyer (2007). "Central insulin resistance as a trigger for
sporadic Alzheimer-like pathology: an experimental approach." J Neural Transm
Suppl(72): 217-233.
Saltiel, A. R. and C. R. Kahn (2001). "Insulin signalling and the regulation of glucose and
lipid metabolism." Nature 414(6865): 799-806.
Samulski, R. J., L. S. Chang and T. Shenk (1989). "Helper-free stocks of recombinant
adeno-associated viruses: normal integration does not require viral gene expression."
Journal of virology 63(9): 3822-3828.
Sandbrink, R., C. L. Masters and K. Beyreuther (1996). "APP gene family. Alternative
splicing generates functionally related isoforms." Ann N Y Acad Sci 777: 281-287.
Sanna, P. P., M. Cammalleri, F. Berton, C. Simpson, R. Lutjens, F. E. Bloom and W.
Francesconi (2002). "Phosphatidylinositol 3-kinase is required for the expression but not
for the induction or the maintenance of long-term potentiation in the hippocampal CA1
region." J Neurosci 22(9): 3359-3365.
Santacruz, K., J. Lewis, T. Spires, J. Paulson, L. Kotilinek, M. Ingelsson, A. Guimaraes,
M. DeTure, M. Ramsden, E. McGowan, C. Forster, M. Yue, J. Orne, C. Janus, A.
Mariash, M. Kuskowski, B. Hyman, M. Hutton and K. H. Ashe (2005). "Tau suppression
in a neurodegenerative mouse model improves memory function." Science 309(5733):
476-481.
Schaffer, B. A., L. Bertram, B. L. Miller, K. Mullin, S. Weintraub, N. Johnson, E. H.
Bigio, M. Mesulam, M. Wiedau-Pazos, G. R. Jackson, J. L. Cummings, R. M. Cantor, A.
I. Levey, R. E. Tanzi and D. H. Geschwind (2008). "Association of GSK3B with
Alzheimer disease and frontotemporal dementia." Arch Neurol 65(10): 1368-1374.
Schmelzle, K., S. Kane, S. Gridley, G. E. Lienhard and F. M. White (2006). "Temporal
dynamics of tyrosine phosphorylation in insulin signaling." Diabetes 55(8): 2171-2179.
Selkoe, D. J. (1991). "The molecular pathology of Alzheimer's disease." Neuron 6(4):
487-498.
Selkoe, D. J. (2001). "Alzheimer's disease: genes, proteins, and therapy." Physiol Rev
81(2): 741-766.

178

Sergeant, N., B. Sablonniere, S. Schraen-Maschke, A. Ghestem, C. A. Maurage, A.
Wattez, P. Vermersch and A. Delacourte (2001). "Dysregulation of human brain
microtubule-associated tau mRNA maturation in myotonic dystrophy type 1." Hum Mol
Genet 10(19): 2143-2155.
Sergeant, N., A. Wattez and A. Delacourte (1999). "Neurofibrillary degeneration in
progressive supranuclear palsy and corticobasal degeneration: tau pathologies with
exclusively "exon 10" isoforms." J Neurochem 72(3): 1243-1249.
Seshadri, S., A. L. Fitzpatrick, M. A. Ikram, A. L. DeStefano, V. Gudnason, M. Boada, J.
C. Bis, A. V. Smith, M. M. Carassquillo, J. C. Lambert, D. Harold, E. M. Schrijvers, R.
Ramirez-Lorca, S. Debette, W. T. Longstreth, Jr., A. C. Janssens, V. S. Pankratz, J. F.
Dartigues, P. Hollingworth, T. Aspelund, I. Hernandez, A. Beiser, L. H. Kuller, P. J.
Koudstaal, D. W. Dickson, C. Tzourio, R. Abraham, C. Antunez, Y. Du, J. I. Rotter, Y.
S. Aulchenko, T. B. Harris, R. C. Petersen, C. Berr, M. J. Owen, J. Lopez-Arrieta, B. N.
Varadarajan, J. T. Becker, F. Rivadeneira, M. A. Nalls, N. R. Graff-Radford, D.
Campion, S. Auerbach, K. Rice, A. Hofman, P. V. Jonsson, H. Schmidt, M. Lathrop, T.
H. Mosley, R. Au, B. M. Psaty, A. G. Uitterlinden, L. A. Farrer, T. Lumley, A. Ruiz, J.
Williams, P. Amouyel, S. G. Younkin, P. A. Wolf, L. J. Launer, O. L. Lopez, C. M. van
Duijn and M. M. Breteler (2010). "Genome-wide analysis of genetic loci associated with
Alzheimer disease." JAMA : the journal of the American Medical Association 303(18):
1832-1840.
Seshasai, S. R., S. Kaptoge, A. Thompson, E. Di Angelantonio, P. Gao, N. Sarwar, P. H.
Whincup, K. J. Mukamal, R. F. Gillum, I. Holme, I. Njolstad, A. Fletcher, P. Nilsson, S.
Lewington, R. Collins, V. Gudnason, S. G. Thompson, N. Sattar, E. Selvin, F. B. Hu and
J. Danesh (2011). "Diabetes mellitus, fasting glucose, and risk of cause-specific death."
The New England journal of medicine 364(9): 829-841.
Shanley, L. J., A. J. Irving and J. Harvey (2001). "Leptin enhances NMDA receptor
function and modulates hippocampal synaptic plasticity." J Neurosci 21(24): RC186.
Shanley, L. J., A. J. Irving and J. Harvey (2001). "Leptin enhances NMDA receptor
function and modulates hippocampal synaptic plasticity." The Journal of neuroscience :
the official journal of the Society for Neuroscience 21(24): RC186.
Sheetz, M. J. and G. L. King (2002). "Molecular understanding of hyperglycemia's
adverse effects for diabetic complications." JAMA 288(20): 2579-2588.
Sherrington, R., E. I. Rogaev, Y. Liang, E. A. Rogaeva, G. Levesque, M. Ikeda, H. Chi,
C. Lin, G. Li, K. Holman, T. Tsuda, L. Mar, J. F. Foncin, A. C. Bruni, M. P. Montesi, S.
Sorbi, I. Rainero, L. Pinessi, L. Nee, I. Chumakov, D. Pollen, A. Brookes, P. Sanseau, R.
J. Polinsky, W. Wasco, H. A. Da Silva, J. L. Haines, M. A. Perkicak-Vance, R. E. Tanzi,
A. D. Roses, P. E. Fraser, J. M. Rommens and P. H. St George-Hyslop (1995). "Cloning
179

of a gene bearing missense mutations in early-onset familial Alzheimer's disease." Nature
375(6534): 754-760.
Shevtsova, Z., J. M. Malik, U. Michel, M. Bahr and S. Kugler (2005). "Promoters and
serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central
nervous system in vitro and in vivo." Exp Physiol 90(1): 53-59.
Shioda, S., H. Funahashi, S. Nakajo, T. Yada, O. Maruta and Y. Nakai (1998).
"Immunohistochemical localization of leptin receptor in the rat brain." Neuroscience
letters 243(1-3): 41-44.
Shiurba, R. A., K. Ishiguro, M. Takahashi, K. Sato, E. T. Spooner, M. Mercken, R.
Yoshida, T. R. Wheelock, H. Yanagawa, K. Imahori and R. A. Nixon (1996).
"Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer
pathology." Brain Res 737(1-2): 119-132.
Sinha, M. K., J. P. Ohannesian, M. L. Heiman, A. Kriauciunas, T. W. Stephens, S.
Magosin, C. Marco and J. F. Caro (1996). "Nocturnal rise of leptin in lean, obese, and
non-insulin-dependent diabetes mellitus subjects." J Clin Invest 97(5): 1344-1347.
Sladek, R., G. Rocheleau, J. Rung, C. Dina, L. Shen, D. Serre, P. Boutin, D. Vincent, A.
Belisle, S. Hadjadj, B. Balkau, B. Heude, G. Charpentier, T. J. Hudson, A. Montpetit, A.
V. Pshezhetsky, M. Prentki, B. I. Posner, D. J. Balding, D. Meyre, C. Polychronakos and
P. Froguel (2007). "A genome-wide association study identifies novel risk loci for type 2
diabetes." Nature 445(7130): 881-885.
Spillantini, M. G. and M. Goedert (2000). "Tau mutations in familial frontotemporal
dementia." Brain : a journal of neurology 123 ( Pt 5): 857-859.
Spillantini, M. G., J. R. Murrell, M. Goedert, M. R. Farlow, A. Klug and B. Ghetti
(1998). "Mutation in the tau gene in familial multiple system tauopathy with presenile
dementia." Proc Natl Acad Sci U S A 95(13): 7737-7741.
Srivastava, A., E. W. Lusby and K. I. Berns (1983). "Nucleotide sequence and
organization of the adeno-associated virus 2 genome." Journal of virology 45(2): 555564.
Stambolic, V. and J. R. Woodgett (1994). "Mitogen inactivation of glycogen synthase
kinase-3 beta in intact cells via serine 9 phosphorylation." Biochem J 303 ( Pt 3): 701704.
Steele, J. C., J. C. Richardson and J. Olszewski (1964). "Progressive Supranuclear Palsy.
A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum
180

with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia." Arch
Neurol 10: 333-359.
Stegmayr, B. and K. Asplund (1995). "Diabetes as a risk factor for stroke. A population
perspective." Diabetologia 38(9): 1061-1068.
Stephenson, J. (2001). "Studies illuminate cause of fatal reaction in gene-therapy trial."
JAMA : the journal of the American Medical Association 285(20): 2570.
Tanaka, M., M. Sawada, S. Yoshida, F. Hanaoka and T. Marunouchi (1995). "Insulin
prevents apoptosis of external granular layer neurons in rat cerebellar slice cultures."
Neurosci Lett 199(1): 37-40.
Tanzi, R. E. and L. Bertram (2005). "Twenty years of the Alzheimer's disease amyloid
hypothesis: a genetic perspective." Cell 120(4): 545-555.
Tanzi, R. E., R. D. Moir and S. L. Wagner (2004). "Clearance of Alzheimer's Abeta
peptide: the many roads to perdition." Neuron 43(5): 605-608.
Tartaglia, L. A., M. Dembski, X. Weng, N. Deng, J. Culpepper, R. Devos, G. J. Richards,
L. A. Campfield, F. T. Clark, J. Deeds, C. Muir, S. Sanker, A. Moriarty, K. J. Moore, J.
S. Smutko, G. G. Mays, E. A. Wool, C. A. Monroe and R. I. Tepper (1995).
"Identification and expression cloning of a leptin receptor, OB-R." Cell 83(7): 12631271.
Tatemichi, T. K., D. W. Desmond, R. Mayeux, M. Paik, Y. Stern, M. Sano, R. H.
Remien, J. B. Williams, J. P. Mohr, W. A. Hauser and et al. (1992). "Dementia after
stroke: baseline frequency, risks, and clinical features in a hospitalized cohort."
Neurology 42(6): 1185-1193.
Tatemichi, T. K., M. Paik, E. Bagiella, D. W. Desmond, Y. Stern, M. Sano, W. A. Hauser
and R. Mayeux (1994). "Risk of dementia after stroke in a hospitalized cohort: results of
a longitudinal study." Neurology 44(10): 1885-1891.
Thurston, V. C., R. P. Zinkowski and L. I. Binder (1996). "Tau as a nucleolar protein in
human nonneural cells in vitro and in vivo." Chromosoma 105(1): 20-30.
Tian, H., E. Davidowitz, P. Lopez, S. Emadi, J. Moe and M. Sierks (2013). "Trimeric tau
is toxic to human neuronal cells at low nanomolar concentrations." Int J Cell Biol 2013:
260787.
Tolnay, M., N. Sergeant, A. Ghestem, S. Chalbot, R. A. De Vos, E. N. Jansen Steur, A.
Probst and A. Delacourte (2002). "Argyrophilic grain disease and Alzheimer's disease are
181

distinguished by their different distribution of tau protein isoforms." Acta Neuropathol
104(4): 425-434.
Tuomilehto, J., D. Rastenyte, P. Jousilahti, C. Sarti and E. Vartiainen (1996). "Diabetes
mellitus as a risk factor for death from stroke. Prospective study of the middle-aged
Finnish population." Stroke 27(2): 210-215.
Turenne, G. A. and B. D. Price (2001). "Glycogen synthase kinase3 beta phosphorylates
serine 33 of p53 and activates p53's transcriptional activity." BMC Cell Biol 2: 12.
Udd, B., G. Meola, R. Krahe, D. G. Wansink, G. Bassez, W. Kress, B. Schoser and R.
Moxley (2011). "Myotonic dystrophy type 2 (DM2) and related disorders report of the
180th ENMC workshop including guidelines on diagnostics and management 3-5
December 2010, Naarden, The Netherlands." Neuromuscul Disord 21(6): 443-450.
Uotani, S., C. Bjorbaek, J. Tornoe and J. S. Flier (1999). "Functional properties of leptin
receptor isoforms: internalization and degradation of leptin and ligand-induced receptor
downregulation." Diabetes 48(2): 279-286.
Valerio, A., V. Ghisi, M. Dossena, C. Tonello, A. Giordano, A. Frontini, M. Ferrario, M.
Pizzi, P. Spano, M. O. Carruba and E. Nisoli (2006). "Leptin increases axonal growth
cone size in developing mouse cortical neurons by convergent signals inactivating
glycogen synthase kinase-3beta." J Biol Chem 281(18): 12950-12958.
Valerio, A., V. Ghisi, M. Dossena, C. Tonello, A. Giordano, A. Frontini, M. Ferrario, M.
Pizzi, P. Spano, M. O. Carruba and E. Nisoli (2006). "Leptin increases axonal growth
cone size in developing mouse cortical neurons by convergent signals inactivating
glycogen synthase kinase-3beta." The Journal of biological chemistry 281(18): 1295012958.
van Eersel, J., Y. D. Ke, X. Liu, F. Delerue, J. J. Kril, J. Gotz and L. M. Ittner (2010).
"Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in
Alzheimer's disease models." Proceedings of the National Academy of Sciences of the
United States of America 107(31): 13888-13893.
Vermersch, P., N. Sergeant, M. M. Ruchoux, H. Hofmann-Radvanyi, A. Wattez, H. Petit,
P. Dwailly and A. Delacourte (1996). "Specific tau variants in the brains of patients with
myotonic dystrophy." Neurology 47(3): 711-717.
Viollet, B., L. Lantier, J. Devin-Leclerc, S. Hebrard, C. Amouyal, R. Mounier, M. Foretz
and F. Andreelli (2009). "Targeting the AMPK pathway for the treatment of Type 2
diabetes." Front Biosci (Landmark Ed) 14: 3380-3400.

182

Virkamaki, A., K. Ueki and C. R. Kahn (1999). "Protein-protein interaction in insulin
signaling and the molecular mechanisms of insulin resistance." The Journal of clinical
investigation 103(7): 931-943.
Wang, C., C. M. Wang, K. R. Clark and T. J. Sferra (2003). "Recombinant AAV serotype
1 transduction efficiency and tropism in the murine brain." Gene therapy 10(17): 15281534.
Wang, M. Y., Y. T. Zhou, C. B. Newgard and R. H. Unger (1996). "A novel leptin
receptor isoform in rat." FEBS Lett 392(2): 87-90.
Wang, P., Y. Jiang, Y. Wang, J. Y. Shyy and K. A. DeFea (2010). "Beta-arrestin inhibits
CAMKKbeta-dependent AMPK activation downstream of protease-activated-receptor2." BMC Biochem 11: 36.
Watanabe, A., K. Takio and Y. Ihara (1999). "Deamidation and isoaspartate formation in
smeared tau in paired helical filaments. Unusual properties of the microtubule-binding
domain of tau." J Biol Chem 274(11): 7368-7378.
Watanabe, N., T. Tomita, C. Sato, T. Kitamura, Y. Morohashi and T. Iwatsubo (2005).
"Pen-2 is incorporated into the gamma-secretase complex through binding to
transmembrane domain 4 of presenilin 1." J Biol Chem 280(51): 41967-41975.
Wayner, M. J., D. L. Armstrong, C. F. Phelix and Y. Oomura (2004). "Orexin-A
(Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo." Peptides
25(6): 991-996.
Webster, S. J., A. D. Bachstetter and L. J. Van Eldik (2013). "Comprehensive behavioral
characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease."
Alzheimers Res Ther 5(3): 28.
Weingarten, M. D., A. H. Lockwood, S. Y. Hwo and M. W. Kirschner (1975). "A protein
factor essential for microtubule assembly." Proc Natl Acad Sci U S A 72(5): 1858-1862.
Welsh, G. I. and C. G. Proud (1993). "Glycogen synthase kinase-3 is rapidly inactivated
in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B." Biochem J
294 ( Pt 3): 625-629.
Weng, Z., A. P. Signore, Y. Gao, S. Wang, F. Zhang, T. Hastings, X. M. Yin and J. Chen
(2007). "Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via
mitogen-activated protein kinase signaling." J Biol Chem 282(47): 34479-34491.

183

Whitmer, R. A., E. P. Gunderson, E. Barrett-Connor, C. P. Quesenberry, Jr. and K. Yaffe
(2005). "Obesity in middle age and future risk of dementia: a 27 year longitudinal
population based study." BMJ 330(7504): 1360.
Wilson, J. M. (2009). "Medicine. A history lesson for stem cells." Science 324(5928):
727-728.
Winocur, G., C. E. Greenwood, G. G. Piroli, C. A. Grillo, L. R. Reznikov, L. P. Reagan
and B. S. McEwen (2005). "Memory impairment in obese Zucker rats: an investigation of
cognitive function in an animal model of insulin resistance and obesity." Behavioral
neuroscience 119(5): 1389-1395.
Wittmann, C. W., M. F. Wszolek, J. M. Shulman, P. M. Salvaterra, J. Lewis, M. Hutton
and M. B. Feany (2001). "Tauopathy in Drosophila: neurodegeneration without
neurofibrillary tangles." Science 293(5530): 711-714.
Wolf, P. A., A. Beiser, M. F. Elias, R. Au, R. S. Vasan and S. Seshadri (2007). "Relation
of obesity to cognitive function: importance of central obesity and synergistic influence
of concomitant hypertension. The Framingham Heart Study." Curr Alzheimer Res 4(2):
111-116.
Woodgett, J. R. (1990). "Molecular cloning and expression of glycogen synthase kinase3/factor A." EMBO J 9(8): 2431-2438.
Wu, P., M. I. Phillips, J. Bui and E. F. Terwilliger (1998). "Adeno-associated virus
vector-mediated transgene integration into neurons and other nondividing cell targets."
Journal of virology 72(7): 5919-5926.
Xiao, X., J. Li and R. J. Samulski (1998). "Production of high-titer recombinant adenoassociated virus vectors in the absence of helper adenovirus." Journal of virology 72(3):
2224-2232.
Xu, Q., B. Chou, B. Fitzsimmons, A. Miyanohara, V. Shubayev, C. Santucci, M.
Hefferan, M. Marsala and X. Y. Hua (2012). "In vivo gene knockdown in rat dorsal root
ganglia mediated by self-complementary adeno-associated virus serotype 5 following
intrathecal delivery." PloS one 7(3): e32581.
Xu, W., C. Qiu, M. Gatz, N. L. Pedersen, B. Johansson and L. Fratiglioni (2009). "Midand late-life diabetes in relation to the risk of dementia: a population-based twin study."
Diabetes 58(1): 71-77.

184

Xu, W. L., C. X. Qiu, A. Wahlin, B. Winblad and L. Fratiglioni (2004). "Diabetes
mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study."
Neurology 63(7): 1181-1186.
Yan, S. D., X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher, T. Slattery, L. Zhao, M.
Nagashima, J. Morser, A. Migheli, P. Nawroth, D. Stern and A. M. Schmidt (1996).
"RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease." Nature
382(6593): 685-691.
Yao, H. B., P. C. Shaw, C. C. Wong and D. C. Wan (2002). "Expression of glycogen
synthase kinase-3 isoforms in mouse tissues and their transcription in the brain." J Chem
Neuroanat 23(4): 291-297.
Yassa, M. A. (2014). "Ground zero in Alzheimer's disease." Nat Neurosci 17(2): 146147.
Yoshida, H., R. A. Crowther and M. Goedert (2002). "Functional effects of tau gene
mutations deltaN296 and N296H." J Neurochem 80(3): 548-551.
Young, M. J., A. Veves, M. G. Walker and A. J. Boulton (1992). "Correlations between
nerve function and tissue oxygenation in diabetic patients: further clues to the aetiology
of diabetic neuropathy?" Diabetologia 35(12): 1146-1150.
Zaiss, A. K., Q. Liu, G. P. Bowen, N. C. Wong, J. S. Bartlett and D. A. Muruve (2002).
"Differential activation of innate immune responses by adenovirus and adeno-associated
virus vectors." Journal of virology 76(9): 4580-4590.
Zhang, F., S. Wang, A. P. Signore and J. Chen (2007). "Neuroprotective effects of leptin
against ischemic injury induced by oxygen-glucose deprivation and transient cerebral
ischemia." Stroke; a journal of cerebral circulation 38(8): 2329-2336.
Zhao, A. Z., J. N. Huan, S. Gupta, R. Pal and A. Sahu (2002). "A phosphatidylinositol 3kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on
feeding." Nature neuroscience 5(8): 727-728.
Zhao, W., H. Chen, H. Xu, E. Moore, N. Meiri, M. J. Quon and D. L. Alkon (1999).
"Brain insulin receptors and spatial memory. Correlated changes in gene expression,
tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze
trained rats." J Biol Chem 274(49): 34893-34902.
Zincarelli, C., S. Soltys, G. Rengo and J. E. Rabinowitz (2008). "Analysis of AAV
serotypes 1-9 mediated gene expression and tropism in mice after systemic injection."

185

Molecular therapy : the journal of the American Society of Gene Therapy 16(6): 10731080.
Zincarelli, C., S. Soltys, G. Rengo and J. E. Rabinowitz (2008). "Analysis of AAV
serotypes 1-9 mediated gene expression and tropism in mice after systemic injection."
Mol Ther 16(6): 1073-1080.

Copyright © Thomas L. Platt 2014

186

VITA
Thomas Lowell Platt
EDUCATION:
2010 – Present
2006 – 2010

University of Kentucky
Doctoral Candidate in Cellular and Molecular Biochemistry
Lexington, KY
Morehead State University
Bachelors of Science in Biology
Morehead, KY

ACADEMIC HONORS:
University of Kentucky Max Steckler Award 2014
University of Kentucky Predoctoral Domestic Travel
Award, Spring 2012
University of Kentucky Predoctoral Domestic Travel
Award, Fall 2012
American Society for Molecular Biology and Biochemistry
(ASBMB) Predoctoral Travel Award, Spring 2009
PUBLICATIONS:
1. Niedowicz DM, Studzinski CM, Weidner AM, Platt TL, Kingry KN, Beckett TL,
Bruce-Keller AJ, Keller JN, Murphy MP. Leptin regulates amyloid β production via
the γ-secretase complex. Biochim Biophys Acta. (2013); 1832(3):439-44.
2. Platt TL, Reeves VL, Murphy MP. Transgenic models of Alzheimer's disease: Better
utilization of existing models through viral transgenesis. Biochim Biophys Acta.
(2013); 1832(9):1437-48.
3. Farr SA, Ripley JL, Sultana R, Zhang Z, Niehoff ML, Platt TL, Murphy MP, Morley
JE, Kumar V, Butterfield DA (2014).Antisense oligonucleotide against GSK-3β in
brain of SAMP8 mice improves learning and memory and decreases oxidative stress:
Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free
Radic Biol Med. (2014) 67:387-95
4. Holler CJ, Davis PR, Beckett TL, Platt TL, Webb RL, Head E, Murphy MP.
Bridging Integrator 1 (BIN1) Protein Expression Increases in the Alzheimer’s Disease
Brain and Correlates with Neurofibrillary Tangle Pathology (Accepted)
5. Niedowicz DM, Reeves VL, Kohler K, Beckett TL, Platt TL, Powell DK, Sudduth T,
Sexton T, Song ES, Brewer LD, Latimer CS, Hersh L, Porter N, Wilcock D, Murphy
187

MP. "Obesity and diabetes cause cognitive dysfunction in the absence of accelerated
beta-amyloid deposition in a novel murine model of mixed or vascular dementia."
Acta Neuropathol Commun (2014) 2(1): 64.
6. Platt TL, Beckett TL, Kohler K, Niedowicz DM, Murphy MP. Obesity, Diabetes,
and Leptin Resistance Promote Tau Pathology in a Mouse Model of Disease. (In
Revision)

188

